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 Sprouty (Spry) proteins function as inhibitors of receptor tyrosine kinase (RTK) 
signaling. Through their action, they play a crucial role in regulating branching 
morphorgenesis, development and cell migration. The best characterized function of Spry 
proteins is their role in inhibiting RTK-mediated ERK1/2 activation. In the past few years, 
studies by different groups have been carried out to elucidate the mechanisms by which Spry 
proteins are able to inhibit ERK activity. Most of the work performed to date concentrate on 
the canonical RTK-Grb2-Sos-Ras-Raf-MEK-ERK pathway. Current evidence suggests 
different points of action, including upstream of Ras and Raf. 
 In this study, the question was raised as to whether Spry proteins could influence 
other signaling pathways, and what impact they would have. Identification of novel 
interacting proteins using a yeast two-hybrid screen was employed as a strategy to answer 
this question. Phospholipid scramblase 3 (Plscr3) was isolated from this screen, and through 
this protein, protein kinase Cδ (PKCδ) was further identified to be a FGF stimulation-
dependent interacting partner of Spry2. The interaction between Spry2 and PKCδ was also 
found to be both specific and direct, and it depends on the conformation of the two proteins. 
 The binding of Spry2 and PKCδ does not inhibit phosphorylation or activation of 
PKCδ. Instead, it inhibits the phosphorylation of a PKCδ substrate, protein kinase D1 
(PKD1), on two serine residues within its activation loop. Further analysis showed that 
Spry2, PKCδ and PKD1 form a trimeric complex. In order for Spry2 to interact with PKCδ, 
PKD1 and PKCδ must first bind to each other. The role that Spry2 plays within this complex 
is to lock the interaction between PKCδ and PKD1, and block the transfer of a phosphate 
 XIV
 XV
group from PKCδ to PKD1. The interaction between Spry2 and PKCδ therefore effectively 
creates a kinase-dead PKCδ. 
 In this study, the kinase activity of PKCδ is demonstrated to be required for ERK1/2 
phosphorylation. Therefore, by inhibiting the ability of PKCδ to phosphorylate its substrates, 
Spry2 is able to limit the contribution of PKCδ signaling to ERK1/2 activation. This takes 
place through the absence of phosphorylation of PKD1, which is necessary for its activation. 
It is proposed that its substrate, Ras inhibitor 1 (RIN1), is maintained in an unphosphorylated 
state, which acts as an effective competitor of Raf for Ras binding. Signal propagation 
between Ras and Raf would therefore be reduced. Results from this study indicate that the 
expression of Spry2 increases the interaction between active Ras and RIN1.  
 Reports have suggested that the kinase activity of PKCδ is required for the invasive 
potential of prostate cancer cells. Cell invasion assays in this study show that by inhibiting 
phosphorylation of its substrates, Spry2 is able to block PKCδ-mediated cell invasion. 
 The results from this study indicate that Spry2 is able to regulate a pathway that is 
distinct from the canonical Ras/ERK signaling pathway. Furthermore, it is demonstrated that 
this pathway contributes to ERK phosphorylation. The interaction between Spry2 and PKCδ, 





1.1 Cell Signaling 
 The capacity to sense and respond to information from the surrounding 
environment is important to a cell’s function. As the complexity of organisms increase, 
moving across the spectrum from unicellular organisms to multicellular ones possessing 
multiple tissues and organs, the ability to communicate with and respond to the external 
environment becomes more critical. This necessitates the cell to have the capacity to 
recognize different signals and respond to each one in an appropriate manner. 
Physiological functions, such as development, tissue and organ patterning and growth of 
the organism as a whole are dependent on this capacity to recognize and respond. 
Extracellular signals that a cell may respond to come in various forms, including proteins, 
peptides, carbohydrates, lipids and inorganic ions. These signals are recognized by their 
appropriate receptors at the cell membrane, and the ‘message’ is passed through the cell 
from the membrane to its target, by means of intermediaries in a signaling cascade. In the 
nucleus, gene expression changes occur in response to the signals received, resulting in a 
physiological outcome. This process is referred to as ‘signal transduction’ or ‘cell 
signaling’. 
 In order to ensure that the correct signal is being propagated through the cell, the 
signaling process is both finely tuned and highly regulated, with positive and negative 
networks being employed to achieve a desired outcome. Normal physiological processes 
are therefore a result of a fine balance achieved between both the positive and negative 
networks. A disruption of this balance results in improper cellular function, and this often 
manifests itself as a disease, such as cancer, or neuro-degenerative disorders. Since the 
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process of cell signaling is of such fundamental importance, it is therefore the focus of 
much research to understand the signaling networks in both normal and diseased states. 
 
1.2 Receptor tyrosine kinase signaling 
 Receptor tyrosine (Tyr) kinases (RTKs) are a class of membrane-spanning cell 
surface receptor proteins that are endowed with intrinsic protein Tyr kinase activity and 
play a pivotal role in cell signaling. They do so by recognizing signaling molecules such 
as growth factors at the cell membrane and facilitating transmission of the signal to the 
interior of the cell, thereby eliciting the appropriate cellular responses. RTKs specifically 
recognize their respective growth factor ligands, including epidermal growth factor 
(EGF), fibroblast growth factor (FGF), platelet derived growth factor (PDGF), vascular-
endothelial growth factor (VEGF) and insulin, and act as conduits through which 
extracellular signals may affect the intracellular environment (Schlessinger, 2000). 
Cytokine receptors, such as the erythropoietin receptor (EPO-R), mediate signal 
transduction in a similar manner, but their relatively short cytoplasmic domains do not 
contain an intrinsic protein Tyr kinase activity and, instead associate constitutively 
through non-covalent interactions with the JAK family of cytoplasmic Tyr kinases. The 
basic RTK structure comprises an extracellular domain that binds specifically to its 
ligand, which is connected via a single transmembrane helix to an intracellular domain 
that possesses an intrinsic Tyr kinase activity (Schlessinger, 2000) (Figure 1.2). The 
extracellular domain is often glycosylated, and depending on the subclass, may contain 
globular immunoglobulin-like, EGF-like, cysteine (Cys)-rich or leucine (Leu)-rich 
domains (Hubbard and Till, 2000).  
Class I II III IV V



























Adapted from Hubbard and Till, 2000
Figure 1.2 Domain organization of different RTK classes
Schematic representation of the different domains present in the extracellular and 
cytoplasmic regions of different classes of RTKs. 
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1.2.1 Activation of RTKs 
 In unstimulated cells, RTKs often exist as monomers in the cell membrane. 
Ligand binding induces the dimerization of the receptors, either because a single ligand 
can bind to and stabilize two molecules of the receptor, or because the ligand itself is a 
dimer (Schlessinger, 2000). This brings the cytoplasmic kinase domains of the RTKs into 
close proximity, such that the Tyr residues within the activation loop can be 
phosphorylated. This stabilizes the conformation of the catalytic domain of the RTK, and 
allows its full activation. The RTK then phosphorylates several Tyr residues either within 
its own sequence, as in the case of the EGF receptor (EGFR), or in a closely-associated 
docker protein, as in the case of the FGF receptor (FGFR). FGFR phosphorylates the 
docker protein FGF receptor substrate 2 (FRS2), and the phosphorylated Tyr (pTyr) 
residues on FRS2 serve as binding sites for downstream signaling molecules. (Pawson 
and Nash, 2000). These docking and activation complexes subsequently serve as docking 
sites for further downstream signaling molecules.  
 
1.2.2 Intracellular pathways 
 Once the extracellular signal has been recognized by the receptor, it has to be 
propagated intracellularly to elicit a proper cellular response. The paradigmatic model in 
intracellular signaling is the use of modular domains in protein-protein interactions to 
propagate the signal. These domains recognize specific amino acid (a.a) sequences, post-
translational modifications such as phosphorylated Tyr or Thr/Ser residues, chemical 
second messengers or lipids to propagate the signal (Pawson and Nash, 2003). A few of 
these domains, such as the src homology 2 (SH2) and the phospho-Tyr binding (PTB) 
domains recognize pTyr residues in a specific motif. Other domains such as the 14-3-3, 
forkhead associated (FHA) and WD40 domains recognize phosphorylated Ser and Thr 
 4
residues. The src homology 3 (SH3) domains, on the other hand, have been known to 
recognize and bind to proline- (Pro) rich sequences (Pawson and Nash, 2000).  
 Activation of RTKs occur upon ligand binding, after which the phosphorylated 
Tyr residues on the activated RTKs or their respective docking proteins form binding 
sites for SH2 or PTB domains of downstream cytoplasmic adaptors and enzymes. 
Proteins that are recruited to RTKs include growth factor receptor-bound 2 (Grb2), the 
p85 subunit of the phosphoinositide 3’-kinase (PI3K) and phospholipase Cγ (PLCγ). 
These adaptors and enzymes in turn often serve as connectors to other downstream 
signaling molecules by interacting with them through other domains, thus recruiting them 
to the active complex at the membrane. This interaction process results in the activation 
of other signaling molecules, either due to membrane anchoring, Tyr phosphorylation by 
the RTK, or both (Schlessinger, 2000).  
 Recruitment of each of these adaptors and enzymes allows activation of a limited 
number of distinct signaling pathways by RTKs within the cells. The specificity of 
cellular responses from these limited pathways is achieved from the use of modular 
domains within these adaptors. Therefore while a single molecule may be involved in 
different signaling pathways, its association with different protein partners elicits distinct 
and unique responses for each signal received. For example, the recruitment and 
activation of PLCγ allows the hydrolysis of its substrate phosphatidyl inositol 4,5- 
bisphosphate [PtdIns(4,5)P2], ultimately resulting in the release of two second 
messengers, inositol 1,4,5-trisphophate [Ins(1,4,5)P3] and subsequently Ca2+, and 
diacylglycerol (DAG).  On the other hand, activation of the phospholipid kinase PI3K 
leads to the phosphorylation of PtdIns(4,5)P2 and induction of the protein kinase B 
(PKB/Akt) survival pathway (Schlessinger, 2000). In a similar manner, the recruitment of 
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Grb2 initiates one of the main signaling pathways in the cell, the Ras-ERK (extracellular 
signal-regulated kinase) pathway.  
 
1.3 Overview of the Ras-ERK signaling pathway 
 The Ras-ERK signaling pathway is central to the cellular and physiological 
functions of survival, growth, development, differentiation and transformation (Johnson 
and Lapadat, 2002). This pathway, as shown schematically in Figure 1.3.1, represents one 
of the best understood and thoroughly studied pathways, even while newer components 
and regulatory mechanisms are being discovered. Briefly, upon ligand binding, the RTK 
becomes phosphorylated on specific Tyr residues, either on itself or its cognate docker 
protein. This allows Grb2 to recognize and bind to the RTK via its SH2 domain, while 
simultaneously interacting with another protein Sos, a guanine nucleotide exchange 
factor, which is an activator of the Ras family of small guanosine triphosphatases 
(GTPases). By interacting with Grb2, Sos is translocated to the membrane, which results 
in the activation of Ras. This then induces a sequential phosphorylation relay involving 
three kinases, Raf, MEK and ERK. The net result is the activation of ERK, which then 
enters the cell nucleus, and phosphorylates its transcription factor substrates. Genes that 
are under the control of these transcription factors consequently experience an 
upregulation in various combinations in their expression. The individual components of 
this pathway are introduced in greater depth in the following sections. 
 
1.3.1 Components of the Ras-ERK signaling pathway 
1.3.1.1 Grb2 
 Grb2 (then called Sem-5) is a widely employed docker protein in cells and is 
























Figure 1.3.1 Schematic representation of the Ras-ERK pathway induced by 
RTKs.
Binding of growth factors to the extracellular domain of RTKs leads to 
dimerization and activation of the cytoplasmic kinase domains through 
autophosphorylation. RTKs recruit the Grb2/Sos complex to the membrane via 
their phosphorylated Tyr residues. The resulting activation of Ras by Sos leads to 
the sequential phosphorylation an activation of the kinases Raf, MEK and ERK. 
Active ERK translocates to the nucleus to phosphorylate transcription factors such 
as Elk1, allowing them to initiate gene expression from their downstream 
promoters.
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Caenorhabditis elegans (C. elegans) vulva induction pathway (Clark et al., 1992). Two 
other independent groups later discovered the mammalian homologue (Matuoka et al., 
1992; Lowenstein et al., 1992), which was given the name growth factor receptor bound 
protein 2 (Grb2). Structurally, Grb2 comprises 3 domains – one SH2 domain flanked by 2 
SH3 domains (Schlessinger and Lemmon, 2003). The SH2 domain of Grb2 primarily 
recognizes and binds to pTyr residues in the motif pYXN (where ‘X’ represents any 
amino acid). In quiescent cells, Grb2 are cytoplasmically localized. Upon growth factor 
stimulation of the RTK, Grb2 translocates to the plasma membrane by binding specific 
pTyr on the RTK via its SH2 domain (Yamazaki, et al., 2002). Other proteins, such as the 
FRS2 (Kouhara et al., 1997; Hadari, et al., 1998) and Shc (Skolnik et al., 1993) docking 
proteins also contain this pTyr motif, and are consequently also able to bind to the SH2 
domain of Grb2 upon RTK activation. 
 SH3 domains are among the most common protein binding domains. They 
typically bind to proline (Pro)-rich sequences by recognizing the motif PXXP, and the 
combination of the motif’s neighbouring residues and basic residues such as arginine 
(Arg) or lysine (Lys) confers ligand specificity (Pawson and Nash, 2003). There are two 
classes of SH3 domains. The N-terminal SH3 domain of Grb2 belongs to Class II, which 
recognizes the motif PXXPXR (Feng et al., 1994). A large number of signaling proteins 
are able to bind to this SH3 domain of Grb2, including Sos (Buday and Downward, 
1993). In contrast, the C-terminal SH3 domain of Grb2 belongs to Class I, and recognizes 
the motif PXXXRXXKP (Lock et al., 2000). This C-terminal SH3 domain has so far been 
reported to bind only to Gab1 (Grb2-associated binder 1) and SLP-76 (Schaeper et al., 
2000; Lewitzky et al., 2001).  
 As with most SH3 domain interactions, the N-terminal SH3 domain of Grb2 binds 
constitutively to the Pro-rich sequences within the C-terminus of Sos (Pawson and Nash, 
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2003). Upon stimulation, Grb2 is recruited to the activated RTK via its SH2 domain. Its 
constitutive interaction with Sos through its SH3 domain means that Sos is also 
translocated to the signaling complex at the membrane. This then allows Sos to be in 
sufficiently close proximity with its membrane-bound substrate, Ras, which then results 
in the activation of Ras and downstream propagation of the signal.  
 The central role of the Ras-ERK pathway in development, together with the 
critical function of Grb2 within this pathway, implies that Grb2 plays an important part in 
development. Mouse embryos lacking both alleles of Grb2 are not viable at E4.0 days 
(Cheng et al., 1998), while mutating one of the alleles so that the protein no longer binds 
pTyr also results in embryonic lethality by 11.5 days, mostly resulting from placental 
defects (Saxton et al., 2001). These studies highlight the importance of Grb2 in RTK 
signaling during development.  
 
1.3.1.2 Sos 
 Sos (son of sevenless) was first identified in Drosophila in a genetic screen as a 
crucial downstream target of the RTK sevenless (Simon et al., 1991). There are two 
mammalian homologues, Sos1 and Sos 2 (Bowtell, et al., 1992). Sos is a guanine 
nucleotide exchange factor (GEF) for small GTPases of the Ras and Rac family by 
allowing exchange of GDP for GTP, thereby converting the GTPases from their inactive 
form to the active form. Sos contains multiple domains, including RhoGEF, RasGEF and 
pleckstrin homology (PH) domains as well as several Pro-rich sequences that bind the N-
terminal SH3 domain of Grb2 (Nimnual and Bar-Sagi, 2002).  
 Sos is localized to the membrane via Grb2 in RTK signaling. Supporting evidence 
is presented by replacing the Pro-rich sequences of Sos1 with a membrane targeting 
sequence from Ras. This negates the necessity for the interaction between Grb2 and Sos1 
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(Quilliam et al., 1994). Secondly, the Grb2-null phenotype in mice is rescued when a 
fusion protein carrying the SH2 domain of Grb2 in the C-terminus of Sos1 is expressed 
(Cheng et al., 1998).  
 The importance of Sos in development is seen in sos1-null mice. They are 
embryonic lethal, due to an impairment in placental development, and low ERK activity 
in the placenta (Qian et al., 2000). Furthermore, sos1 lacking cells are resistant to 
transformation by activated RTKs. This is reversed by a constitutively active form of Ras, 
which is a downstream target of both the RTK and Sos. This emphasizes the importance 
of Sos function, both in normal development and in the early stages of RTK-induced 
transformation leading to oncogenesis. 
 
1.3.1.3 Ras 
 Ras (rat sarcoma) is the first member of the small GTPases to be discovered. It is 
a 21kDa protein from a family consisting of more than 150 members, and is 
evolutionarily conserved in yeast, Dictyostelium, C. elegans, Drosophila, higher animals 
and plants (Colicelli, 2004). Ras is activated by a diversity of extracellular signals 
through RTKs and G-protein coupled receptors (GPCRs), and is involved in the 
regulation of cell proliferation, differentiation, survival, cytoskeletal reorganization, lipid 
metabolism and apoptosis. 
 Ras acts as a molecular switch that cycles between an inactive GDP-bound state 
and an active GTP state (Wittinghofer, 1998; Dhillon et al., 2007). In quiescent cells, 
most of the cellular Ras exists in the inactive GDP-bound state. Upon activation, the GDP 
is exchanged for GTP, which is facilitated by guanine nucleotide exchange factors 
(GEFs), such as Sos. Most transmembrane receptors, including RTKs activate Ras by 
recruiting one of its GEFs to the plasma membrane to be in close proximity with Ras. As 
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a GTPase, Ras intrinsically possesses the capacity to hydrolyze GTP back to GDP, 
essentially inactivating itself. This constitutes a built-in mechanism to terminate 
propagation of the signal from the activated RTK, and ensures that the life span of the 
signal only lasts for as long as needed. However, the intrinsic GTP hydrolyzing activity of 
GTPases is very inefficient, thus necessitating the assistance of GTPase activating 
proteins (GAPs) such as RasGAP. The relative amounts of the two states of Ras, and 
hence its activity, depends on the balance between GEFs and GAPs.  
There are three main isoforms of Ras, namely H-, K- and N-Ras. They share 
approximately 90% similarity over most of their sequences, and are most divergent in the 
last 25 a.a residues. This divergent region is known as the hypervariable region (HVR) 
(Hancock, 2003). All three isoforms are farnesylated on conserved cysteine (Cys) 
residues forming the motif CAAX within this region but H-Ras and N-Ras also undergo 
palmitoylation on additional  Cys residues. K-Ras lacks these Cys residues, but instead 
contains a poly-lysine stretch in its HVR. H-Ras and K-Ras were first discovered as 
oncoproteins of the Harvey and Kirsten strain of murine sarcoma virus (Wong-Staal et 
al., 1981; Weinberg, 1982), while N-Ras was found in a neuroblastoma cell line (Hall et 
al., 1983). The structure of the three isoforms of Ras is represented schematically in 
Figure 1.3.1.3. 
Physiologically, K-Ras has been found to be essential for mouse development. A 
homozygous loss of both alleles of this Ras isoform results in embryonic lethality 
(Johnson et al., 1997; Koera et al., 1997). In contrast, H-Ras and N-Ras single and double 
knock-out mice do not show any defects in development and were embryonically viable, 
suggesting that these two isoforms are dispensable for development (Esteban et al., 
2001). While it is possible that the function of K-Ras cannot be fully compensated for by 










Figure 1.3.1.3 The primary structure of Ras isoforms.
The three isoforms of Ras are highly conserved except for their C- 
terminal hypervariable region (HVR) that contains the membrane- 
targeting sequence. The C-terminal-most Cys residue (in blue) is 
farnesylated. The poly-Lys stretch of K-Ras is highlighted in red. The 
last four amino acid residues form the CAAX motif. 
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development that lack H- or N-Ras, making functional compensation impossible (Bar-
Sagi, 2001).  
The active, GTP-bound form of Ras specifically binds to and activates a number 
of downstream ‘effector’ proteins. The Raf kinases, the p110 catalytic subunit of PI3K 
and RalGEFs are often referred to as its classical effectors (Cullen, 2001). More recently 
identified effectors include RIN1 (Ras interactor 1), Tiam1, AF6, phospholipase Cε 
(PLCε) and Nore1 (Han and Colicelli, 1995; Roudriguez-Viciana et al., 2004). All Ras 
effectors contain a ‘Ras binding domain’ (RBD), which allows for a specific and high-
affinity interaction with the GTP-bound form of Ras. Through this interaction, Ras is able 
to activate its effectors by recruiting them to the membrane. This membrane translocation 
alone is often sufficient for the activation of the effectors, which was demonstrated when 
effectors fused with the Ras C-terminal targeting motif were activated when artificially 
membrane anchored (Oldham et al., 1996). Although the Ras isoforms all contain an 
identical N-terminal effector binding domain, specific differential activation of the 
effectors possibly results from the different membrane microdomains to which they locate 
differently (Yan et al., 1998; Walsh and Bar-Sagi, 2001). Different affinities of the 
effector isoforms to the various Ras isoforms could also result in this phenomenon 
(Rodriguez-Viciana et al., 2004).  
 
1.3.1.4 Raf 
 The signal from activated Ras is transmitted through its effector, Raf. The viral 
oncogene v-Raf (rapidly growing fibrosarcomas) gene was first cloned by Rapp et al. 
(1983). Subsequently, its vertebrate orthologue was isolated and named c-Raf (Jansen et 
al., 1983). The gene encodes the protein Raf1 (or c-Raf), which possesses 
serine/threonine (Ser/Thr) kinase activity, and was the first protein kinase oncogene 
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characterized (Moelling et al., 1984). Homologues of Raf have been identified in higher 
vertebrates as well as C. elegans, Drosophila. In higher vertebrates, three isoforms of Raf 
have been identified, namely A-Raf, B-Raf and c-Raf (or Raf1). All the Raf isoforms are 
expressed ubiquitously, although B-Raf is more highly expressed in neurons (Wellbrock 
et al., 2004).  
 Structurally, the three Raf isoforms are very similar, and share three conserved 
regions (CR), CR1-3. The Ras binding domain (RBD), which is common to all three 
isoforms, is contained in the N-terminal CR1, and binds to GTP-bound Ras with high 
affinity. In addition to the RBD, CR1 also contains a Cys-rich domain. Both the RBD and 
Cys-rich domain are essential in targeting Raf1 to the plasma membrane (Wellbrock et 
al., 2004). CR2, which is also located in the N-terminus of the protein, contains several 
Ser and Thr residues, of which one forms a Ser phosphorylation site which is part of the 
consensus motif for the interaction with the adaptor protein 14-3-3 (S259 in Raf1). The 
N-terminal half of Raf is collectively known as the regulatory domain, and is responsible 
for holding the protein in an inactive conformation in unstimulated cells. The C-terminal 
CR3 encompasses the catalytic kinase domain of Raf (Wellbrock et al., 2004). The 
structure of Raf is shown schematically Figure 1.3.1.4.  
 The activation of Raf is a complex process, involving intra- and inter-molecular 
interactions, membrane translocation, phosphorylation and de-phosphorylation 
(Wellbrock et al., 2004). In the unactivated state, Raf is phosphorylated on certain Ser 
residues, of which two (Ser259 and Ser621) form part of the consensus binding motif 
R(S/T)XpSXP for the 14-3-3 adaptor proteins. When bound to 14-3-3, Raf remains in an 
inactive state in the cytosol. When cells are stimulated with growth factors, GTP-bound 
Ras recruits Raf to the plasma membrane by binding to the RBD (Wittinghofer and 
Nassar, 1996). It is thought that recruitment to the plasma membrane brings 
CR1 CR2 CR3







Regulatory domain Catalytic domain
1 648
Figure 1.3.1.4 Schematic representation of the primary structure of 
Raf.
The different domains and phoshorylation sites for Raf1 are shown here. 
CR1 contains the Ras binding domain (RBD) and a Cys-rich domain 
(CRD). S259 within CR2 and S621 in the C-terminal tail form binding 
sites for 14-3-3 adaptor proteins. Phosphorylation of S338, Y341, 
T491and S494 is essential for activation. T491 and S494 lie within the 
catalytic domain in CR3. Positive phosphorylation sites are represented in 
blue while negative sites are represented in red. 
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Raf closer to its modulators. Additionally, the interaction between Ras and Raf is also 
believed to release intramolecular inhibitory interactions arising from the N-terminal 
regulatory domain of Raf (Wellbrock et al., 2004).  
 Displacement of 14-3-3 from Raf follows Ras binding, as a result of the 
dephosphorylation of Raf by PP2A and/or PP1 (Abraham et al., 2000; Jaumot and 
Hancock, 2001). Phosphorylation then occurs on Ser338 and Tyr341 just upstream of 
CR3. While it has been shown that the Src family of Tyr kinases phosphorylates the 
Tyr341 residue (Marais et al., 1995), the identity of the kinase responsible for 
phosphorylating Ser338 remains inconclusive. Full activation of Raf is achieved when 
phosphorylation of two residues within the catalytic domain, Thr491 and Ser494 occurs, 
possibly through auto-phosphorylation by Raf itself. While all three isoforms of Raf are 
direct effectors of Ras, they show isoform-specific differences in terms of expression, 
activation and their function in the Ras-ERK signaling pathway (Pritchard et al., 1995; 
Wu et al., 1996; Marais et al., 1997; Chong et al., 2001).  
 Germline loss-of-function mutations in all three Raf isoforms lead to distinct 
phenotypes, implying that they are not functionally redundant. Mice lacking the a-raf 
gene are not embryonic lethal, but die shortly after birth due to neurological and 
gastrointestinal abnormalities (Pritchard et al., 1996). On the other hand, mice lacking 
functional b-raf and raf1 genes are embryonic lethal, and hence both genes are considered 
essential for development. The lack of functional B-Raf in mice leads to vascular defects, 
while raf1-/- embryos die due to increased apoptosis in the fetal liver and placental 
defects (Wojnowski et  al., 1997; Mikula et al., 2001). Interestingly, further studies on 
these cells show that the MEK/ERK pathway is intact, implying that compensation by the 




 MEK 1 (MAPK/ERK kinase 1) was first discovered as a Ser/Thr kinase capable 
of activating ERK1/2 and identified as a genuine substrate of the Raf1 kinase (Crews et 
al., 1992; Kyriakis, et al., 1992). C. elegans, Drosophila and Xenopus all encode a single 
MEK protein in their genomes, but mammals possess two closely related isoforms, 
MEK1 and MEK2 that share about 80% similarity (Zheng and Guan, 1993). There are 
currently six members of the MEK family, MEK1-6, that have been identified (Lee and 
McCubrey, 2002). These have been shown to be responsible for activating members of 
the MAPK family other than ERK1 and ERK2, such as p38MAPK, Jun kinase (JNK) and 
ERK5 (Derijard et al., 1995; Zhou et al., 1995; Han et al., 1996; Wu et al., 1997; 
Kamakura et al., 1999).  
 Activation of MEK1 depends on the phosphorylation of two Ser residues by Raf1 
(Kyriakis et al., 1992). The two Ser residues (Ser217 and Ser221) are contained within 
the motif SXAXS/T located in the activation loop (Alessi et al., 1994, Zheng and Guan, 
1994). Two other regulatory phosphorylation sites are present in MEK1, namely Ser212 
and Ser298. Phosphorylation on Ser298 by PAK1 (p21-activating kinase) primes MEK1 
for activation by Raf1 (Coles and Shaw, 2002), while phosphorylation on Ser212 results 
in a strong decrease in MEK1 activity (Gopalbhai et al., 2003).  
 The two MEK isoforms, MEK1 and MEK2 show very different physiological 
functions despite their similar biochemical properties and expression patterns. Studies 
show that mice lacking Mek1 are embryonic lethal at day 10.5 (Giroux et al., 1999), 






 The extracellular signal-regulated kinases (ERKs) are Ser/Thr kinases that are 
activated in response to a diverse range of signals, and were first discovered in a screen 
for protein kinases which are activated upon growth factor stimulation (Boulton et al., 
1991). Although their effects can vary based on the cellular context and duration of 
activation, the ERKs are generally positively-associated with cell proliferation, growth, 
migration and differentiation (Schaeffer and Weber, 1999).  
The ERK subfamily, which is part of the MAPK superfamily, consists of at least 
eight members (Pearson et al., 2001; Bogoyevitch and Court, 2004). Two very closely 
related isoforms of ERK, ERK1 (44kDa) and ERK2 (42kDa) are possibly the only 
physiological substrates of MEK1/2. Upon stimulation, ERK1 and ERK2 are co-
phosphorylated on Tyr and Thr residues in the TEY motif, where the Thr residue is 
phosphorylated by the upstream kinases, MEK1/2. A conformational change in the ERK 
protein follows its phosphorylation so that a pocket is formed to position Ser or Thr 
residues of the substrate for phosphorylation (Zhang et al., 1994; Canagarajah et al., 
1997). This conformational change is also necessary for homodimerization, which is a 
prerequisite for the nuclear translocation of ERK (Khokhlatchev et al., 1998). Activated 
ERK in turn phosphorylates its substrates such as the transcription factor Elk1 to bring 
about changes in gene expression (Yoon and Seger, 2006).  
 
1.3.1.6.1 ERK substrates 
 The ERKs are proline-directed kinases that phosphorylate their substrates mainly 
on Ser/Thr residues contained in an (S/T)P motif. Unlike their upstream kinases Raf and 
MEK, ERKs have a wide range of substrates, of which there are currently approximately 
160 reported (Yoon and Seger, 2006). Nuclear transcription factors feature prominently, 
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such as the Ets family, of which Elk1 is a member (Yordy and Muise-Helmericks, 2000). 
Upon activation, ERK phosphorylates Elk1 on specific residues, thus enhancing its 
binding to DNA, which then recruits coactivators like CBP and p300, and eventually 
induces the transactivation of genes. Other nuclear substrates reported include NFAT, 
MEF-2, c-fos, c-jun and c-myc (Krishna and Narang, 2008). The cytosolic substrates of 
ERK are more recent discoveries, and are often part of negative feedback loop that 
regulates ERK itself. For example, FRS2, Sos1 and Raf1 have ERK phosphorylation 
sites, which serve to negatively regulate their function, and hence attenuate ERK 
signaling (Langlois et al., 1995; Lax et al., 2002; Dougherty et al., 2005). Other cytosolic 
substrates include the ribosomal 6 kinase (RSK) family members, which can 
independently translocate into the nucleus and phosphorylate a distinct set of substrates 
there after activation (Krishna and Narang, 2008).  
 
1.3.1.6.2 Scaffolds 
 Scaffold proteins play an important role in signaling by bringing the different 
components of a signaling cascade together, and in modulating the strength, amplitude 
and duration of the signaling pathway. In addition to providing efficiency in signal 
transduction, scaffold proteins also insulate individual pathways from “noise” or “signal 
drifting” from adjacent signaling pathways, thereby providing specificity in terms of 
enzyme-substrate reactions and temporal regulation. Like most other pathways, the Ras-
ERK pathway also employs different scaffold proteins to regulate the propagation of its 
signal. 
 Kinase suppressor of Ras (KSR) is perhaps one of the most well-characterized 
scaffold proteins of the Ras-ERK signaling pathway, and was first identified as a 
regulator of Ras signaling in Drosophila (Therrien et al., 1995) and C. elegans (Kornfeld 
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et al., 1995). Contrary to its name, KSR is a positive regulator of Ras-ERK signaling 
pathway, capable of binding to Raf, MEK and ERK (Kolch, 2005). Its sequence contains 
several distinct domains, of which one is a kinase-like domain; however, it is unclear if 
the kinase domain is functional (Dhanasekaran et al., 2007). The interaction of KSR with 
MEK is constitutive, but its interaction with Raf and ERK appears to be stimulation 
dependent (Kolch, 2005).  
 The scaffolding function of KSR is in turn dynamically regulated through its 
interaction with many different signaling molecules. In quiescent cells, KSR interacts 
with MEK and PP2A, and this complex is held in the cytosol through the interaction 
between KSR and 14-3-3 (Ory et al., 2003; Ory and Morrison, 2004). Growth factor 
stimulation leads to the dephosphorylation of KSR1 at specific Ser residues involved in 
14-3-3 binding via PP2A, and the resultant dissociated KSR-MEK complex translocates 
to the plasma membrane. Once there, KSR completes its scaffolding function by 
assembling the upstream Raf and downstream ERK together with MEK (Kolch, 2005; 
Dhanasekaran et al., 2007).  
 Other scaffolds include CNK (connector enhancer of KSR), a multi-domain 
protein that is believed to be involved in the activation of Raf (Clapéron and Therrien, 
2007), paxillin, a cytoskeletal protein which provides context-specific scaffolding with 
hepatocyte growth factor (HGF)-mediated epithelial cell morphogenesis (Ishibe et al., 
2003) and β-arrestin, which facilitates the endocytic internalization process of β-arrestin 
scaffolded ERK and GPCRs (Dhanasekaran et al., 2007; Song et al., 2009).  
 
1.4 Regulation of Ras-ERK signaling 
 As the Ras-ERK signaling cascade plays a critical role in cellular function, 
different mechanisms to control the pathway at each step exist. These controls provide 
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fine-tuning measures to modulate the strength and duration of the signal, as well as 
checks and compensations in situations where signaling may be deregulated. The high 
correlation between disease states such as cancer and deregulated ERK signaling 
underscores the importance of this pathway in normal biological function. 
 Attenuation of signaling by silencing of cell surface receptors is a key regulatory 
mechanism employed by cells (Haglund and Dikic, 2005). This occurs through receptor 
endocytosis, where ligand-bound receptors are internalized in endosomes, and the 
receptors are either recycled back to the plasma membrane, or targeted for degradation 
via a process known as ubiquitination. Ubiquitin is a small versatile protein that, when 
covalently attached to a lysine (Lys) residue of its target protein, directs the 
compartmentalization of that target and its subsequent degradation through the lysosomal 
or proteasomal pathway (Kirkin and Dikic, 2007). The process of ubiquitination involves 
an enzymatic cascade, which requires a ubiquitin-activating enzyme, E1, a ubiquitin-
conjugating enzyme, E2, and a ubiquitin-ligase, E3 (Kirkin and Dikic, 2007). The E3 
ligases bind specific sequences within their target proteins and bring them into close 
proximity with the E2 conjugase, thus allowing ubiquitin transfer. 
 One of the best understood examples of downregulation through ubiquitination is 
the case of EGFR and c-Cbl (Casitas B-lineage lymphoma) (Thien and Langdon, 2001; 
Dikic et al., 2003). A Tyr-kinase binding (TKB) domain in c-Cbl binds to sequence 
specific phosphorylated Tyr residues on activated EGFR, and targets it for ubiquitination. 
After the receptor is ubiquitinated, it is sorted and internalized into endosomes and 
lysosomes, resulting in the termination of signaling from the active receptor (Haglund and 
Dikic, 2005; Dikic and Schmidt, 2007). 
 As most of the proteins along the Ras-ERK pathway require phosphorylation to 
become active, it is reasonable to expect that phosphatases play a major role in regulating 
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this pathway. Protein Tyr phosphatases such as PTP1B dephosphorylate RTKs on their 
activating residues to return them to their basal state of activity and attenuate signaling 
(Ostman et al., 2006). Downstream of RTKs, the Ser/Thr phosphatase PP5 
dephosphorylates the essential activating site, Ser338 on Raf1 (von Kriegsheim et al., 
2006; Raman et al., 2007). The double phosphorylation of Thr and Tyr residues on ERK 
in the TEY motif located in the kinase domain can also be removed by dual specificity 
phosphatses such as DUSP6/MKP-3 and DUSP1/MKP-1 (Owens and Keyse, 2007).  
 One of the most efficient methods of regulating a signaling pathway would be to 
incorporate a feedback loop into the pathway. The tight regulation required by the Ras-
ERK pathway implies that such a feedback mechanism should exist as part of its 
regulatory network. Currently, it has been reported that activated ERK phosphorylates 
Sos1, leading to a decrease in its association with Grb2, and consequently resulting in 
decreased Ras activation by Sos1 (Langlois et al., 1995; Dong et al., 1996; Shin et al., 
2008). Phosphorylation of Raf on different sites by activated ERK similarly desensitizes 
it to further stimulation (Dougherty et al., 2005). This desensitization is not limited only 
to the activated Raf molecules, but occurs on the entire cellular Raf population, thus 
rendering the entire cell refractory to further stimulation.   
 Another method of keeping signaling under control is through the use of 
intracellular inhibitors. In the Ras-ERK signaling pathway, perhaps one of the most well 
studied inhibitors is RKIP (Raf kinase inhibitor protein). Rather than interfering with the 
catalytic activity of kinases in the pathway as in the case of the phosphatases, RKIP binds 
to both Raf and MEK and prevents their physical interaction (Kolch, 2005). In the 
absence of phosphorylation by Raf, MEK is unable to activate ERK. RKIP functions 
mainly in unstimulated cells to ensure that aberrant signaling does not occur. During 
mitogen stimulation, RKIP dissociates from Raf to allow MEK activation (Kolch, 2005).  
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 Unlike RKIP, the inhibitor Sef (similar expression to FGF) is a product of an 
FGF-induced gene, and its expression is a result of the Ras-ERK pathway itself 
(Furthauer et al., 2002). While the exact mechanism of inhibition remains elusive, it 
appears the Sef selectively binds to the activated MEK-ERK complex, and prevents the 
nuclear translocation of active ERK, thus preventing phosphorylation of its nuclear 
targets (Torri et al., 2004; Kolch 2005).  
 Two other groups of proteins known to inhibit the Ras-ERK pathway downstream 
of RTK signaling are the Sprouty family and the related SPRED family of proteins. These 
proteins are described in greater detail in a later section. 
 
1.5 The ERK pathway in cancer 
 Historically, ERK signaling is synonymous with cell proliferation, growth, 
survival and migration, processes essential to normal cellular function and physiology. It 
is now clear that deregulation of this pathway, with the consequently disrupted cellular 
and physiological processes, plays a key part in cellular transformation, oncogenesis and 
metastasis (Roberts and Der, 2007). In many instances of cancer, early signaling events 
such as the overexpression of RTKs or activating mutations in RTKs occur, ultimately 
resulting in the activation of the ERK pathway (Bache et al., 2004; Dhillon et al., 2007). 
Besides RTKs, the high frequency of activating mutations centred around the Ras-Raf 
axis suggests that this is a regulatory hotspot of the pathway. Mathematical modeling also 
supports this observation (Dhillon et al., 2007). Activating mutations in K-Ras and N-Ras 
occur in varying frequencies in different types of cancer (Downward, 2003). These 
mutations, invariably found at codons 12, 13 or 61, prevent efficient GTP hydrolysis, 
maintaining Ras in an active, GTP-bound state.  
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 Besides Ras, the b-raf gene is found mutated in 66% of malignant melanomas, 
and at a lower frequency in many other human cancers (Davies et al., 2002). The most 
common mutation is a change from valine (Val) 600 to glutamate (Glu) within the 
activation loop. This induces the constitutive activation of the catalytic activity of B-Raf 
(Wan et al., 2004). In contrast, mutations in Raf1 are very rare, and no A-raf mutations 
have been identified in cancers. However, it has been suggested that B-Raf 
heterodimerizes with Raf-1 to activate the ERK pathway in these cases (Garnett et al., 
2005; Rushworth et al., 2006). As the ERK signaling pathway is critical for the 
maintenance and progression of cancer, various MEK/ERK inhibitors are currently being 
studied for their potential as anti-cancer drugs (Roberts and Der, 2007).  
 
1.6 Sprouty 
1.6.1 Sprouty as an inhibitor of RTK signaling 
 Sprouty (Spry) was first discovered in Drosophila as a negative feedback inhibitor 
of RTK signaling in a screen aimed at identifying genes involved in tracheal branching 
(Hacohen et al., 1998). In Drosophila the branchless (bnl) gene encodes a homologue of 
the vertebrate FGF (Sutherland et al., 1996). The secreted Bnl protein activates the 
breathless (btl) FGF receptor, and guides tracheal cell migrations during the formation 
and patterning of the branching process. Loss-of-function mutations in the spry gene 
caused overactivity of the Bnl signaling pathway, resulting in excessive branching of the 
tracheal system, while overexpression of the spry gene product blocked induction of 
downstream effectors and branching by Bnl (Hacohen et al., 1998). The dSpry protein 
sequence was found to consist of 591 a.a. containing no known domains. Its most striking 
feature is a 124 a.a. stretch of Cys-rich residues that is flanked by non-Cys-containing 
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sequences. It was suggested then that dSpry was secreted by apical cells of primary 
branches so as to inhibit branching from adjacent stalk cells (Hacohen et al., 1998).  
 dSpry was again isolated in an independent genetic screen to identify new 
components of EGFR (epidermal growth factor receptor) signaling during eye 
development in Drosophila (Casci et al., 1999). In this study, Spry null mutants show 
enhanced recruitment of photoreceptor, cone and pigment cells to the eyes. Additionally, 
it was proposed that Spry is an intracellular protein and associated with the inner surface 
of the plasma membrane, as opposed to an extracellular protein, as suggested earlier by 
Hacohen et al. (1998). The study also established Spry as a general inhibitor of RTK 
signaling Drosophila, as it was found to inhibit not only FGFR and EGFR signaling, but 
also that of two unrelated RTKs, Torso and Sevenless. Apart from inhibiting the activity 
of the RTKs, the expression of the spry gene was also induced by those same RTKs. 
Furthermore, dSpry was found to interact with Drk, an SH2-SH3 containing adaptor 
protein homologous to mammalian Grb2, and Gap1, a Ras GTPase-activating protein, 
two components of the Ras-ERK pathway. This data adds strength to the argument that 
dSpry acts as a negative feedback inhibitor of RTK signaling in general, by attenuating 
the signal at a point in between the RTK and Ras (Casci et al., 1999). 
 
1.6.2 Primary structure of Spry 
 After the initial discovery of dSpry, four mammalian homologues, Spry 1-4, have 
been identified (Hacohen et al., 1998, de Maximy et al., 1999; Minowada et al., 1999). 
All four isoforms show significant homology with dSpry across the Cys-rich domain, 
which is conserved with about 51% identity within that region (Hacohen et al., 1998; 
Minowada et al., 1999). Within the Cys-rich domain, a putative RBM (Raf1-binding 
motif) is also present. There is little similarity in sequences outside of this Cys-rich 
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residue between the isoforms except for a short stretch in the N-terminus that is centred 
around a conserved Tyr residue motif (Tyr55 in Spry2), NE/DYS/TXXP (Sasaki et al., 
2001). The mammalian Spry proteins range from 32 to 35 kDa, shorter than their 
Drosophila counterpart, which is approximately 63 kDa (Hacohen et al., 1998, de 
Maximy et al., 1999). The primary structure of the different mammalian Spry isoforms is 
shown in Figure 1.6.2.  
 A similar family of negative regulators containing a similar Cys-rich domain, 
named Spred (Sprouty-related proteins with an EVH-1domain) has also been identified 
(Wakioka et al., 2001). This family, consisting of two members contain an Enabled 
(Ena)/ vasodilator-stimulated phosphoprotein (VASP) homology (EVH) domain in the N-
terminus, a Cys-rich domain very similar to that of Spry in the C-terminus, and a central 
domain that mediates the binding to KIT, the KIT-binding domain (KBD) (Kim and Bar-
Sagi, 2004).  
 
1.6.3 Post-translational modifications on Spry 
 Spry has been reported to be phosphorylated on a number of residues within its 
sequence. Phosphorylation of Spry2 on the conserved Tyr55 is one of its most well 
characterized post-translational modifications. It was first shown that this particular Tyr 
residue is critical for the ability of Spry to inhibit FGF signaling. A point mutation on this 
residue abrogated the regulatory function of Spry (Sasaki et al., 2001). It was later 
demonstrated that the Tyr55 residue is phosphorylated upon FGF and EGF stimulation, 
and that its neighbouring a.a. residues in the ND/EYS/TXXP motif are required for the 
full inhibitory function of Spry (Rubin et al., 2003; Fong et al., 2003; Mason et al., 2004). 
Phosphorylation on Tyr55 also allows its interaction with the E3 ligase c-Cbl, which 








Figure 1.6.2 The structure and isoforms of Spry.
(A) A schematic representation of the structure of Spry. The residue numbers are 
according to their position in Spry. The conserved Y55 motif is shown in brown, and 
the expanded sequence shown is from Spry2. The Ser-rich region is shown in blue 
and the Raf-binding motif (RBM) is shown in red. (B) Sequence alignment of the 
three most commonly studied mammalian Spry isoforms. The conserved N-terminal 
Tyr residue is shown in red, and its surrounding motif in cyan. The Ser-rich region is 
highlighted in blue. The conserved residues within the Cys-rich domain are 
highlighted in yellow, while residues that do not retain sequence identity but retain 
functional homology are shown in orange. The PXXPXR SH3-binding motif of 
Spry2 is shown in pink.
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also been shown that Tyr55 phosphorylation plays a central role in its interaction with 
Grb2 (Lao et al., 2006). Although the Tyr kinase responsible for the phosphorylation of 
Tyr55 on Spry2 has been suggested to belong to the Src family, this has not been 
conclusively shown (Mason et al., 2004; Li et al., 2004). Dephosphorylation of this 
residue, on the other hand, has been attributed to the SH2-domain-containing phosphatase 
2 (SHP2) (Hanafusa et al., 2004), although it is possible that Spred1 is a more likely 
substrate (Chan et al., 2008). Further studies also show that additional phosphorylation on 
Tyr227 is required for maximal inhibitory activity of Spry2, although this could be due to 
a change in the tertiary structure resulting from mutating that residue (Rubin et al., 2005).  
 The observation that Spry2 migrated as two distinct bands in SDS-PAGE led to 
the conclusion that Spry2 is basally phosphorylated on specific Ser residues, leading to its 
characteristic electrophoretic migration pattern of two distinct protein bands 
(Impagnatiello et al., 2001). Later reports show that this particular phosphorylation plays 
an important role in maintaining a steady state level of Spry within the cell (DaSilva et 
al., 2006), as well as inhibiting the interaction between Spry2 and Grb2 (Lao et al., 2007). 
Dephosphorylation of a particular set of these Ser residues plays an important role in the 
ability of Spry2 to inhibit ERK phoshorylation, and that the Ser/Thr phosphatase 
responsible for this is PP2A.  
 Both Spry1 and Spry2 have also been shown to be palmitoylated on their C-
terminal Cys residues, which may facilitate their membrane anchoring (Impagnatiello et 
al., 2001).  
 
1.6.4 Sprouty localization 
 Spry was first postulated to be an extracellular protein (Hacohen et al., 1998; 
Kramer et al., 1999). It was later shown that dSpry is an intracellular protein that 
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associates with the inner leaflet of the plasma membrane (Casci et al., 1999). A similar 
localization pattern has been observed for the mammalian isoforms of Spry (Lim et al., 
2000; Impagnatiello et al., 2001; Hanafusa et al., 2002). However, this localization occurs 
only upon ligand stimulation, and in unstimulated cells, the proteins have a cytosolic (for 
Spry1 and 4) or microtubular localization (for Spry2). Translocation of the proteins is 
mediated by a 105 a.a sequence (residues 178-282 in Spry2) within the Cys-rich domain, 
also known as the Spry translocation domain (TD). The TD binds to the lipid 
phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2), which determines its cellular 
localization.  Mutation of a conserved arginine residue to aspartate (R252D in Spry2) 
abolishes lipid binding and hence membrane translocation. In the case of Spry2, this 
interferes with its ability to inhibit ERK phosphorylation (Lim et al., 2000). 
 
1.6.5 Inhibition of the Ras-ERK signaling pathway by Spry 
 It has been well established by different groups that one of the most recognizable 
functions of Spry is its capacity to modulate ERK signaling downstream of RTK 
activation (Impagantiello et al., 2001; Sasaki et al., 2003). Currently, there exists 
evidence from different groups with respect to the point of action of Spry on the Ras-
ERK pathway, these being at the point of receptor-ligand binding, upstream of Ras, 
upstream of Raf, and at the level of or downstream of Raf (Guy et al., 2003; Kim and 
Bar-sagi, 2004). 
The study conducted by Casci and colleagues (1999) demonstrated that dSpry is 
an intracellular protein that could potentially interact with Drk, the Drosophila 
homologue or Grb2, and Gap1 (a Ras-GAP protein). The implication is that dSpry is able 
to inhibit the ERK pathway by antagonizing a step that is common to the separate 
pathways induced by different RTKs through its interaction with these two proteins. 
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Although not conclusively shown, it was hypothesized that dSpry recruits Gap1 to the 
signaling complexes at the membrane, where it could then inactivate Ras. It was also 
suggested that by binding Drk, dSpry prevents the recruitment of Sos or another positive 
regulator of signaling, thereby blocking the activation of Ras. 
 Likewise, the evidence gathered to date indicates that mammalian Spry, like their 
Drosophila counterpart, are able to inhibit Ras-ERK signaling (Gross et al., 2001; 
Impagnatiello et al., 2001; Yusoff et al., 2002). Current reports show that mammalian 
Spry may act at different points along this pathway (Guy et al., 2003; Kim and Bar-Sagi 
et al., 2004). Adding to this complexity is the observation that the different mammalian 
Spry isoforms exhibit varying degrees of ERK inhibition based on the extracellular signal 
received and the specific individual pathways induced. Most of the research regarding 
ERK inhibition by mammalian Spry has concentrated on the Spry2 isoform, as it has been 
reported to exhibit the highest inhibitory effect on RTK signaling (Yusoff et al., 2002). 
The specific points of action are described in greater detail in the following sections. 
 
1.6.6 Points of action of Spry 
1.6.6.1 Upstream of Ras 
 There are at least two independent reports that indicate that Spry interacts with the 
adaptor protein Grb2 upstream of Ras, and that this interaction is essential for the 
inhibitory effect of Spry2. Hanafusa et al. (2002) proposed that a conserved N-terminal 
Tyr residue, Tyr55 in Spry2 and Tyr53 in Spry1, when phosphorylated upon RTK 
activation, becomes a binding site for the SH2 domain of Grb2. This would mean that 
Spry is able to effectively compete off the interaction of the Grb2-Sos complex with the 
phosphorylated Tyr residues on either the docker protein FRS2 or the adaptor protein 
SHP2. However, this conclusion does not explain the absence of interaction between 
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Spry4 and Grb2, since that particular Tyr residue is conserved in all the mammalian Spry 
isoforms. It also does not account for the observed different inhibitory effects on RTK 
signaling of the Spry isoforms (Yusoff et al., 2002), since in theory, all the Spry isoforms 
should be able to bind Grb2 equally well. Lastly, direct interaction between Grb2 and 
Spry was also not demonstrated, and the YXN motif recognized by the SH2 domain of 
Grb2 does not agree with the motif surrounding the Tyr55 residue. 
 A subsequent study has provided evidence that instead of the SH2 domain, Spry2 
binds directly to the N-terminal SH3 domain of Grb2. This disrupts its recruitment of 
Sos1 to the RTK complex at the plasma membrane (Lao et al., 2006). This interaction is 
mediated by the Pro-rich sequence, PXXPXR, at the C-terminus of Spry2. The 
distinguishing factor is that this particular motif is unique to Spry2, which helps to 
account for the observation that Spry2 is more effective at inhibiting ERK 
phosphorylation than Spry1 or Spry4. In order for this interaction to occur however, The 
conserved Tyr55 residue must first be phosphorylated, and as mentioned in Section 1.6.3, 
specific basally phosphorylated Ser residues, in particular Ser112 and Ser115 are 
dephosphorylated by PP2A (Lao et al., 2007). Interestingly, a recent report has shown 
that Tesk1 (testicular protein kinase 1) is able to prevent the dephosphorylation of these 
Ser residues, possibly by competing away PP2A (Chandramouli et al., 2007). Whether 
this constitutes a significant form of regulatory mechanism by Spry2 is currently 
unknown.  
 While both the above studies do not agree on the exact mechanistic details, they 
both support the same hypothesis that the Spry2-Grb2 interaction is essential for the 
inhibitory effect of Spry2 on ERK phosphorylation, and that its point of action is 
upstream of Ras. 
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1.6.6.2 Upstream of Raf 
 Some other studies offer an alternative view of the point of action of Spry. 
Evidence has been put forward to show that Spry is capable of inhibiting ERK 
phosphorylation downstream of an active Ras mutant, but not active Raf, and therefore 
implying that the point of action of Spry in this case is upstream of Raf (Yusoff et al., 
2002). In a separate study, it has been shown that Spry4 is able to inhibit the vascular 
endothelial growth factor (VEGF)-induced phosphorylation of ERK via a Ras-
independent pathway (Sasaki et al., 2003). This was accomplished through a Spry4-Raf1 
interaction, and the subsequent inhibition of activation of Raf1. The VEGF-induced 
activation of Raf1 was postulated to rely more on the PLCγ-PKCδ pathway than through 
Ras. It was however, not demonstrated how activation of Raf1 through PKCδ occurs. A 
later report suggested that Spry4 inhibits the PLCγ-PKCδ pathway by preventing the 
hydrolysis of phosphatidylinositol 4,5-biphosphate (PIP2) (Ayada et al., 2009). The 
interaction between Spry4 and Raf1 was shown to occur through a stretch of sequence 
known as the Raf binding motif (RBM), that is conserved in all the Spry isoforms. As this 
motif is conserved between all the mammalian Spry isoforms, this implies that all of them 
can potentially interact with Raf1. However, it is unknown why this mechanism of 
inhibition should be restricted only to a Ras-independent scenario. 
 
1.6.7 Regulation of receptor ubiquitination and endocytosis by Spry2 
 One of the most well-known interactions involving Spry2 is its association with 
the E3 ubiquitin ligase c-Cbl (Wong et al., 2001). Phosphorylation of the Tyr55 residue 
on Spry2 occurs upon RTK stimulation, which then forms part of a recognition motif for 
the TKB domain of c-Cbl (Fong et al., 2003). Interaction with c-Cbl causes Spry2 to 
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become ubiquitinated and subsequently sorted for proteasomal degradation (Rubin et al, 
2003; Hall et al., 2003).  
 Interestingly, the effect of the interaction between Spry2 and c-Cbl contradicts all 
other earlier observations made regarding Spry2 and its inhibitory effect on RTK 
signaling. By associating with c-Cbl, Spry2 is able to effectively compete with other c-
Cbl targets, such as EGFR. This results in reduced ubiquitination on EGFR, as well as its 
accompanying degradation, and a concurrent ubiquitination of Spry2 followed by its 
degradation (Wong et al., 2002; Hall et al., 2003). The EGFR signaling is thus sustained, 
and downstream events, such as ERK phosphorylation, are prolonged. A later study also 
showed that Spry2 is able to interact with both c-Cbl and the Cbl-interacting protein of 85 
kDa (CIN85), which serves to inhibit the processing of EGFR for endocytosis and 
degradation (Haglund et al., 2005). Evidence from structural analysis shows that Spry2 
has a higher binding affinity to c-Cbl than EGFR, making this mechanism of inhibiting 
EGFR ubiquitination and downregulation theoretically possible (Ng et al., 2008).  
 In contrast, a separate study claims that intracellular signaling can occur through 
endosome-internalized EGF-bound receptors, suggesting that endocytosis does not 
necessarily imply degradation of the internalized EGFR by default. The report indicates 
that Spry2 blocks endosome trafficking from early to late endosomes, by interacting with 
hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs), a key endocytic 
regulatory protein (Kim et al., 2007). The net result is a block in intracellular signal 
propagation via endosomally-localized EGFR. 
 While it would appear that the function of mammalian Spry is more complex than 
in Drosophila, since it can act as both a positive and negative feedback regulator of RTK 
signaling, fewer studies have also been done in the Drosophila system (Christofori, 
2003). It may therefore be possible that dSpry plays other as yet identified roles. 
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1.6.8 Physiological functions 
 Spry expression has been detected in different tissues, including the brain, heart, 
lung, kidney, gut and muscle and across different stages of the life cycle, from embryonic 
to adult (Minowada et al., 1999; de Maximy et al., 1999; Chambers and Mason, 2000; 
Thum et al., 2008). Expression of Spry has been shown to be correlated with the sites of 
action by FGF, implying a close association in their physiological functions (Chambers et 
al., 2000) and Spry proteins have been shown to be involved in regulating different 
physiological processes where FGF signaling plays a crucial role. These are described in 
further detail in the following sections.  
 
1.6.8.1 Inhibition of cell proliferation and migration 
 The mammalian Spry proteins have been reported to inhibit cell proliferation in 
response to growth factors and serum (Gross et al., 2001; Lee et al., 2001; Yigzaw et al., 
2001). Intuitively, while it is likely that Spry is able to inhibit cell proliferation via ERK 
signaling, as shown in B-cell lymphomas (Frank et al., 2009), it is also possible that the 
anti-proliferative effects of Spry are independent of its effect on ERK phosphorylation. 
Spry2 was found to reduce the proliferation of non-small cell lung cancer (NSCLC) cells 
with no discernible effect on phospho-ERK levels (Sutterlüty et al., 2007). Another report 
has recently proposed that Spry2 affects cell proliferation by modulating the 
phosphorylation status of the tumour suppressor protein PTEN (phosphatase and tensin 
homolog deleted on chromosome 10) (Edwin et al., 2006). Based on the information 
available, it would appear that Spry is able to inhibit cell proliferation through different 
pathways, possibly depending on the cell type and the stimulus received. 
 Spry proteins have also been reported to inhibit cell migration in wound-healing 
assays (Lee et al., 2001; Yigzaw et al., 2001; Wang et al., 2006). In the case of Spry2, it 
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has been proposed that this function involves the regulation of protein tyrosine 
phosphatase 1B (PTP1B) (Yigzaw et al., 2003), and the inhibition of Rac activation, since 
an active mutant of Rac1 is able to rescue the inhibitory effect of Spry2 on migration 
(Poppleton et al., 2004). The negative effect of Spry proteins on migration appears to be 
separate and independent on its anti-proliferative function. Regulation of PTP1B by 
Spry2 affected cell migration, but had no detectable effects on cell proliferation (Yigzaw 
et al., 2003), while Spry4 is also able to inhibit cell migration without any perceptible 
consequences on cell proliferation in prostate cancer cells (Wang et al., 2006).  
 
1.6.8.2 Inhibition of branching morphogenesis 
 Collective evidence from separate loss-of- and/or gain-of-function experiments 
performed demonstrates that Spry is involved in regulating the branching process of 
different tissues and organs. The first instance of such an observation was during the 
identification of dSpry, where the Drosophila protein was found to inhibit tracheal 
branching (Hacohen et al., 1998). Subsequently, it was shown that mammalian Spry2 
fulfills a similar function in mice, where it was demonstrated that loss of Spry2 function 
generated from anti-sense oligonucleotides enhances lung branching morphogenesis 
(Tefft et al., 1999), whereas overexpression of Spry2 leads to reduced levels of branching 
(Mailleux et al., 2001).  
 Similar observations were made in kidney development. Targeted ectopic Spry2 
expression in mouse kidney uretic buds leads to reduced ureteric branching and postnatal 
death resulting from kidney failure (Chi et al., 2004). This process is dependent on 
coordinated signaling by FGF, GDNF (glial cell line-derived neurotropic factor) and 
Wnt11. Similarly, Spry1 null mice develop multiple ureteric buds due to hypersensitivity 
of the Wolffian ducts to GDNF signaling (Basson et al., 2005). GDNF signaling in 
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enteric nerve cells is also regulated by Spry2, which is demonstrated in Spry2 knock-out 
mice (Taketomi et al., 2005).  
 The process of angiogenesis, another form of branching morphogenesis, is 
inhibited in vivo by Spry4. Mouse embryos overexpressing Spry4 show little evidence of 
organized sprouting of smaller blood vessels from large ones (Lee et al., 2001; Taniguchi 
et al., 2009).  
 
1.6.8.3 Role of Sprouty in development 
 Other than their well-studied inhibitory function in branching morphogenesis, the 
Spry proteins are also involved in regulating other developmental processes. Sprouty has 
been reported to be involved in mesoderm formation in Xenopus. It was shown through 
gain- and loss-of-function studies that upon FGF stimulation, Spry modulates pathways 
leading to morphogenesis, but not mesoderm specification, through PKCδ (Sivak et al., 
2005). Interestingly, this occurs independently of the Ras/ERK pathway. A later study 
also showed that Spry contributes to dorsoventral patterning in Xenopus during mesoderm 
formation (Hanafusa et al., 2009). However, it contradicts the first report by indicating 
that Spry carries out this function through regulating the duration of ERK activity 
downstream of FGF signaling.  
 Expression of FGF has been shown to be important during vertebrate limb 
formation, and is expressed in close association with its regulator Spry. Overexpression of 
Spry in the prospective wing tissues of the chick embryo caused a reduction in limb bud 
outgrowth (Minowada et al., 1999). Subsequent studies support this observation, when 
Spry gene expression was detected in limb mesenchyme and later in muscle masses 
during limb development in chick and mouse embryos (Chambers and Mason, 2000; 
Eloy-Trinquet et al., 2009).  
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 Spry2-/- mice have been found to suffer from loss of hearing due to excessive 
FGF8 signaling during the development of the organ of Corti (Shim et al., 2005), while 
loss of Spry2 and Spry4 led to tooth developmental abnormalities due to hyper-
responsiveness to FGF3 and FGF 10 (Klein et al., 2006). Further studies by the latter 
group also showed that loss-of-function of Spry genes leads to bilateral enamel deposition 
on mouse incisors, thus impeding incisor abrasion and unchecked tooth elongation (Klein 
et al., 2008).  
 Based on the collective evidence described, Spry proteins are involved in various 
physiological processes. It therefore stands to reason that disruption of Spry expression is 
highly likely to lead to diseases such as cancer.  
 
1.6.9 Sprouty in cancer 
 Overexpression or activating mutations of RTKs have been implicated in cancer. 
As regulators of RTK signaling, the Spry proteins are therefore natural suspects in cancer. 
Recent studies have shown that expression of Spry proteins is downregulated in a variety 
of cancers. These include Spry1 and Spry2 in breast cancer (Lo et al., 2004), Spry1 and 
Spry4 in prostate cancer (Kwabi-Addo et al., 2004; Wang et al., 2006), Spry2 in liver 
cancer (Fong et al., 2006), lung cancer (Sutterlüty et al., 2007) and B-cell lymphoma 
(Frank et al., 2009). Current evidence suggests that the main mechanism of silencing Spry 
expression in these cancers is through hypermethylation of promoters (Wang et al., 2006; 
Frank et al., 2009). However, this mechanism seems to be cancer-specific as 
hypermethylation has not been deomonstrated in all the cancer types which show a down-
regulation of Spry. Currently efforts are mainly focused on determining whether the Spry 




1.7 PLCγ-PKC signaling 
 The cellular responses elicited by the interaction of many extracellular signaling 
molecules with their cell surface receptors are triggered by the rapid hydrolysis of the 
membrane phospholipids, phosphatidyl inositol 4,5-bisphosphate [PtdIns(4,5)P2]. This 
reaction is catalyzed by the phosphoinositide-specific phospholipase C (PLC) isozymes 
and results in the generation of two intracellular messengers, diacylglycerol (DAG) and 
inositol 1,4,5-trisphosphate [Ins(1,4,5)P3]. These messengers subsequently induce the 
activation of the protein kinase C family of Ser/Thr kinases and the release of Ca2+ from 
intracellular stores (Rhee, 2001). The overview of PLCγ-PKC signaling is shown in 
Figure 1.7.  
 
1.7.1 Primary structure of PLCγ 
 The PLC family comprises at least thirteen mammalian isozymes that differ in 
structure and tissue distribution. The proteins are divided into six types: PLCβ (four 
members), PLCγ (two members), PLCδ (four members), PLCε, PLCζ and PLCη (Harden 
and Sondek, 2006). Lower eukaryotes such as yeast contain only the δ-type isozymes, 
which suggests that other isoforms present in higher eukaryotes evolved from the 
archetypal PLCδ (Rhee, 2001).  
 In terms of sequence conservation, the amino acid sequences of the different PLC 
isoforms are relatively unconserved except for two regions, known as the X and Y 
domains that form the catalytic core. The amino acid sequence similarity in these two 
domains is approximately 60% among all the PLC isozymes, and is much higher between 
enzymes of the same type. PLCγ contains multiple domains which facilitates its 
interaction with upstream signaling molecules such as RTKs as well as downstream 
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between the catalytic core X and Y domains. As in the case of Grb2, the SH2 domains of 
PLCγ1 recognizes phospho-Tyr sequences in proteins such as RTKs, while the SH3 
domain mediates interactions with proteins containing Pro-rich sequences (Kim et al., 
2000; Pawson and Nash, 2003). Additionally, PLCγ1 contains a C2 domain, which allows 
interaction with Ca2+ and phospholipids, and two putative PH domains, one of which is 
split, which mediates interaction with phosphoinositides (Kim et al., 2000). The primary 
structure of PLCγ1 is shown in Figure 1.7.1.  
 
1.7.2 Activation of PLCγ 
 Growth factors such as PDGF, EGF, FGF, VEGF, GDNF, nerve growth factor 
(NGF), and hepatocyte growth factor (HGF) induce PtdIns(4,5)P2 turnover by activating 
PLCγ1 in a wide variety of cells. Upon activation and Tyr phosphorylation of the RTKs, 
PLCγ1 binds to them via its N-terminal SH2 domain and becomes phosphorylated on 
three Tyr residues, 771, 783 and 1254. The association of PLCγ1 with activated RTKs 
allows the recruitment of PLCγ1 to the plasma membrane which brings it into the vicinity 
of its substrate PtdIns(4,5)P2. Membrane association is further facilitated by the 
interaction of the PH and C-terminal SH2 domains of PLCγ1 with PtdIns(3,4,5)P3, which 
is generated through the phosphorylation of PtdIns(4,5)P2 by the PtdIns-3 kinase (PI3K) 
(Rhee, 2001).  
 The activation of PLCγ1 results in the hydrolysis of PtdIns(4,5)P2 to generate 
DAG and Ins(1,4,5)P3. The latter triggers the release of Ca2+ from cellular stores. Both 
these signals, DAG and Ca2+, either singly or together, are able to activate a separate class 
of proteins, known as protein kinase C. 
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Adapted from Kim et al., 2000.
Figure 1.7.1 Schematic representation of the primary structure of 
PLCγ1.
The different domains within the PLCγ1 sequence are shown here. The N- 
terminal PH domain is known to bind to lipids, while the split PH domain is 
not known to be functional. The catalytic core X and Y domains are shown 
in red. Upon RTK activation, the N-terminal SH2 domain is able to bind to 
phosphorylated Tyr residues on the RTKs. Activation also results in 
phosphorylation of three Tyr residues on PLCγ1, shown in yellow.
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1.8 The protein kinase C family 
 The protein kinase C (PKC) family comprises a multigene family of related 
Ser/Thr kinases that play key roles in growth regulation and programmed cell death. In 
mammals, this family is composed of at least ten isozymes divided into three subfamilies 
based on their structure and cofactor requirements for activation. The conventional PKCs 
(α, βI, βII and γ) require both DAG and Ca2+ for activation, while the novel PKCs (δ, ε, η 
and θ) are dependent on only DAG. PKCδ is the first of this subfamily to be cloned, 
being isolated from a rat brain cDNA library (Ono et al., 1987). Atypical PKCs (ζ and ι) 
on the other hand, are activated independently of both DAG and Ca2+. The mechanisms of 
activation for atypical PKCs are still not well understood (Steinberg, 2004).  
 
1.8.1 Primary structure of PKC 
 All the PKC isoforms are single polypeptide chains with N-terminal regulatory 
domains that contain an autoinhibitory pseudosubstrate domain, two membrane-targeting 
modules termed C1 and C2, and a highly conserved C-terminal catalytic domain. In most 
of the isoforms, the C1 domain is further split into C1A and C1B (Steinberg, 2004). DAG 
binds to the C1 domain to form a hydrophobic surface which promotes the enzyme to the 
cell membrane. The second membrane-targeting motif, the C2 domain, binds anionic 
phospholipids, and in the case of conventional PKCs (cPKCs), Ca2+. In novel PKCs 
(nPKCs), the C2 domain precedes the twin C1 domains in the N-terminal regulatory 
domain. However, the C2 domain sequences of nPKCs lack calcium-coordinating 
residues that are present in cPKCs.  Furthermore, the C2 domain of PKCδ contains an 
accessible sequence that conforms to an optimal src family kinase substrate. Within the 
regulatory region, there is also a pseudosubstrate sequence, which allosterically regulates 
the enzyme. This domain serves to mask the substrate-binding domain within the C-
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terminus until the kinase is activated (Newton, 2001). The C-terminal catalytic domains 
of all the PKCs are highly conserved and contain an ATP-binding site (on lysine 376 for 
PKCδ) and a substrate-binding site. An activation loop is also located within the catalytic 
domain, which upon phosphorylation, allows the protein to assume the necessary 
conformation to achieve catalytic competence. Two other motifs, the turn motif and 
hydrophobic motif, are also present within the catalytic domain. These motifs mainly 
serve to stabilize the active conformation of the kinase (Newton, 2001). A schematic 
diagram of the structure of PKCδ is shown in Figure 1.8.1.  
 
1.8.2 Phosphorylation on PKCδ 
 It is now widely accepted that the different PKC proteins undergo a series of 
Ser/Thr ‘priming’ phosphorylations that lock the enzymes in a closed and stabilized 
conformation before they are fully catalytically active. Most of these studies have been 
carried out on cPKCs, and the results were then extended to the other members of the 
PKC family. However, nPKCs, and in particular PKCδ, have shown some exceptions to 
the rules observed in cPKCs. The main phosphorylation events in PKCs are described 
below.  
 In cPKCs, phosphorylation of a Thr residue within their activation loop segment 
must occur before it is possible for the PKCs to phosphorylate their substrates. This aligns 
the activation loop to allow substrate binding (Knighton et al., 1991; Taylor and Radzio-
Andzelm, 1994). The kinase responsible for this phosphorylation has been proposed to be 
phosphoinositide-dependent kinase 1 (PDK1). PKCδ also goes through a similar 
‘priming’ phosphorylation on Thr505 within its activation loop. Although it has been 
reported that the glutamate (Glu) residue at position 500 renders phosphorylation on 
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1 673
Adapted from Steinberg, 2004
Figure 1.8.1 Primary structure of PKCδ.
The different domains of PKCδ
 
are schematically represented here. The two 
Cys-rich domains (C1 and C2) are located in the N-terminal regulatory 
domain. The C2 domain is non-functional in binding Ca2+ in PKCδ. The 
pseudosubstrate domain masks the substrate-binding domain in the C- 
terminal part of protein. The caspase cleavage site is cleaved by caspase 3 
upon apoptotic stimulation. The Lys376 (shown in red) residue within the 
ATP-binding site is required for ATP binding. Phosphorylation on three 
conserved residues takes place upon activation: S643, S662 and T505 (shown 
in blue within the activation loop). Further stimulus-specific Tyr 
phosphorylations also take place on the residues shown in blue.
44
phosphorylation on Thr505 (Stempka et al., 1999; Rybin et al., 2007). Both the kinases 
PDK1 and PKCε have variously been implicated in phosphorylating PKCδ (Newton, 
2003; Steinberg, 2004; Rybin et al., 2004).  
 Like cPKCs, PKCδ is auto-phosphorylated on two other sites on its C-terminal 
tail, on Ser643 within the turn motif, and Ser662 within the hydrophobic motif. These two 
phosphorylations are necessary for reversible stimulation by agonists, and allows the 
release of PKCδ from membranes and facilitates PKCδ down-regulation (Newton, 2003; 
Steinberg, 2004). The mechanism by which these phosphorylations on these residues 
mediates downregulation of PKCδ activation is however unclear.  
 PKCδ has also been demonstrated to be phosphorylated on different Tyr residues, 
depending on stimulation. These phosphorylations have been reported to occur within 
both the catalytic and regulatory domains, on Tyr residues 52, 155, 187, 311 and 332 
(Kronfeld et al., 2000; Steinberg, 2004). In contrast with the sites for Ser/Thr 
phosphorylation, these Tyr residues are not conserved across the PKC family members. 
Hence Tyr phosphorylation is a relatively specific regulatory mechanism for PKCδ, and 
not a common one for the entire PKC family. It is also possible that the precise 
configuration of Tyr phosphorylation on PKCδ depends on the nature of the stimulus, and 
dictates the functional properties of the enzyme.  
 
1.8.3 Activation of PKCδ 
 Various signals, including but not restricted to G-protein coupled receptors 
(GPCRs), RTKs and oxidative stress, can lead to PKCδ activation (Kronfeld et al., 2000; 
Wert and Palfrey, 2000; Gliki et al., 2001; Qiu et al., 2003; Storz et al, 2004). As in the 
case of PKC phosphorylation, the bulk of the studies regarding kinase activation were 
conducted with cPKCs, and then extrapolated to nPKCs. While there are similarities in 
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the mechanism of activation between the two subfamilies of kinases, differences also 
exist.  
 In the case of cPKCs, newly synthesized kinases associate weakly with 
membranes, and become phosphorylated within its activation loop by PDK1, followed by 
auto-phosphorylation at the two C-terminal Ser residues. Phosphorylation of the C-
terminal sites results in conformational rearrangements that lock PKCs into a stable, 
phosphatase-resistant conformation. This is known as the mature form of PKC, which is 
catalytically competent, but is not active because it is maintained in the autoinhibited state 
by its pseudosubstrate sequence. The mature PKC then loses its membrane anchor and 
localizes to the cytosol (Parekh et al., 2000; Newton, 2003). Upon extracellular 
stimulation, DAG is generated and Ca2+ is released, allowing these cofactors to interact 
with cPKCs, resulting in their high-affinity interaction with the membrane, and the 
allosteric displacement of the pseudosubstrate from the substrate-binding site. The mature 
PKC is thus able to bind its substrates and effect downstream signaling (Newton, 2003).  
 While PKCδ also undergoes the same three ‘priming’ phosphorylations, the 
sequence of events leading to PKCδ activation appears to differ from that of cPKCs. It 
was noted that in unstimulated cells, PKCδ retains little phosphorylation at its activation 
loop (Thr505). This implies that newly synthesized PKCδ does not go through the same 
maturation process as cPKCs. Rather, phosphorylation on Thr505 is observed only after 
phorbol ester phorbol 12-myristoyl 13-acetate (PMA) treatment, a synthetic mimic of 
DAG, or receptor stimulation (Rybin et al., 2003). Therefore, while the overall 
requirements for PKCδ activation are known, the specific mechanistic process remains 
inconclusive. In general, however, for both cPKC and nPKC isoforms, translocation to 




 Most cells co-express multiple PKC isoforms that display only limited substrate 
specificity in vitro, but elicit distinct and specific cellular responses in intact cells. This is 
attributed to isoform-specific interactions with different anchoring proteins that localize 
the individual PKC isoforms to specific membrane microdomains, in close proximity with 
their allosteric activators and/or substrates. One such group of scaffolds is RACKs 
(receptors for activated C-kinase). Current opinion states that cells express a unique 
RACK, with a distinct subcellular localization, for each PKC isoform. By selectively 
binding only the activated conformation of a PKC, each RACK recruits its cognate PKC 
isoform to a specific membrane compartment (Mackay and Mochly-Rosen, 2001). To 
date, the following RACKs have been identified: RACK1 (PKCβ), RACK2 (PKCε) and 
p32/gC1qBP (PKCδ) (Robles-Flores et al., 2002; Steinberg, 2004). However, it is also 
important to note that RACKs can also act as scaffolds for other signaling molecules such 
as PLCγ, ras-GAP, dynamin, c-Src and integrins (Schechtman and Mochly-Rosen, 2001).  
 
1.8.5 Regulation of PKC signaling 
 As with all kinases, the activity of PKCs has to be tightly regulated to ensure that 
both the timing and duration of the signal is appropriate. Currently, evidence for isoform-
specific regulatory mechanisms is lacking. However, a few methods applicable to 
different PKC isozymes have been proposed. A novel E3 ubiquitin ligase, RINCK 
(RING-finger protein that interacts with C kinase) has been identified that mediates the 
ubiquitination and subsequent degradation of all PKC isoforms (Chen et al., 2007). 
Knockdown of endogenous RINCK was shown to result in the upregulation of PKC 
levels. In this instance, amplitude control of PKC activity is carried out through the direct 
downregulation of protein expression. 
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 As the stability of PKCs is tightly controlled by multiple phosphorylation and 
dephoshorylation steps, it is unsurprising to find that phosphatases regulate PKC 
signaling. Evidence has been presented to show that PP2A is able to dephosphorylate 
PKCα, ε and δ (Srivastava et al., 2002). Furthermore, it would appear that 
dephosphorylation of these proteins occur prior to their ubiquitin-mediated degradation. 
A second group of phosphatases, PHLPP (PH domain leucine-rich repeat protein 
phosphatase) 1 and 2 has also been recently identified to dephosphorylate PKCs. These 
phosphatases have been found to contain a PP2C-like phosphatase domain, and also 
dephosphorylate Akt in vitro. It was demonstrated that both PHLPP1 and 2 are able to 
dephosphorylate the hydrophobic site of both PKCβII and PKCα (Gao et al., 2008). 
Dephosphorylation of the enzymes leads to their degradation. 
 
1.8.6 Substrates of PKCδ and downstream signaling 
 A number of proteins have been identified as PKCδ substrates. These include 
STAT3, phospholipid scramblase 3 (Plscr3), src family kinases (SFK), c-Abl and protein 
kinase D (Liu et al., 2003; Steinberg, 2004; Storz et al., 2004). PKCδ-dependent 
phosphorylation of Ser727 on STAT3 reduces its DNA-binding and transcriptional 
activity. PKCδ also plays a role in apoptosis by phosphorylating Plscr3, a mitochondrial 
protein involved in UV-induced apoptosis. In the case of PKD, PKCδ is responsible for 
the phoshorylation of two Ser residues (738 and 742) in PKD upon oxidative stress, and 
leads to NF-κB activation. Both SFK and c-Abl are also phosphorylated by PKCδ, 
although there is some question as to whether src is directly phosphorylated by PKCδ, 
and they in turn further phosphorylate PKCδ, which increases its kinase activity. 
 PKCδ, by phosphorylating its different substrates, is able to regulate various 
signaling pathways. Two of the better studied ones are the NF-κB pathway in response to 
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oxidative stress, and ERK signaling upon growth factor stimulation. Storz and colleagues 
(2004) indicate that PKCδ is able to phosphorylate PKD in response to oxidative stress, 
which then participates in a signal relay to NF-κB via activation of the canonical IκB and 
IκB kinase (IKK) complexes.  
 Another pathway linked to PKCδ is the ERK signaling pathway. ERK activation 
through PKCδ is unlike the canonical ERK pathway where the signal is received through 
Ras. In all the reports so far, growth factor stimulation can result in the activation of ERK 
through PKCδ via a Raf-dependent, but Ras-indpendent pathway (Ueda et al., 1996; 
Takahashi et al., 1999; Sasaki et al., 2003; Kuriyama et al., 2004).  
 
1.8.7 Physiological functions of PKCδ 
 PKCδ has been implicated in various physiological functions, sometimes with 
seemingly opposing results. In different contexts, PKCδ has been linked to both cell death 
and cell proliferation. While evidence has been presented to show that PKCδ is able to 
regulate apoptosis, a common mechanism by which it does so has not emerged. One of 
the most frequently cited mechanisms is the cleavage of PKCδ by caspase-3 in response 
to apoptotic stimuli, thus releasing a constitutively active catalytic fragment (Steinberg, 
2004). However, cleavage of PKCδ is not observed in the apoptosis of certain cell types 
that were treated with phorbol esters or UV irradiated (Basu, 2003; Brodie and Blumberg, 
2003). On the other hand, PKCδ has also been implicated in cell proliferation via ERK 
signaling in, for example, breast cancer cells (Keshamouni et al., 2002), which directly 
opposes the apoptotic function suggested for PKCδ.  
 The involvement of PKCδ in development has also been well documented. PKCδ 
has been reported to be essential for proper mesoderm formation in Xenopus embryos 
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(Kinoshita et al., 2003; Sivak et al., 2005). In Xenopus cells where PKCδ has been 
knocked down, gastrulation movements and convergent extension movements were 
blocked (Kinoshita et al., 2003). Interestingly, Spry2 has been reported to inhibit PKCδ 
signaling during development in Xenopus cells (Sivak et al., 2005).  
Other physiological functions that have been reported to involve PKCδ include 
angiogenesis, monocyte lineage specification and cardiac development (Murakami et al., 
2002; Hamplova et al., 2005; Pearn et al., 2007; Basu et al., 2008; Koyanagi et al., 2009).  
 
1.8.8 PKCδ in disease 
 As PKCδ is involved in several physiological functions, it is logical that 
dysregulation of PKCδ signaling will result in various disease states. One of the most 
commonly studied diseases involving PKCδ is cardiac hypertrophy. Many PKC isoforms 
have been implicated in this disease with each isoform exerting distinct cardiac actions 
(Steinberg, 2004). PKCδ, along with PKCε, has been implicated in the downregulation of 
SERCA2 [sarco(endo)plasmic reticulum Ca2+-ATPase] expression, a characteristic 
feature of the hypertrophic phenotype (Porter et al., 2003). Subsequent studies by 
different groups suggest that PKCδ-activated signaling from mTOR/S6K1 or CREB can 
also lead to cardiac hypertrophy. Over-expression of a kinase-dead form of PKCδ leads to 
a decrease in markers for cardiac hypertrophic phenotype (Moschella et al., 2007; Ozgen 
et al., 2008).  
 PKCδ has also been implicated in cancer progression, although its role in various 
cancers is not very clear-cut. The kinase has been shown to promote cell proliferation and 
cellular survival in breast cancer and non-small cell lung cancer cells. Introduction of 
kinase-dead PKCδ increased apoptosis of these cells (Keshamouni et al., 2002; Clark et 
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al., 2003). However, in the case of prostate cancer cells, active PKCδ increased the level 
of apoptosis (Gonzalez-Guerrico and Kazanietz, 2005). Interestingly, PKCδ was instead 
found to positively regulate cell migration in prostate cancer cells (Villar et al., 2007). 
This leads to the intriguing question as to whether PKCδ is involved in different 
processes and stages of cancer, depending on the type and location of cancer. In the case 
of haemtopoietic cells PKCδ is involved in lineage selection of the cells, and 
dysregulation of PKCδ may lead to a bias in the production of cells of a particular 
lineage, and subsequently, leukemogenesis (Pearn et al., 2007).  
 
1.9 Protein Kinase D (PKD) 
 The protein kinase D (PKD) family of Ser/Thr kinases consists of three proteins 
that, like the PKC enzymes, are DAG-stimulated. The members of this protein family are 
PKD1 (formerly known as PKCμ), PKD2, and PKD3 (formerly PKCν). PKD1 and PKD3 
were originally classified within the PKC family, owing to the similarity of their C1 
domains with the PKC C1 domains. However, based on the distinct differences between 
the PKD proteins and PKCs, and their sequence similarities with the kinase domain of the 
calcium/calmodulin-dependent protein kinases (CAMK), the PKD enzymes have been re-
classified as a novel subgroup of the CAMK family (Rykx et al., 2003).  
 
1.9.1 Primary structure of PKD 
 All three PKD enzymes share a similar modular structure. Like the PKCs, all three 
PKD proteins consist of an N-terminal regulatory domain and a C-terminal kinase 
domain. The N-terminus of both PKD1 and PKD2 starts with alanine (Ala)- and/or Pro-
rich apolar region, which is absent in PKD3. The N-terminal regulatory domains of the 
three isozymes also contain Cys-rich domains (CRD) that are highly homologous to those 
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found in PKCs. Like the PKCs, PKD binds DAG with high affinity through these 
domains. Interposed between the CRD and the catalytic domain, PKD also contains a PH 
domain. The PH domain binds to membrane lipids, and plays an autoregulatory role in 
PKD. Mutants with deletions or amino acid substitutions within the PH domain are fully 
active, indicating that this domain helps to maintain PKD in an inactive state (Waldron 
and Rozengurt, 2003; Rozengurt et al., 2005).  
The C-terminal catalytic domain contains an activation loop, where two Ser 
residues (Ser738 and Ser742 in human PKD1, Ser744 and Ser748 in mouse) must be 
phosphorylated for the protein to be active. Additionally, a site (Ser916 in mPKD1, 
Ser910 in hPKD1) on the C-terminus is autophosphorylated. While this is not required for 
kinase activation, it regulates the conformation of PKD1 Waldron et al., 2001; Rykx et 
al., 2003, Storz et al., 2004). The primary structure of PKD1 is summarized in Figure 
1.9.1. 
 
1.9.2 Activation and phosphorylation of PKD1 
 PKD1 has been shown to be activated by GPCRs, growth factors and oxidative 
stress (Storz et al., 2004; Wong and Jin, 2005; Sinnett-Smith et al., 2009). In 
unstimulated cells, PKD is in a state of very low kinase activity through repression by the 
CRD and PH domains. Upon growth factor stimulation, DAG is generated through PLCγ 
activity, thus activating PKCs such as PKCδ, PKCε, PKCη and PKCθ. Production of 
DAG also induces CRD-mediated PKD1 translocation from the cytosol to the plasma 
membrane in close proximity with the PKCs. This then allows transphosphorylation of 
Ser738 and Ser742 in the activation loop of PKD1.  
Oxidative stress also results in the activation of PKCs through Src-mediated 
phosphorylation. However, it is currently unclear how DAG might be generated to 







Regulatory domain Catalytic domain
Adapted from Rykx et al., 2003
Figure 1.9.1 Primary structure of PKD1.
The different domains within the PKD1 protein are shown here. PKD1 
contains an apolar region in its N-terminus. It also has a Cys-rich domain, 
consisting of the C1 and C2 domains. The PH domain has been shown to 
provide inhibitory regulation of the protein as mutations within this region 
activate the protein. The C-terminal kinase domain contains the activation 
loop, within which two residues, S738 and S742 must be phosphorylated for 
the kinase to be active. Three other phosphorylation events on S203, S255 
and S910 take place on activation. 
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activate the PKCs. GPCR-activation of PKD1, on the other hand, occurs independently of 
PKC (Rykx et al., 2003; Storz et al., 2004; Rozengurt et al., 2005; Sinnett-Smith et al., 
2009). Three other phosphorylations also occur within the PKD1 protein upon activation: 
autophosphorylations on Ser916 at the C-terminus and Ser203 within the regulatory 
domain, and transphosphorylation at Ser255, which is also in the regulatory domain. It is 
currently unclear what the functions of the last three phosphorylations are, but it is 
believed that they are necessary for maintaining the active conformation of PKD1. 
 
1.9.3 Substrates and downstream signaling 
 PKD1 has been reported to activate several downstream signaling pathways. At 
first glance, this would seem to imply that there are several substrates for PKD1. 
However, only a few genuine substrates have currently been identified. Both Syk and 
PLCγ have been reported to be phosphorylated by PKD1 in B-cell receptor signaling. 
However, the phosphorylation was only shown to occur in vitro, and not within a cellular 
context (Van Lint et al., 2002). Evidence has also been presented to show that histone 
deacetylase 5 (HDAC5) is phosphorylated by PKD1 upon VEGF stimulation in 
endothelial cells (Huynh and McKinsey, 2006; Ha et al., 2008). Phosphorylation of 
HDAC5 occurs on the residues Ser259 and Ser498, which leads to HDAC5 nuclear 
exclusion and myocyte enhancer factor-2 (MEF2) transcriptional activation. This 
subsequently mediates cell migration and tube formation of the endothelial cells. 
 Another substrate of PKD1 is the Ras effector RIN1. This protein directly 
competes with Raf for Ras binding, and is also regulated by 14-3-3. RIN1 was found to 
bind to 14-3-3 through a phosphorylated Ser351 residue. Mutational analysis of this 
residue showed that lack of binding with 14-3-3 led to a more efficient blockade of Ras-
mediated transformation. This particular residue was found to be phosphorylated by 
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PKD1 (Wang et al., 2002). Phosphorylation of RIN1 by PKD1 on this residue allows its 
release from Ras, thereby allowing the interaction of activated Ras with Raf. This then 
potentiates ERK1/2 phosphorylation. 
 A third recently identified substrate is the slingshot 1L (SSH1L) protein, which 
mediates cofilin activity and actin reorganization. PKD1 phosphorylates SSH1L on 
Ser978 in response to RhoA activation (Eisler et al., 2008).  
 Two of the most well-studied signaling pathways downstream of PKD1 are the 
ERK and NF-κB signaling pathways. Evidence was presented showing that transient 
expression of a constitutively active form of PKD1 is capable of activating ERK (Hausser 
et al., 2001). A subsequent study also showed that PKD1 was found to activate ERK 
signaling downstream of RTKs such as VEGF. This pathway was proposed to involve the 
activation of both PLCγ and PKC (Wong and Jin, 2005), and possibly involves the 
phosphorylation of RIN1 (Wang et al, 2002).  
 As part of oxidative stress response, PKD1 participates in the activation of the 
transcription factor NF-κB. Two separate phosphorylation events occur on PKD1 to 
mediate this. Phosphorylation on Tyr463 by Abl promotes a second phosphorylation 
within the activation loop of PKD1 by PKCδ. This synergistic activation of PKD1 allows 
efficient signal relay to NF-κB in cells exposed to reactive oxygen species (Storz et al., 
2004).  
 
1.9.4 Physiological functions of PKD1 
 One of the best characterized functions of PKD1 is its role in regulating the fission 
of transport carriers from the trans-Golgi network (TGN) to the plasma membrane. In this 
process, Golgi stacks undergo fission to form small vesicular transport carriers that 
transport proteins to the cell surface. PKD1 is phosphorylated at the Golgi complex by a 
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heterotrimeric G-protein subunit β1γ2-activated PKCη. Experiments conducted using 
kinase-dead and constitutively active PKD1, as well as knock-down studies, show that 
PKD1 causes vesiculation of Golgi stacks (Liljedahl et al., 2001; Hausser et al., 2005; 
Bossard et al., 2007).  
 PKD1 has been suggested to be involved in cell proliferation and angiogenesis 
(Wong and Jin., 2005; Qin et al., 2006; Ha et al., 2008). One of the studies proposed that 
angiogenesis is mediated by PKD1-phosphorylated HDAC5. Overexpression of kinase-
dead PKD1 prevents HDAC5 phosphorylation, and a HDAC5 mutant deficient in PKD1-
dependent phosphorylation inhibits endothelial cell migration and in vitro angiogenesis. 
A separate study showed that inhibition of PKD1 activation and knock-down of PKD1 
expression results in significantly attenuated ERK activation and proliferation of 
endothelial cells. 
 A recent study has implicated PKD1 in the regulation of cell motility (Eiseler et 
al., 2009). PKD1, through its phosphorylation of SSH1L, is able to alter cofilin activity, 
actin reorganization and decrease directed cell motility. Expression of constitutively 
active PKD1 in invasive tumour cells enhanced the phosphorylation of cofilin and 
blocked directed cell migration. 
 
1.10 Research objectives 
The Spry proteins, and in particular, Spry2, have long been recognized as 
inhibitors of the Ras-ERK pathway. Furthermore, it appears that Spry2 is able to act on 
different points along this pathway to regulate it. This implies that Spry2 has more than 
one mechanism of action. Current literature also indicates that Spry2 is able to act on 
more than one signaling pathway. The collective observations suggest one of two, or even 
both, possibilities: Spry2 is able to inhibit signaling pathways distinct from the canonical 
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Ras-ERK pathway, or that there is cross-talk between the Ras-ERK pathway and other 
signaling pathways, and Spry2 is able to impinge at some junction between these 
pathways.  
To gain a deeper understanding into the role that Spry2 plays in regulating 
pathways other than the canonical Ras-ERK pathway, the following questions were 
asked: 
1. Does Spry2 associate with proteins involved in pathways other than the canonical 
Ras-ERK pathway? 
2. Does this interaction have an impact on ERK activation? 
3. What is the likely mechanism of action of Spry2 in the context of this interaction? 
 
CHAPTER 2 
MATERIALS AND METHODS 
 
2.1 Chemicals and reagents 
 All chemicals and reagents were purchased from Sigma-Aldrich (St Louis, 
MO) or BDH Laboratory Supplies (Poole, England), unless otherwise stated. IPTG, 
Glycerol, Ultra pureTM Agarose were obtained from Invitrogen (Carlsbad, CA). 
 
2.2 Antibodies 
 Mouse anti-FLAG (M2), rabbit anti-FLAG, agarose-conjugated anti-FLAG 
M2 beads, rabbit anti-HA, rabbit anti-Spry2 (N-terminal) and bFGF were from 
Sigma-Aldrich (St Louis, MO). Rabbit and goat anti-PKCδ and rabbit antibodies 
against PKD1, FGFR1, GST, PLCγ1, PKCα, PKCε, PKCζ and myc were from Santa 
Cruz Biotechnology (Santa Cruz, CA). Mouse and rat anti-HA were from Roche 
Molecular Biochemicals (Mannheim, Germany). Mouse antibody against pan-ERK 
and rabbit anti-RIN1 was from BD Transduction Laboratories (Lexington, KY). 
Mouse anti-phospho ERK1/2, rabbit anti-phospho PKCδ pT505, rabbit anti-phospho 
PKD1 pS744/748 were purchased from Cell Signaling Technology (Beverly, MA). 
Mouse anti-β-actin was from Abcam (Cambridge, UK). Alexa Fluor 488 donkey anti-
mouse IgG, Alexa Fluor 546 goat anti-rabbit IgG, Alexa Fluor 546 donkey anti-rabbit 
IgG and Alexa Fluor 647 donkey anti-goat IgG were purchased from Molecular 





2.3 Plasmid constructs 
2.3.1 Phospholipid Scramblase 3 
Phospholipid scramblase 3 (Plscr3) was cloned using complementary DNA 
(cDNA) derived from mouse liver tissue and primers designed based on sequences in 
the NCBI GenBank entry (accession number: NM_023564). The primers were 
designed so as to create BamHI (5’) and XhoI (3’) digest sites flanking the ORF to 
facilitate cloning into pXJ40-HA vectors. Polymerase chain reaction (PCR) using a 
5:1 mixture of Taq DNA polymerase (Roche) and the proof-reading Pfu DNA 
polymerase (Promega, Madison, WI) was performed using the cDNA template and 
the products were separated on a 1% agarose gel. The major band corresponding to 
891 bp was cut from the gel and purified using the QIAquick Gel Extraction Kit from 
Qiagen (Hilden, FRG) and subjected to restriction enzyme digestion. The sequence of 




 Full-length mouse PKCδ was subcloned from pcDNA3 into pXJ40-myc and 
pXJ40-HA vectors. Primers were designed to incorporate BamHI and XhoI restriction 
sites into the 5’ and 3’ positions, respectively. The cDNA was amplified using PCR 
with Pfu DNA polymerase (Promega, Madison, WI). 
 
2.3.3 PKD1 
 Human PKD1 was subcloned from pcDNA3 into both pXJ40-HA and pXJ40-
myc vectors. The cDNA encoding PKD1 was amplified using primers that include 
BamHI and XhoI restriction sites at the 5’ and 3’ positions, respectively. PCR was 
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performed using Pfu DNA polymerase (Promega, Madison, WI), and the products 
were separated on a 1% agarose gel.  
 
2.3.4 Other plasmid constructs 
 pXJ40-FLAG tagged Spry1-4  and their mutants, FGFR1 were provided by 
colleagues within the group and have been described previously (Wong et al., 2001; 
Yusoff et al., 2002; Lao et al., 2006). The N- and C-terminal mutants of Spry2 (N1-
144 and C145-315) were generated using PCR and cloned into pXJ40-FLAG vectors. 
3 x HA-tagged Ras G12V was purchased from the UMR cDNA Resource Center 
(www.cdna.org). Mouse PKCδ and human RIN1 were kind gifts from Drs. Peter J. 
Parker (London Research Insitute, Cancer Research UK, London) and Dr. John 
Colliceli (David Geffen School of Medicine, Department of Biological Chemistry, 
Molecular Biology Institute, University of California, Los Angeles) resepectively. 
Human PKD1 was purchased from Addgene (plasmid 10808), which was deposited 
by Dr. Alex Toker (Department of Pathology, Beth Israel Deaconess Medical Center, 
Harvard Medical School).  
 
2.4 DNA methodology 
2.4.1 Expression vectors 
 Plasmid constructs were cloned in the pXJ40 vectors (Manser et al., 1997) 
containing either FLAG, HA or myc epitope tags for mammalian expression, unless 
otherwise stated. These vectors contain a multiple cloning site (MCS) under the 
control of a CMV enhancer/promoter to drive constitutive protein expression in 
mammalian cells, and a SV40 polyadenylation signal sequence. There is also a T7 
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promoter site upstream of the MCS, and an ampicillin resistance gene for bacterial 
selection. The sequence of the MCS for pXJ40 is shown in Figure 2.1.  
 
   /EcoRI/       ...........HA/FLAG/myc Tag.........../ BamHI/ 
T7 GAATTC ACC ATG TAC CCA TAC GAC GTG CCA GAC TAC GCA GGA TCC 
     Kozak  M   Y   P   Y   D   V   P   D   Y   A   G   S 
/ Hind3 / Xho1  /   Not1  / Sma1  / Pst1  / Sac1  / Kpn1  / Bgl2  / 
AAG CTT CTC GAG GCG GCC GCC CCG GGC TGC AGG AGC TCG GTA CCA GAT CT 
 K   L   L   E   A   A   A   P   G   C   R   S   S   V   P   D 
Figure 2.1  Multiple cloning site sequence of pXJ40 eptiope tagged vector.  
 
The commercially available pcDNA3.1(-) mammalian expression vector 
(Invitrogen, Carlsbad, CA) was also used for cloning. Protein expression is also 
driven by the CMV promoter in this vector and bacterial selection is also based on 
ampicillin resistance.  
 
2.4.2 Agarose gel electrophoresis 
 DNA fragments were separated in 1% agarose gels cast in TAE buffer (40 
mM Tris-acetate, 10 mM EDTA) containing GelRed for visualization of the DNA 
bands. The DNA samples were mixed with a loading dye (0.1% Orange G, 30% 
Ficoll 400) in a 5:1 ratio and loaded into the agarose gel. A 1 kb DNA ladder (New 
England Biolabs) was run alongside the DNA samples for molecular weight 
determination. Detection of DNA bands was carried out using a UV-transilluminator. 
 
2.4.3 Restriction enzyme digestion and ligation 
 Restriction enzymes were purchased from New England Biolabs (NEB), 
Roche (Mannheim, Germany) or Promega (Madison, WI). All restriction digests were 
carried out at 37°C, unless otherwise stated, for at least 2 h. Digestion products that 
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were to be used for ligation were purified using either the Gel Extraction or PCR 
Purification kit (Qiagen, Hilden, FRG). Digested vector DNA was further treated with 
shrimp alkaline phosphatase (SAP) (Roche, Mannheim) at 37°C for 1 h to remove the 
5’ phosphate groups to reduce self-ligation. Ligation was carried out for a minimum 
of 4 h at 16°C using the PCR Cloning kit (Qiagen). The enzymes were subsequently 
heat inactivated at 65°C for 5 min, and the ligation products were used for 
transformation using the electroporation technique.  Transformed DH10B E. coli cells 
were plated onto ampicillin-containing LB agar plates. Single colonies of E. coli were 
selected for plasmid extraction (Section 2.4.6) and the sequences of positive clones 
were verified using T7 and either BGH (for pcDNA3.1) or pXJrev (for pXJ40) 
primers. The BGH primer is specific to the bovine growth hormone (BGH) 
polyadenylation sequence in pcDNA3.1, while the pXJrev primer was designed 
specifically to reverse-complement the sequence just 3’ to the MCS of the pXJ40 
vectors. 
 
2.4.4 Electrocompetent E. coli cell preparation 
 An overnight culture of E. coli bacterial strain DH10B was grown in 10-50 ml 
LB broth at 37°C. An aliquot of the overnight bacterial culture was diluted 100 times 
in fresh, pre-warmed LB broth, and allowed to grow at 37°C with constant shaking to 
an OD600 of 0.8-0.9. The cells were cooled on ice before being pelleted at 6000 rpm 
for 15 min at 4°C. All further steps were carried out in ice-cold conditions. Cell 
pellets were resuspended in ice-cold sterile 10% glycerol (400 ml of 10% glycerol 
was used for every 400 ml of initial culture) and centrifuged again. The washes were 
repeated a further three times in reducing volumes of 200 ml, 20 ml and 10 ml to 
remove all traces of salt. After the final wash, cell pellets were resuspended in 2-4 ml 
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ice-cold 10% glycerol. The cells were then divided into 50 μl individual aliquots, snap 
frozen in liquid nitrogen and stored at -80°C.  
 
2.4.5 Electroporation 
 Prior to electroporation, individual aliquots of frozen E. coli cells were thawed 
on ice, before being gently mixed with the appropriate amount of DNA and 
transferred into an electroporation cuvette (Bio-Rad, Hercules, CA). Electroporation 
was carried out with the Bio-Rad Micro Pulser (Hercules, CA), using the pre-set 
conditions in program EC2. The cells were then recovered using SOC medium (2% 
bactotryptone, 0.5% yeast extract, 10 mM NaCl, 2 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4, 20 mM glucose) for 45 min – 1 h at 37°C before being plated onto antibiotic 
selection LB agar plates. 
 
2.4.6 Plasmid DNA preparation 
 Single bacterial colonies were selected from the antibiotic selection LB agar 
plates and inoculated in LB broth containing the appropriate antibiotic. Overnight 
cultures were used for plasmid preparation. Isolation of plasmids was done using the 
QIAprep Spin Miniprep (for culture volumes up to 5 ml) or the Qiagen Plasmid Maxi 
(for culture volumes up to 400ml) kits (Qiagen, Hilden, FRG), according to the 
manufacturer’s protocols. The methods used were based on the principles of alkaline 
lysis, where chromosomal DNA was separated from plasmid DNA under high salt 





2.4.7 Polymerase Chain Reaction (PCR) 
 Polymerase Chain Reaction (PCR) was performed using the Taq DNA 
polymerase from Roche (Mannheim, FRG) where a proof-reading function was not 
required, or the Pfu DNA polymerase from Promega (Madison, WI) in instances such 
as cloning, where proof-reading was required. Primers for PCR were designed based 
on sequences available in the NCBI Genbank website. The amount of template used 
for the reactions was dependent on the DNA polymerase used: up to 10ng for Taq 
DNA polymerase and up to 200ng for Pfu DNA polymerase. PCR was performed 
according to the following cycling program: an intial denaturation at 95°C for 2 min, 
followed by 21 cycles of denaturation (95°C, 30 s), annealing (55°C, 30 s), and 
extension (72°C, 1 min/kb), and finishing with a final extension at 72°C for 10 min. 
For reactions using Pfu polymerase, the extension conditions were optimized at 74°C 





95°C, 30 s 
Annealing 
55°C, 30 s 
Final 
extension 







95°C, 2 min 
21 cycles 
 
* Extension conditions are described only for reactions using Taq DNA polymerase. For 
reactions using Pfu polymerase, the extension conditions are changed to 74°C, 2 min/kb  
Figure 2.2  Summary of the cycling program used for PCR. 
 
2.4.8 DNA purification 
 DNA products from either PCR or restriction digest reactions were separated 
on 1% agarose gels. The desired bands were cut out and purified using the QIAquick 
Gel Extraction kit (Qiagen, Hilden, FRG), according to the manufacturer’s 
instructions. The DNA was eluted from the columns provided with 30 μl of the 
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elution buffer and stored at -20°C for future use. Empty vector plasmid DNA that had 
been subjected to restriction digest was purified with the QIAquick PCR purification 
kit (Qiagen, Hilden, FRG). The reaction volume was made up to 100 μl with the 
provided binding buffer (Buffer PB) before proceeding with the purification 
according to the protocol provided. 
 
2.4.9 Reverse Transcriptase PCR 
 Total RNA was extracted from mouse liver tissue using the RNeasy Mini 
RNA extraction kit (Qiagen, Hilden, FRG). Approximately 1-2 μg of total RNA was 
used as template in a reverse transcriptase reaction to synthesize complementary DNA 
(cDNA) using the SuperScript® First-Strand Synthesis System for RT-PCR kit 
(Invitrogen, Carlsbad, CA), according to the manufacturer’s instructions. After the 
synthesis was complete, the RNA was digested with the RNaseH supplied, and 
approximately 10% of the reaction was used for PCR amplification using specific 
primers and a 5:1 mixture of Taq and Pfu DNA polymerase according to the cycling 
program described in Section 2.6. 
 
2.4.10 Site-directed mutagenesis 
 Point mutants of plasmid constructs were generated using the Pfu proof-
reading DNA polymerase (Promega, Madison, WI). A single primer for each mutation 
was designed to incorporate the region of interest, with the chosen mutation in the 
centre, flanked by 12-16 nucleotides on either side of that region. These primers were 
used in PCR reactions with approximately 200ng of each plasmid template. The PCR 
cycling program was carried out as described in Section 2.6, using the alternative 
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extension conditions for Pfu DNA polymerase. The length of the product was 
calculated by including both the length of the vector and the insert.  
 The final product of the PCR reaction was digested with DpnI restriction 
enzyme to remove methylated template DNA. A 2 μl aliquot of the reaction was used 
to transform electrocompetent E. coli cells, which was then plated on LB agar plates 
containing ampicillin. Single bacterial colonies were picked and the presence of the 
desired mutation was verified by sequencing the purified plasmid DNA. The entire 
length of the cDNA of positive clones was also sequenced to ensure the absence of 
random mutations.  
 
2.5 Cell Culture 
2.5.1 Maintenance and propagation of mammalian cells 
 All cell lines were obtained for the American Type Culture Collection 
(ATCC) (Manassas, VA), and grown at 37°C, in a 5% CO2 atmosphere. HEK293T 
and PC-3 cells were grown in RPMI medium while COS1 cells were grown in 
Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10 mg/ml glucose. All 
media were supplemented with 10% fetal bovine serum (FBS) and 10 mM L-
glutamine. Cells were propagated by first removing the culture media and then 
detached by using 0.125% trypsin/EDTA diluted to a 1:10 ratio with PBS. PC-3 cells 
were further incubated at 37°C in the diluted trypsin/EDTA solution for about 10 min 
for better detachment. Cells were washed down with their respective complete media 
containing FBS and L-glutamine and pelleted down at room temperature. These were 
resuspended in an appropriate volume of complete media and subcultured at a ratio of 
1:6 to 1:10 in fresh complete media.  
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2.5.2 Mammalian cell transfection 
 All mammalian cell transfections were carried out using the Lipofectamine 
2000 reagent from Invitrogen (Carlsbad, CA), according to the manfacturer’s 
protocol. About 20 h prior to transfection, cells were split to achieve approximately 
80% confluence at the time of transfection. Plasmid DNA was diluted in pre-warmed 
OptiMEM media so that a total volume of 60 μl of DNA and OptiMEM mix was 
obtained for every 1 μg of DNA used. For every 1 μg of plasmid DNA, 3 μg (1 
μg/μ1) of Lipofectamine was used. This was diluted in a separate tube to also obtain a 
final volume of 60 μl for every 3 μg of Lipofectamine used. The total amount of DNA 
used for each transfection set was kept constant by using empty vector DNA to make 
up the difference. In general, the total amount of DNA used did not exceed 4 μg for 6 
cm dishes, 8 μg for 10 cm dishes and 15 μg for 15 cm dishes. Transfection mixes 
were prepared by adding equal volumes of the DNA mix and Lipofectamine mix and 
incubating them at room temperature for 20 min. Prior to adding the transfection mix, 
the culture medium was changed to pre-warmed OptiMEM. Cells were incubated at 
37°C for 4-5 h with the transfection mix before the OptiMEM was replaced with their 
respective pre-warmed complete media. Further experiments with the transfected cells 
were generally conducted 24 h post-transfection. 
 
2.5.3 Serum starvation and growth factor stimulation of mammalian cells 
 Basic fibroblast growth factor (bFGF) was purchased from Sigma-Aldrich (St 
Louis, MO). Stock solutions of bFGF were prepared by dissolving the lyophilized 
product in sterile PBS containing 0.1% BSA to a final concentration of 50 ng/μl, 
aliquoted and stored at -20°C. Cells were serum starved 2½-4 h prior to stimulation 
with bFGF. For serum starvation, complete culture medium was removed and 
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replaced with medium containing no FBS. Growth factor stimulation was carried out 
on serum starved cells with the addition of the necessary amount of growth factor up 
to the required final concentration. After the prerequisite length of time, stimulated 
cells were washed with cold PBS and processed for further experiments.  
 
2.5.4 UV irradiation 
 Transfected 293T cells were irradiated with unfiltered UV lamps at 4 J/m2 24 
h after transfection. The cells were allowed to recover at 37°C for 6 h before being 
harvested in the appropriate volume of lysis buffer for further processing (Section 
2.6.1).  
 
2.6 Protein biochemistry 
2.6.1 Preparation of cell extracts 
 RIPA lysis buffer containing 1% Triton-X 100, 150 mM NaCl, 50 mM Tris 
(pH 7.5), 0.25 mM EDTA, 0.2% NaF, and 1% sodium deoxycholate was used for 
extraction of total proteins from mammalian cells. 1mM sodium orthovanadate (pH 
10) and a cocktail of protease inhibitors (Complete Protease Inhibitor Cocktail) from 
Roche (Mannheim, FRG) were added to the lysis buffer immediately before use. Cells 
were washed with ice-cold PBS to remove residual medium before being harvested. 
Cells were scraped down using a manual cell scraper and cell debris was pelleted by 
centrifugation at 16 000 x g at 4°C. Whole cell lysates (WCL) were prepared after 
protein quantification by mixing a 50 μl aliquot of the lysates with an equal volume of 
Laemmli buffer (125 mM Tris-HCl, pH 6.8, 4% SDS, 10% β-mercaptoethanol, 20% 
glycerol and 0.004% bromophenol blue). WCL samples were then boiled at 95°C for 
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5 min and stored at -20°C for future use. The remaining cell lysates were immediately 
used for immunoprecipitation.  
 
2.6.2 Protein quantification 
 Total protein concentration was measured using the Bradford assay-based 
method with the Bio-Rad Dye Reagent (Hercules, CA). To measure protein levels, 
200 μl of the dye was diluted with 800 μl water along with 1-2 μl of each protein 
sample. The absorbance at wavelength 595 nm was measured using the Ultrspec 2100 
spectrophotometer (GE Healthcare, Buckinghamshire, England). Standard curves 
were constructed by using known amounts of BSA.  
 
2.6.3 Immunoprecipitation 
 0.5-1 mg of total protein in a minimum volume of 400 μl of cell lysate was 
used for each immunoprecipitation (IP) assay. About 1-2 μg of antibody was added to 
cell lysate samples from 6 cm or 10 cm dishes, while 5 μg of antibody was added to 
samples from 15 cm dishes, followed by 2 h of end-to-end rotation at 4°C to ensure 
sufficient distribution of the antibody. Approximately 10 μl of Protein A-conjugated 
agarose beads (Roche, Mannheim, FRG) were added for every 1 μg of antibody used, 
and rotation was carried out for a further 1 h. For IP of endogenous proteins, 12 μg of 
antibody was added to each sample and rotated at 4°C before the addition of the 
Protein A-conjugated agarose beads. Samples were washed three times in 1 ml lysis 
buffer for 1 h each time, and resuspended in 30μl lysis buffer and an equal volume of 
Laemmli buffer after the final wash. These were boiled at 95°C for 5 min and used for 
SDS-PAGE and immunoblotting. 
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2.6.4 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 WCL and immunoprecipitates were analysed by SDS-PAGE using the Bio-
Rad Mini Protean II system. The stacking gel consists of 4% acrylamide/Bis (30:1) 
(Bio-Rad), 0.125 M Tris-HCl (pH 6.8), 0.1% SDS, 0.1% ammonium persulfate (APS) 
and 0.01% TEMED. The separating gel was composed of 10-12.5% acrylamide/Bis, 
0.375 M Tris-HCl (pH 8.8), 0.1% SDS, 0.1% APS and 0.01% TEMED. In most cases, 
a 10% separating gel was used, except where the protein sizes were smaller than 25 
kDa. In such instances, 12.5% separating gels were used. WCL and 
immunoprecipitation samples were boiled at 95°C for 5 min before being loaded into 
the gels. An electrophoresis buffer comprising 25 mM Tris-HCl (pH 8.3), 192 mM 
glycine and 0.1% SDS was used. The samples were separated in the gels with a 
constant current of 30-40 mAmp for each gel. 
 Detection of separated proteins was carried out by staining the separating gel 
with a solution of Coomassie Brilliant Blue (0.2% Coomassie Brilliant Blue in 45% 
methanol and 10% acetic acid). Background staining was removed by destaining the 
gels in 40% methanol and 10% acetic acid. Alternatively, Western blot analysis was 
used to detect specific protein bands. 
 
2.6.5 Western blot (immunoblot) analysis 
 Proteins that were separated in SDS-PAGE gels were immediately transferred 
onto methanol pre-activated PVDF membranes using the Bio-Rad Trans-Blot system 
(Hercules, CA) in a transfer buffer (25 mM Tris-HCl, pH 8.3, 192 mM glycine, and 
20% methanol), at 110V for about 1 h. Membranes were blocked in blocking buffer 
(5% skimmed milk powder and 0.1% Tween 20 in PBS) for 1 h at room temperature 
with constant agitation, after which they were incubated in primary antibodies 
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overnight at 4°C. After washing three times in wash buffer (0.1% Tween 20 in PBS), 
for 10-15 min per wash, membranes were incubated in horseradish peroxidase (HRP)-
conjugated secondary antibodies for 1 h at room temperature. Primary and secondary 
antibodies were diluted in PBS containing 1% skimmed milk powder and 0.1% 
Tween 20, except for phospho-specific primary antibodies, which were prepared in 
blocking buffer containing 1% BSA instead of skimmed milk. The washing steps 
were repeated, and the enhanced chemiluminescence (ECL) system (GE Healthcare) 
was used to detect positive bands. The membranes were exposed to X-ray films for 
visualization of the positive bands. 
 
2.6.6 Expression and purification of GST-fusion proteins 
 GST-fusion Spry2 was produced by growing E. coli cells transformed with 
pGEX4T1-Spry2 in LB broth containing 150 μg/ml ampicillin overnight at 37°C. An 
aliquot of the overnight culture was added to pre-warmed fresh LB broth containing 
ampicillin and allowed to grow to an OD600 of about 0.2. The expression of GST-
fusion Spry2 was induced using 1 mM IPTG for 6 h at 30°C, with constant shaking. 
Bacterial cells were collected by centrifuging the culture at 6000 x g for 10 min at 
4°C. The cell pellet was washed with cold PBS and frozen at -80°C for 1 h, after 
which it was thawed on ice, and the cells were lysed by sonication in 15 ml lysis 
buffer (PBS containing 1% Triton X-100 and a cocktail of protease inhibitors 
(Roche)) using the ultrasonic processor XL2020 (Heat Systems Inc., Farmingdale, 
N.Y.). The bacterial lysate was cleared by centrifugation (20 000 x g for 30 min at 
4°C), and the supernatant was incubated rotating constantly with glutathione-
conjugated sepharose beads (GE Healthcare), in the proportion of 1 ml for every 1 L 
of culture, at 4°C overnight to capture the GST-fusion proteins. The protein-bound 
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beads were washed five times with cold PBS containing 0.1% Triton X-100, after 
which the proteins were eluted in an elution buffer composed of 50 mM Tris-HCl (pH 
8) and μM glutathione. An aliquot of the GST-fusion Spry2 produced was run on 
polyacrylamide gels and its presence was verified using both Coomassie Brilliant 
Blue staining and immunoblotting the transferred membranes with GST antibody. 
 
2.6.7 Far-Western Assay 
 Far-Western assays were carried out to determine direct binding between 
proteins, and were performed according to the method described by Dans et al. 
(2001). HA-tagged PKCδ, PKD1 and Cdc2 were expressed in 293T cells with FGFR1 
and immunoprecipitated with HA antibody. The immunoprecipitates were separated 
using SDS-PAGE and transferred onto PVDF membranes, which were blocked in 
blocking buffer comprising TBS with 0.1% Tween 20 (TBST) containing 5% 
skimmed milk powder, before being incubated in 1 μg/ml of either GST protein or 
GST-Spry2 fusion protein for 2 h at room temperature. Both GST proteins were 
diluted in TBST containing 2.5% skimmed milk powder, 1 mM DTT and a cocktail of 
protease inhibitors. The membranes were washed three times with TBST before being 
incubated with GST antibody for 1 h at room temperature. The washing steps were 
repeated and the membranes were probed with HRP-conjugated secondary antibodies. 
Membranes were again washed three times in TBST and a further two times in TBST 
containing 0.2% Triton X-100 before being visualized using the ECL system. To 
verify that immunoprecipitation of the HA-tagged proteins was successful, the 
membranes were incubated in HA antibody immediately after the proteins were 
transferred onto the membranes and immunoblotting was carried out as described in 
Section 2.6.5. 
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2.6.8 Small hairpin RNA knockdown 
 Knockdown of PKCδ was carried out using small hairpin RNA (shRNA) from 
Origene Technologies Inc and Sigma Aldrich. Four different shRNA constructs were 
provided by each company and these were tested for their silencing efficiency. The 
two shRNA constructs which showed the highest silencing efficiencies were used to 
knockdown endogenous PKCδ. An empty pRS vector and a shRNA against GFP were 
also used in each experiment as negative controls to eliminate the possibility of 
interferon responses and non-specific knockdown. The shRNA constructs were 
transfected into mammalian cells using the transfection procedure with Lipofectamine 
2000 described earlier. All samples used in knockdown experiments were also probed 
for the presence of β-actin when carrying out Western blot analysis to verify that 
equal amounts of samples were loaded.  
 
2.7 Immunofluorescence 
 COS1 cells were grown on sterile glass coverslips in 6-well tissue culture 
dishes containing 2 ml complete media per well. The cells were transfected and 
subsequently serum starved overnight followed by FGF stimulation (100 ng/ml for 45 
min). The cells were washed twice in cold PBS and fixed using 4% paraformaldehyde 
for 20 min at room temperature. The following washing steps were then carried out to 
remove the fixing solution: once with PBS, twice with PBS containing 100 mM 
ammonium chloride and another time with PBS. Cells were then permeabilized with 
0.2% Triton X-100 for 15 min and blocked at room temperature for 1 h in blocking 
buffer (sterile filtered PBS containing 2% BSA and 5% FBS) before being incubated 
in primary antibodies overnight at 4°C. The cells were washed thrice with PBS to 
remove excess primary antibodies and incubated in the dark with fluorophore-
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conjugated secondary antibodies. The washing steps were repeated, and after the final 
wash, the coverships were mounted on glass slides using Gel-Mount (Biømeda). After 
allowing the slides to dry in the dark overnight, immunofluorescent images were 
captured using a Zeiss LSM 510 META (Car Zeiss Microimaging). Alex Fluor 647 
signals were pseudo-coloured to beige using the LSM program. 
 
2.8 Cell invasion assay 
 Cell invasion assays were carried out using the Boyden chamber cell invasion 
assay-based QCM 24-well Cell Invasion Assay system from Chemicon (Billerica, 
MA) with PC-3 cells. Transfection of PC-3 cells was carried out with the necessary 
plasmid DNA constructs using the Lipofectamine 2000 system. The culture medium 
was changed to serum-free culture medium 24 h post-transfection, and cells were 
serum starved for a further 24 h. The transfected cells were then detached from the 
dishes using PBS diluted 0.125% trypsin/EDTA and washed down using quenching 
medium (serum free RPMI containing 5% BSA). The cells were pelleted and 
resuspended in a small volume of quenching medium. The number of cells present in 
the culture was determined by counting an aliquot of the resuspended cells in a 
hemacytometer. Prior to initiating the assay, the plates and reagents to be used were 
brought to room temperature. The chambers containing an 8 μm pore size 
polycarbonate membrane coated with a layer of extracellular matrix (ECM) were 
placed in a sterile 24-well plate. The ECM layer was rehydrated with 300 μl of pre-
warmed serum-free media for 15-30 min at room temperature. After rehydration, 250 
μl of the media was removed from the chamber and replaced with 250 μl quenching 
media containing 1 x 106 /ml of cells. As a chemoattractant, 500 μl of complete media 
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for PC-3 was added to the wells of the 24-well plate. The cells were incubated at 37°C 
for 24 h.  
 Invaded cells were dislodged from the underside of the membrane by first 
removing the media from the chamber and placing it in a well containing 225 μl of 
cell detachment solution before being incubated at 37°C for 30 min. The cells were 
lysed by adding 75 μl of a lysis buffer/CyQyant GR Dye solution (mixed in a 75:1 
ratio) to the cell-containing detachment solution and incubating the mixture for 15 
min at room temperature. A 200 μl aliquot of the mixture was transferred to a 96-well 
plate suitable for fluorescence measurement, and the number of invaded cells was 
quantified using the Spectra Max Gemini EM fluorescence plate reader (Molecular 
Devices, Sunnyvale, CA). For each experiment, a standard curve was set up by 
mixing known numbers of cells in the cell detachment solution with the lysis 
buffer/dye solution and measuring the fluorescence in the fluorescence plate reader. 
 
2.9 Yeast two-hybrid screen 
 The yeast two-hybrid screen was carried out using a pre-transformed 11-day 
embryonic mouse library from Clontech essentially according to the manufacturer’s 
protocol for the MatchMaker III system. The library contains cDNA sequences cloned 
into the pACT2 vector which were transformed into the Saccharomyces cerevisiae 
Y187 MATα yeast strain. The bait was transformed into the S. cerevisiae AH109 
MATa strain. Non-transformed yeast cells were grown on yeast peptone dextrose 
(YPD) agar supplemented with adenine hemisulfate (YPDA), while maintenance and 
selection of yeast clones was done on different drop-out (DO) media coated with 0.2 
mg X-α-gal. Positive clones were identified by both the formation of colonies and a 
blue colouration.  
 75
2.9.1 Cloning and transformation of bait 
 Human Spry2 was cloned into the DNA-binding domain-containing pGBK-T7 
vector (Clontech) to be used as bait in the screen. Full length Spry2 was subcloned 
from pXJ40-FLAG Spry2 using PCR and subsequent ligation into pGBK-T7. The 
pGBK-T7 vector contains an N-terminal myc epitope tag which is expressed as part 
of a fusion protein with Spry2. Positive clones were selected on LB agar plates 
containing 50 μg/ml kanamycin and the presence of the Spry2 insert was verified by 
restriction digest and sequencing. A positive clone free of random mutations was 
transformed into yeast strain AH109 using the PEG/LiAc method adapted from the 
protocol provided by the manufacturers (as described in the Yeast Protocols 
Handbook, Clontech). Competent yeast cells were prepared by growing a culture of 
AH109 yeast cells in YPDA for 20-24 h at 30°C, until reaching an OD600 of at least 
1.5. About 30-50 ml of this culture was transferred to fresh pre-warmed YPDA and 
allowed to grow at 30°C to OD600 0.8-0.9. The cells were pelleted and washed in 
sterile water before the spin was repeated. Cell pellets were resuspended in 1.5 ml 
freshly made 1 x TE/LiAc solution (10mM Tris-HCl, pH7.5, 1mM EDTA, 100mM 
lithium acetate), after which they were divided into 0.25-0.3 ml aliquots. To each 
aliquot of the freshly made competent cells, about 1 μg of plasmid DNA and 0.1 mg 
of heat denatured carrier DNA was added, after which 0.6 ml freshly prepared 
PEG/LiAc (10mM Tris-HCl, pH7.5, 1mM EDTA, 100mM lithium acetate, 40% 
polyethylene glycol 3350) was added. The samples were allowed to mix at 30°C for 
30 min before DMSO was added to a final concentration of 10%. Heat shock was 
applied for 15 min at 42°C, after which the cells were immediately chilled on ice. The 
cells were pelleted, resuspended in 5 ml YPDA and allowed to recover at 30°C for 1 
h. The volume of the cells was minimized by centrifugation and resuspending them in 
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0.25-0.3 ml of 1x TE. The cells were plated onto appropriate SDO plates and 
incubated for about 3 days at 30°C. 
 
2.9.2 Verification of protein expression 
 Yeast cells transformed with either a positive clone of pGBK-T7-Spry2 or an 
empty pGBK-T7 vector were tested for positive expression of the Spry2 protein. 
Overnight cultures grown for 24 h at 30°C were diluted in a 1:5 ratio in approximately 
100 ml YPDA and grown to OD600 0.9, then collected by centrifugation. The cell 
pellet was washed twice with cold PBS and resuspended in lysis buffer (100 mg : 200 
μl) (1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 50 mM Tris-HCl, pH 
7.5, containing a cocktail of protease inhibitors), to which 50 mg glass beads (425-600 
microns) were added. These were vortexed twice for 10 min each time at 4°C. The 
yeast cell lysate was clarified and mixed with an equal volume of 2x Laemmli buffer 
to obtain WCL samples. The samples were separated on SDS-PAGE and 
immunoblotted with Spry2 antibody to verify the expression of the bait protein.  
 
2.9.3 Interaction control 
 The bait protein was tested for its ability to interact by verifying its interaction 
with known interacting partners and the absence of interaction with known non-
interacting partners. Large single colonies of compatible mating yeast strains 
transformed with either the bait plasmid or interacting/non-interacting counterpart 
were mixed in 0.5 ml 2x YPDA. Yeast mating was allowed to take place at 30°C for 
20-24 h with constant shaking, after which they were spread onto DDO (-Leu/-Trp), 
TDO (-Leu/-Trp/-His) and QDO (-Leu/-Trp/-His/-Ade) plates coated with X-α-gal. 
The plates were incubated at 30°C for 4-6 days to allow yeast colony formation. 
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2.9.4 Toxicity testing 
 The bait protein was tested for toxicity in yeast cells. Overnight saturated 
cultures of the bait-containing yeast cells and cells containing the empty pGBK-T7 
vector were grown in single drop-out lacking Trp (SDO -Trp). An aliquot of the 
overnight culture was used to inoculate fresh pre-warmed YPDA liquid media in a 
1:10 ratio, and allowed to grow at 30°C with constant shaking. The growth of the 
separate cultures was monitored over a period of 6-8 h by measuring the OD600 of an 
aliquot of the culture every hour. The growth curves of the two cultures were obtained 
and compared to determine if the bait protein was affecting the rate of growth of the 
yeast cells. 
 
2.9.5 Self-activation test 
 Full-length Spry2 was tested for its suitability as bait in a yeast two-hybrid 
screen by determining if it would activate transcription of the reporter gene (MEL1) in 
the absence of an interacting partner. Yeast colonies containing the pGBK-T7-Spry2 
plasmid were inoculated in 2x YPDA medium with colonies of yeast containing the 
empty pGAD-T7 vector for yeast mating as described in Section 2.8.3. Kanamycin 
(50 μg/ml) was added to the medium to prevent bacterial growth. As a control, yeast 
cells containing only the empty pGBK-T7 plasmid were inoculated with pGAD-T7. 
After growing for 24 h at 30°C, the cells were pelleted and plated out onto DDO (–
Leu/-Trp), TDO (–Leu/-Trp/-His) and QDO (–Leu/-Trp/-His/-Ade) agar plates that 
have been coated with X-α-gal and incubated at 30°C for 4-6 days. The plates were 
observed for both growth and colour of yeast colonies. Growth on DDO plates was an 
indication of the presence of both plasmids, while minimal growth on both TDO and 
QDO plates implied no self-activation. The absence of blue colonies was taken as an 
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indication that the bait protein did not induce self-activation of transcription of the 
reporter gene. 
 
2.9.6 Yeast library screening 
 Yeast cells containing the bait plasmid were grown for 24 h at 30°C in 50 ml 
SDO (-Trp) medium to OD600 1.4-1.5. Kanamycin (50 μg/ml) was added to the 
medium to prevent bacterial growth. The yeast cells were pelleted and resuspended in 
5 ml SDO (-Trp) before being added to 45 ml 2x YPDA containing 50 μg/ml 
kanamycin. A 1 ml aliquot of the yeast pre-transformed library was thawed out and 
added immediately to the medium containing the bait cells. The two yeast strains were 
incubated at 30°C with gentle swirling for 20-24 h to facilitate mating, after which the 
cells were pelleted and resuspended to a final volume of 10 ml in 0.5x YPDA 
containing kanamycin. Aliquots of the cells were then spread onto 50 TDO plates 
coated with X-α-gal for selection of positive clones and incubated at 30°C for 7 days. 
Blue colonies from the screen were then streaked onto QDO/X-α-gal plates for higher 
stringency screening. Only blue colonies QDO/X-α-gal plates were used for further 
experiments. 
 
2.9.7 Large scale plasmid isolation 
 Positive blue colonies from the QDO/X-α-gal plates were inoculated and 
grown in 1 ml cultures in deep 96-well plates at 30°C for 20-24 h. The cells were 
pelleted and washed in 100 μl sterile water. Washing was repeated using 100 μl 
rescue buffer (50 mM Tris-HCl, pH 7.5, 10 mM EDTA, 0.3% β-mercaptoethanol) and 
the final cell pellets were resuspended in 10 μl fresh lysis buffer (rescue buffer 
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containing 50 U lyticase). Cell wall digestion was allowed to take place at 37°C of 1 h 
with constant agitation followed by cell lysis with the addition of 10 μl of 10% SDS. 
Yeast genomic DNA was precipitated at -20°C with 40 μl of 7.5 M ammonium 
acetate and subsequent centrifugation, and the supernatant was used to precipitate 
plasmid DNA by centrifuging with 0.7x volume of isopropanol. The final plasmid 
DNA pellets were washed with 70% ethanol, dried and dissolved in TE buffer (10 
mM Tris-HCl and 1 mM EDTA, pH 8.0). The purified plasmid DNA was 
electroporated into DH10B E. coli cells and grown on LB agar plates containing 
ampicillin. For every original yeast colony, three separate bacterial colonies from the 
transformation were inoculated in liquid LB-ampicillin and cultured overnight at 
37°C. Plasmids were extracted from the bacterial cells and sent for identification 
through sequencing 
 
2.9.8 Sequencing and identification of isolated clones 
 Plasmids isolated from each of the bacterial clones were digested using EcoRI 
and XhoI and separated on a 1% agarose gel. If the pattern and size of the digested 
fragments were the same for all the three bacterial clones that originated from one 
yeast clone, one bacterial clone was chosen as a sequencing template using a T7 
primer. If the pattern was different, one clone corresponding to each pattern was 
chosen for sequencing. The sequences obtained were identified using the BLAST 
program against the NCBI Genbank database. The sequences were also checked to 
determine if the inserts were cloned in the correcting reading frame, according to the 
identity obtained from the BLAST search program. Only in-frame clones were sub-




2.9.9 Subcloning of in-frame clones 
Where possible, in-frame clones were digested with BamHI and XhoI for 
subcloning into the mammalian expression vector pcDNA3.1(-) (BamHI and BglII 
ends are compatible). This would allow the N-terminal HA-tag originally present in 
pACT2 to be carried over into pcDNA3.1(-). The inserts of in-frame clones that had 
internal BamHI or XhoI sites were amplified using PCR and sub-cloned into pXJ40-
HA. Ligated products were transformed into E. coli DH10B cells, and purified 
plasmids from the bacterial cells were digested to verify the presence of the insert.  
 
2.9.10 Expression and binding in mammalian cells 
 Once the library clones were subcloned into either pcDNA3.1(-) or pXJ40-
HA, they were transfected into 293T cells and whole cell lysates were immunoblotted 
with HA antibody to determine expression of the protein. In some cases, expression of 
the proteins was negatively affected by the presence of an unusually long 3’ UTR tail 
in the clone. Since the library was constructed using oligo-dT priming, the clones 
were biased towards the 3’ end of the genes, and 3’ UTR sequences have been known 
to contain degradation signals which downregulate protein expression. For such 
clones, the cDNA was amplified using PCR so as to exclude the 3’ UTR and ligated 
into the pXJ40-HA vector. Once expression of the proteins were verified, the 
plasmids were co-expressed with pXJ40-FLAG-Spry2 in 293T cells, and the lysates 
were subjected to immunoprecipitation with FLAG antibody (as described in Section 







3.1 Characterizing the interaction between Spry2 and its interacting partners 
 While Sprouty2 (Spry2) has been shown to inhibit Ras/ERK activation by 
receptor tyrosine kinases (RTKs), the reported mechanisms by which Spry2 is able to 
carry this function out have been relatively limited. Currently, Spry2 has been 
observed to block the interaction between Grb2 and Sos (Lao et al., 2006), as well as 
block Ras/ERK signaling at the level of Raf (Yusoff et al., 2002) suggesting that 
Spry2 may act at various points along the Ras/ERK pathway. Moreover, since many 
pathways have the capacity to lead to ERK1/2 activation, the question arose as to 
whether Spry2 could also act at different points along alternate pathways to inhibit 
ERK1/2 activation. This study was therefore undertaken to expand upon the existing 
knowledge of Spry2 as an inhibitor of ERK1/2 signaling, and to decipher its role in 
pathways feeding into the canonical Ras/ERK pathway. 
 
3.1.1 Yeast two-hybrid screen to identify interacting partners of Spry2 
 In order to understand how Spry2 might affect other pathways, it was 
necessary to identify its interacting partners. To this end, a yeast two-hybrid screen 
was employed to identify interacting partners of full-length Spry2. As Spry2 has been 
reported to be highly expressed in the mouse embryo during organogenesis 
commencing at E8.5-9.5 (Minowada et al., 1999), an 11-day mouse embryo pre-
transformed library was used. Full-length Spry2 was found to be suitable for use as 
bait; the protein that was expressed in yeast cells was able to interact with a known 
interacting partner, Tesk1 (Chandramouli et al., 2007), and it neither showed any 
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toxicity to the yeast cells, nor demonstrated any self-activation of transcription of the 
reporter gene.  
 From the screen, positive clones were selected under high stringency (as 
described in Materials and Methods) and subcloned into either pcDNA3.1(-) or 
pXJ40-HA for sequencing and subsequent mammalian expression studies. Co-
immunoprecipitation studies were carried out in 293T mammalian cells with 
transfected proteins to verify the yeast interaction. A list of verified, in-frame clones 
is tabulated in Table 3.1.1. Of these, Phospholipid scramblase 3 (Plscr3) has been 
reported to be involved in apoptosis and the maintenance of membrane asymmetry 
(Wiedmer et al., 2000), and Wingless-related MMTV integration site 11 (Wnt11) has 
been demonstrated to be involved in kidney development (Chi et al., 2004). The 
interaction between Spry2 and these two proteins is shown in Figure 3.1.1 as a 
representative set of confirmed interactions from the yeast two-hybrid screen.  
 
3.1.2 Cloning of Plscr3 and its interaction with Spry proteins 
 The recovery of three clones of Plscr3 from the yeast two-hybrid screen was 
the highest representation of a gene whose product interacted with the bait, Spry2. As 
such, this interaction was more closely examined. 
Full-length mouse Plscr3 was cloned from mouse liver tissue and its 
expression was verified in 293T cells. The full-length protein was tested for its 
interaction with Spry1, Spry2 and Spry4, as well as the Y55F mutant of Spry2 in 
293T cells. 293T cells transfected with the three Spry isoforms and Spry2Y55F, in the 
presence or absence of Plscr3, were harvested and subjected to immunoprecipitation 
(IP) with FLAG antibody. As seen in Figure 3.1.2, Plscr3 immunoprecipitates with 
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Spry2, verifying the binding seen in yeast cells. Plscr3 also interacted with the Y55F 




Proteins Genbank accession no. 
Number of 
clones 
Fibrillin 1 (Fbn 1) NM_007993 1 
Cytoskeleton-associated protein 1 NM_025548 2 
Phospholipid scramblase 3 (Plscr3) NM_023564 3 
Wingless-related MMTV integration site 
11 (Wnt11) NM_009519 2 
Ran binding protein 9 (RanBP9) NM_019930 2 
Lim-homeodomain protein Islet 1 NM_021459 1 
 
 
Table 3.1.1 Interacting partners of Spry2 isolated from the yeast two-hybrid 
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Figure 3.1.1. Representative results of binding partners to Sprouty2 
isolated in the yeast two-hybrid screen.
293T cells transfected with FLAG-tagged Sprouty2 and HA-tagged (A) 
Plscr3 and (B) Wnt11 were immunoprecipitated (IP) with an antibody 
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Figure 3.1.2 Plscr3 interacts with all the Spry isoforms
293T cells were transfected with FLAG-tagged Spry1, 2, 4 or the Y55F mutant 
of Spry2 and HA-tagged Plscr3. Lysates were subjected to immunoprecipitation 
(IP), and subsequently immunoblotted using the antibodies indicated. Whole cell 
lysates (WCL) were used as controls to ensure equal expression of the proteins. 
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3.1.3 Spry2 interacts with Plscr3 mainly through its C-terminal domain 
 Since Plscr3 interacted with all the Spry isoforms tested, it was suspected that 
it would interact with the cysteine-rich C-terminal domain of Spry2. This domain is 
relatively conserved between all the mammalian Spry isoforms. In order to map the 
region of interaction on Spry2, Plscr3 was co-expressed with the N- (a.a. 1-179) and 
C- (a.a. 179-315) terminal domains of Spry2 (Figure 3.1.3A), and co-
immunoprecipitation was performed on cell lysates. The results in Figure 3.1.3B 
indicate Plscr3 binds to Spry2 mainly on the C-terminal domain of the protein. There 
is, however, a significant, but weaker binding to Plscr3 with the N-terminus of Spry2. 
This suggests that most of the interaction occurs on the conserved C-terminal 
cysteine-rich domain, and explains in part how Plscr3 is able to interact with all the 
Spry isoforms. The N-terminal domain of Spry2 may also play a key role in the 
interaction between Spyr2 and Plscr3. The N-termini of the Spry isoforms are 
relatively non-conserved, with the exception of a few amino acid residues. Since the 
earlier results show that the interaction between Plscr3 and Spry4 is the strongest 
among all the isoforms tested, this implies that there may be sequences or residues 
present in Spry4, that are either absent or imperfectly substituted in Spry2, that affect 
its interaction with Plscr3. More importantly, the Y55 motif (NXYS/TXXP) of Spry2 
is also present in Spry1 and Spry4. Since the results show that the Y55 residue is not 
needed for interaction between Plscr3 and Spry2, this conserved motif would most 































1      2     3     4      5      6     7
Figure 3.1.3 Spry2 interacts with Plscr3 mainly through its C-terminal 
domain.
(A) Schematic representation of the Spry2 truncation constructs used to map 
the region of interaction with Plscr3. (B) 293T cells were transfected with 
HA-tagged Plscr3 and FLAG-tagged Spry2. Cell lysates were 
immunoprecipitated using FLAG antibody and the presence of Plscr3 in the 




3.1.4 Plscr3 interacts with PKCδ upon UV irradiation 
 In order to understand the role Spy2 plays in Plscr3 signaling, it was necessary 
to identify upstream activators and/or downstream effectors of Plscr3. It has been 
previously reported that PKCδ will phosphorylate Plscr3 upon UV irradiation, as part 
of apoptotic signaling (Liu et al., 2003). To verify this interaction, 293T cells were 
transfected with Plscr3 and PKCδ plasmid DNA, and were subjected to UV 
irradiation. The cell lysates were immunoprecipitated with PKCδ antibody and 
immunoblotted with HA antibody to detect the presence of Plscr3 in the 
immunoprecipitates. As seen in Figure 3.1.4, Plscr3 is able to interact with PKCδ 
upon UV irradiation, thus supporting previously reported data (Liu et al., 2003). 
 
3.1.5 Discussion and Conclusions 
 It is clear from the results obtained that Spry2 interacts strongly with Plscr3. 
Moreover, all the Spry isoforms are able to interact with Plscr3, albeit to varying 
degrees. This suggests that there is probably some commonality in the function of 
Spry proteins with respect to Plscr3. At the time of the experiments, little was known 
about the action of Plscr3. Although a few cellular and physiological functions of 
Plscr3, such as apoptosis and obesity, have been described by other groups (Liu et al., 
2003; Wiedmer et al., 2004), the mechanism by which Plscr3 exerts its effects to 
achieve its physiological outcome is poorly defined. The lack of available functional 
assays restricted further studies regarding the interaction between Sprys and Plscr3. 
Recent research has implicated Plscr3 in tBid signaling and adipocyte development 
(Wiedmer et al., 2004; He et al., 2007); it may be of interest to study the Spry-Plscr3 
interaction more closely in the future experiments. 
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Figure 3.1.4 Verification of PKCδ
 
as an interaction partner of Plscr3.
293T cells were transfected with HA-tagged Plscr3 and myc-tagged PKCδ, 
and UV-irradiated 24h post-transfected. The cells were allowed to recover for 
6h after that before being harvested and subjected to immunoprecipitation 
using PKCδ
 
antibody. Immunoprecipitates and WCL were immunoblotted 
using the antibodies indicated. 
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3.2 Characterization of interaction between Spry2 and PKCδ 
 The observation that Plscr3 is a target of PKCδ is of significant interest. PKCδ 
signaling has been reported to be regulated by Spry2 in Xenopus cells (Sivak et al., 
2005). In addition, studies have also shown PKCδ to be involved in ERK1/2 signaling 
via Raf (Ueda et al, 1996). Notably, this is one point where Spry2 has been reported 
to inhibit ERK1/2 signaling (Yusoff et al., 2002). It would therefore appear that Spry2 
is a common factor between Plscr3 and PKCδ. Based on these observations, it was 
decided that the effect of Spry2 on PKCδ should be more closely studied.  
 
3.2.1 Spry2 interacts with PKCδ 
 In order to understand how Spry2 might influence the action of PKCδ, 
evidence for an interaction between Spry2 and PKCδ was first sought. The different 
isoforms of Spry - Spry1, 2 and 4, as well as the Y55 mutant of Spry2, were 
transfected into 293T cells and tested for their interaction with endogenous PKCδ 
using immunoprecipitation technique. Of the isoforms tested, only Spry2 was able to 
complex with endogenous PKCδ, and only upon FGFR1 activation (Figure 3.2.1). 
Neither Spry1 nor Spry4 had any discernible interaction with endogenous PKCδ. The 
Y55 residue of Spry2 is also important, since mutation of this residue abrogates 
binding with PKCδ. Since PKCδ does not appear to have a domain that would 
recognize the Y55 motif on Spry2, it would seem unlikely that PKCδ binds to the Y55 
motif directly. On the other hand, it has previously been reported by this laboratory 
that phosphorylation on the Y55 residue of Spry2 causes a conformational change to 
facilitate its its binding to Grb2 (Lao et al., 2006). It is possible that this could also be 
the case with PKCδ. 
 91
Sprouty (FLAG) - -S2 Y5
5F











1    2    3     4     5    6     7    8     9    10
76kD
Figure 3.2.1 Sprouty2 interacts with PKCδ
 
upon FGFR1 activation.
Lysates of 293T cells transfected with Spry2, Spry2Y55F, Spry1 or Spry4, 
with or without FGFR1, were immunoprecipitated (IP) using agarose- 
conjugated anti-FLAG. The immunoprecipitates were separated on SDS- 
PAGE and immunoblotted with the antibodies indicated on the left. Expression 
of the respective proteins was verified by immunoblotting whole cell lysates 
(WCL) with indicated antibodies. 
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3.2.2 Spry2 interacts specifically with PKCδ 
 In order to determine if Spry2 interacts specifically with PKCδ, Spry2 was 
tested for interaction with a selection of other PKC family members. The PKC family 
consists of three subfamilies, depending on their co-factor requirements. Spry2 was 
expressed in 293T cells and an endogenous representative of each subfamily was 
assayed for co-immunoprecipitation with Spry2 upon FGFR1 activation. The PKC 
isoforms tested were PKCα (conventional), PKCε (novel) and PKCζ (atypical). The 
results show that, of all the PKC isoforms tested, only PKCδ showed any discernible 
interaction with Spry2 (Figure 3.2.2). This implies that Spry2 interacts specifically 
with PKCδ, and that the mechanism of action of Spry2 in this instance applies only to 
PKCδ. 
 
3.2.3 Interaction between Spry2 and PKCδ occurs with acute FGF stimulation 
 The interaction between Spry2 and endogenous PKCδ was tested with forced 
expression of FGFR1, which is considered auto-activating. While this is reasoned to 
mimic the longer term signaling seen in development and cancer progression, it is 
necessary to verify if this interaction occurs with acute FGF stimulation. Prostate 
cancer PC-3 cells, which have been reported to show high FGFR1 levels, were used 
for the next set of experiments using bFGF stimulation. Spry2 was transfected into 
PC-3 cells and the cells were serum starved 24 h-post transfection. Stimulation using 
bFGF was carried out as described in Materials and Methods, and cell lysates were 
immunoprecipitated with FLAG antibody. The immunoprecipitates were then 
examined for the presence of PKCδ. Similar to the findings with FGFR1 activation, 
the interaction between PKCδ and Spry2 was induced with bFGF stimulation (Figure 




































































Figure 3.2.2 Spry2 interacts specifically with PKCδ.
293T cells were transfected with FLAG-tagged Spry2 and FGFR1, and the 
lysates were immunoprecipitated against anti-FLAG. The immunoprecipitates 
were separated on SDS-PAGE and immunoblotted with the antibodies 
indicated on the left. Expression of the respective proteins was verified by 
immunoblotting whole cell lysastes (WCL) with the indicated antibodies. 





Spry4. This suggests that the results obtained using FGFR1 activation are similar to 
those obtained with bFGF stimulation. 
 
3.2.4 PKCδ and Spry2 form a complex endogenously 
 In order to determine if the interaction between Spry2 and PKCδ is 
physiologically relevant, the interaction would have to occur at the endogenous levels 
of the respective proteins. To verify this, co-immunoprecipitation of the endogenous 
proteins was carried out using lysates from serum starved PC-3 cells, that have been 
either stimulated with bFGF or left untreated. The cell lysates were 
immunoprecipitated using either PKCδ antibody, or normal rabbit IgG as control and 
subsequently assayed for the presence of endogenous Spry2 using a Spry2 N-terminal 
antibody. The results in Figure 2.3.4A indicate that upon FGF stimulation, 
endogenous Spry2 is able to complex with endogenous PKCδ in vivo. This 
experiment was repeated by immunoprecipitating endogenous Spry2, and detecting 
the presence of endogenous PKCδ in the immunoprecipitates. As seen in Figure 
2.3.4B, the results are similar to those shown earlier. This implies that the complex 
formed by PKCδ and Spry2 is likely to be physiologically relevant. 
 
3.2.5 Full-length Spry2 is required for its interaction with PKCδ 
 Since the interaction between Spry2 and PKCδ is specific to Spry2 and not the 
other Spry isoforms, it was hypothesized that binding to PKCδ would occur on the 
relatively less conserved N-terminus, where there are more sequences that are unique 
to each isoform. In order to define the region of interaction, the following truncation 
constructs of Spry2 were made (Figure 3.2.5). The hSpry2N1-179 and C179-315 
constructs essentially divide Spry2 into its less-conserved N-terminal and its 
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Figure 3.2.3 Spry2 interacts with PKCδ
 
upon FGF stimulation.
Transfections were carried out in PC-3 cells, and stimulation was carried out 
using bFGF (50ng/ml) for 2h after 3h serum starvation. Lysates were subjected 
to immunoprecipitation (IP) using FLAG antibody and immunoprecipitates and 
whole cell lysates (WCL) were subjected to immunoblotting using the 






















WCL IP: PKCδ IgG control





















WCL IP: Spry2 IgG control
WB: anti-PKCδ
WB: anti-Spry2
1               2            3              4            5      6
PKCδ
Figure 3.2.4 Spry2 and PKCδ
 
interact with each other endogenously
PC-3 cells were either stimulated with bFGF (50ng/ml) or left untreated for 2h 
after 3h serum starvation, and the lysates were immunoprecipitated with (A) 
PKCδ
 
antibody or normal rabbit immunoglobulin (IgG) as control, and (B) 
with Spry2 antibody or normal rabbit IgG as control. The positions of the co- 




conserved C-terminal regions. Two other sets of complementary N- and C-terminal 
truncation mutants were also made. 
 Full-length Spry2 and the Spry2 complementary truncation mutants 
hSpry2N1-179 and C179-315 were transfected separately into 293T cells and 
immunoprecipitated either in the presence or absence of FGFR1 activation. The 
immunoprecipitates were then immunoblotted for the presence of PKCδ. The results 
as shown in Figure 3.2.6 indicate that PKCδ interacts only with full-length Spry2, and 
with neither its N- nor C-terminal mutants. In order to rule out the possibility that the 
binding site for PKCδ was cleaved upon truncation of the Spry2 protein, two other 
sets of complementary truncation mutants, with the truncation site moved 
progressively towards the N-terminus, were employed. Again, the results in Figure 
3.2.7 indicate that full-length PKCδ is able to interact only with full-length Spry2. 
This would imply that there may be multiple interaction sites on Spry2, and that any 
one region alone is insufficient for its interaction with PKCδ.  
 
3.2.6 Interaction between Spry2 and PKCδ is conformation dependent 
 The next step in identifying the sites necessary for the interaction between 
PKCδ and Spry2 was to map the region of interaction on PKCδ. To do this, a set of 
complementary truncation mutants of PKCδ were made. As shown in Figure 3.2.8A, 
the truncation divides the protein into its N-terminal regulatory domain, and its C-
terminal catalytic domain. In order to determine the interaction sites on PKCδ, the 
two truncation mutants of PKCδ, along with the full-length protein, were co-
expressed separately with Spry2 in 293T cells. The binding was assessed via 
immunoprecipitation with FLAG antibody, and subsequent immunoblotting with myc 










Figure 3.2.5 Construction of Spry2 truncated proteins.
Schematic diagram showing the different domains and truncation constructs 
of Sprouty2. Y55: Y55 residue of the conserved Y55 motif NXYS/TXXP of 
Sprouty2. The truncations were progressively moved N-terminal. 
99






















1      2     3     4      5     6     7      8
Figure 3.2.6 Full length Spry2 protein is required for interaction with 
PKCδ
293T cells were transfected with full-length, N-terminal (Spry2N1-179) or C- 
terminal (Spry2C179-315) Spry2, and FGFR1. Cell lysates were 
immunoprecipitated (IP) using anti-FLAG conjugated beads and then used for 
immunoblotting with the antibodies indicated on the left. WCL samples were 
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Figure 3.2.7 Verification of the requirement of a full-length Spry2 protein 
for its interaction with PKCδ.
Lysates of 293T cells transfected with full length Spry2, the N-terminal or C- 
terminal truncated mutants of Spry2, with or without FGFR1, were 
immunoprecipitated (IP) using agarose-conjugated anti-FLAG. The 
immunoprecipitates were separated on SDS-PAGE and subsequently 
immunoblotted using the antibodies indicated on the left. Expression of the 
respective proteins was verified by immunoblotting whole cell lysates (WCL) 
with the indicated antibodies. 
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Figure 3.2.8B. Both N- and C-terminal domains of PKCδ are able to interact with 
full-length Spry2, with the C-terminal interaction being slightly stronger. These 
interactions increased upon FGFR1 activation. Reiterating the results from earlier 
experiments, full-length PKCδ does not interact with Spry2 in the absence of FGFR1 
activation: the interaction occurs only when FGFR1 is activated. While these results 
support the assumption that there may be more than one possible site of interaction, 
they also suggest that a physical conformational constraint is present in the full-length 
PKCδ protein, which is released only upon FGFR1 activation, thus permitting the 
interaction to take place. By truncating the protein, the physical constraints are 
released, allowing full-length Spry2 to interact even in the absence of FGFR1 
activation. The interactions also appear to be dependent on the occurrence of post-
translational modifications, since they strengthen upon FGFR1 activation. This 
implies that while the residues are available for interaction, post-translational 
modifications are needed for maximum interaction.  
 In order to validate these results, the regulatory and catalytic domains of 
PKCδ were co-expressed with either the N- or C-terminal domains of Spry2. The cell 
lysates were immunoprecipitated using FLAG antibody, and immunoprecipitated 
PKCδ was detected by immunoblotting with myc antibody. The N-terminal region of 
Spry2 was able to interact with the C-terminal catalytic domain of PKCδ in the 
absence of FGFR1 activation, but the interaction increases upon FGFR1 activation 
(Figure 3.2.9). In the reciprocal experiment, the C-terminal region of Spry2 was found 
to interact with the regulatory and catalytic domains of PKCδ in a similar manner. In 
this case, the C-terminus of Spry2 interacts with both the regulatory and catalytic 
domains of PKCδ, and once again, this interaction increased in the presence of 
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(A) Schematic representation of the different domains and truncation 
constructs of PKCδ. (B) Full length, N-terminal (N1-345) and C-terminal 
(C346-674) myc-tagged PKCδ
 
constructs were transfected into 293T cells. 
Lysates were immunoprecipitated (IP) with myc antibody, and 
immunoprecipitates and WCL were immunoblotted with the antibodies 
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Figure 3.2.9 N-terminal Spry2 interacts with C-terminal PKCδ
 
protein: the interaction is conformation-dependent.
Lysates of 293T cells transfected with FLAG-tagged N-terminal Spry2 1- 
179 and either myc-tagged full-length, N-terminal or C-terminal PKCδ, 
with or without FGFR1, were immunoprecipitated using agarose- 
conjugated FLAG antibody. The immunoprecipitates were immunoblotted 
using the antibodies shown on the left after separation on SDS-PAGE. 
Expression of the respective proteins was confirmed by immunoblotting 
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Figure 3.2.10 C-terminal Spry2 interacts with both N- and C- terminal 
PKCδ: the interaction is conformation-dependent.
Lysates of 293T cells transfected with FLAG-tagged C-terminal Spry2 
(179-315) and either myc-tagged full-length, N-terminal or C-terminal 
PKCδ, with or without FGFR1, were immunoprecipitated using agarose- 
conjugated anti-FLAG. The immunoprecipitates were separated on SDS- 
PAGE and immunoblotted using the antibodies shown on the left. Protein 
expression was verified by immunoblotting whole cell lysates using the 
indicated antibodies.
105
Taken together, the results suggest that the interactions take place on multiple 
sites of the proteins. Using only truncation mutants to define specific interaction sites, 
however, is extremely limiting. The results presented also strongly indicate that the 
interaction between Spry2 and PKCδ is dependent on the conformation of both 
proteins. The interaction also appears to be controlled, in part, by the conformation of 
at least one of the proteins, since truncated Spry2 proteins are unable to interact with 
full-length PKCδ, but the full-length and truncated Spry2 proteins are able to interact 
with the separate regulatory and catalytic domains of PKCδ. Lastly, the interaction 
appears to be dependent on some form of post-translational modification that takes 
place upon FGFR1 activation, since the interaction between the truncated proteins 
increases upon FGFR1 activation.  
 
3.2.7 Spry2 co-localizes with PKCδ 
 To validate the biochemical data, the localization of Spry2 and PKCδ was 
examined using immunofluorescence microscopy. Spry2 was transfected into serum 
starved COS1 cells which were either stimulated with bFGF or left untreated. Both 
proteins were detected by first staining fixed permeabilized cells with primary 
antibodies specific to the respective proteins, followed by fluorophore-conjugated 
secondary antibodies. The cells were then viewed using a Zeiss LSM 510 META. 
 The results presented in Figure 3.2.11 show the localization of the proteins in 
the presence and absence of bFGF stimulation. Panels (a) and (b) show the 
localization of PKCδ in the absence of Spry2, before and after bFGF stimulation, as 
controls. PKCδ is cytoplasmically localized in the absence of stimulation, but 
translocates to the cell membrane upon FGF stimulation. In the presence of Spry2, 













Figure 3.2.11 Determining the localization of Spry2 and PKCδ
 
proteins
COS1 cells were transfected with FLAG-tagged Spry2. Transfected cells 
were serum starved overnight and either left untreated (panels c), or 
stimulated with 100ng/ml bFGF (panels d) for 1h. Cells were fixed and 
stained with mouse anti-FLAG and rabbit anti-PKCδ, followed by anti- 
mouse IgG (green) and anti-rabbit IgG (red) staining. Panels a and b show 
untransfected COS1 cells stained for PKCδ
 
as a control. 
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before and after FGF stimulation, as shown in panels (c) and (d). Spry2, on the other 
hand, is localized on the microtubules before FGF stimulation, but translocates to the 
cell membrane after bFGF treatment. The two proteins are therefore found to co-
localize at the cell membrane upon FGF stimulation. This supports the biochemical 
data that Spry2 interacts with PKCδ only upon FGFR1 activation or FGF stimulation. 
Since the two proteins co-localize upon bFGF stimulation, the possibility of them 
interacting is supported. In order to verify this co-localization is not limited to one 
cell, the results of the same experiment showing co-localization in more than one cell 

















Figure 3.2.12 Verification of the co-localization of Spry2 and PKCδ
 
proteins.
COS1 cells were transfected with FLAG-tagged Spry2. Transfected cells 
were serum starved overnight and either left untreated (panels c), or 
stimulated with 100ng/ml bFGF (panels d) for 1h. Cells were fixed and 
stained with mouse anti-FLAG and rabbit anti-PKCδ, followed by anti- 
mouse IgG (green) and anti-rabbit IgG (red) staining. Panels a and b show 
untransfected COS1 cells stained for PKCδ
 
as a control. The image of more 
than one cell per field is taken to verify co-localization of Spry2 and PKCδ
 
in cells expressing both proteins.
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3.3 Mechanism of action of Spry2 
 The experimental evidence so far has suggested that the interaction between 
Spry2 and PKCδ is a complex one, being dependent on FGFR1 activation, multiple 
sites of interaction, conformation and post-translational modification. Since the 
association appears to be physiologically relevant through their endogenous 
interaction, the consequence of this interaction was further investigated by testing the 
mechanism of action of Spry2 on PKCδ. 
 
3.3.1 Spry2 interacts with PLCγ1 
 PLCγ1 operates upstream of PKCδ signaling, and hydrolyzes PtdIns(4,5)P2 to 
diacylglycerol (DAG) and inositol (1,4,5) trisphosphate [Ins(1,4,5)P3]. DAG then 
binds to the pseudosubstrate domain of PKCδ, which allows it to localize to the cell 
membrane to phosphorylate its substrates. In order to determine if Spry2 exerted an 
effect on PKCδ via PLCγ1, a possible interaction between Spry2 and PLCγ1 was 
examined. 
 The different Spry isoforms were expressed in 293T cells in the presence or 
absence of FGFR1 activation. Cell lysates were collected and subjected to 
immunoprecipitation using FLAG antibody and the immunoprecipitates were 
immunoblotted to ascertain the presence of PLCγ1. The results in Figure 3.3.1 
indicate that all the Spry isoforms are able to interact with endogenous PLCγ1 only 
upon FGFR1 activation. In addition, the Y55F mutant of Spry2 is also able to interact 
with PLCγ1. This suggests that PLCγ1 does not interact specifically with any single 
Spry isoform. Furthermore, unlike the case with PKCδ, the Y55 residue of Spry2 is 
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Figure 3.3.1 Spry2 interacts with PLCγ1 in a stimulation-dependent 
manner.
293T cells were transfected with FLAG-tagged Spry proteins, with or without 
FGFR1. Cell lysates were immoprecipitated against FLAG antibody. The 
presence of endogenous PLCγ1 was detected in the immunoprecipitates by 
immunoblotting. Equal protein expression by immunoblotting WCL samples.
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To further verify that the pattern of interaction between PLCγ1 and Spry2 is 
not similar to that between PKCδ and Spry2, the interaction was tested using the N- 
and C-terminal truncations of Spry2, also in the presence or absence of FGFR1 
activation. Immunoprecipitates were assayed by immunoblotting to determine if either 
region of Spry2 interacted with PLCγ1. The results in Figure 3.3.2 indicate that 
PLCγ1 interacts only with the N-terminal region of Spry2. This is interesting since the 
N-terminus of the Spry proteins is considered the less conserved of the two regions. 
The implication of the interaction between the Spry isoforms and PLCγ1 suggests that 
a region or domain common to all the Spry isoforms is necessary for the interaction to 
occur. Since the interaction occurs on the N-terminus of Spry2, however, it suggests 
that the interaction occurs on the few conserved residues in the N-terminus. One of 
the N-terminal motifs conserved between the different Spry isoforms is the Y55 
motif. This would have been a possible interaction site with PLCγ1, given its 
conserved nature and previously reported interaction with other proteins (Fong et al., 
2003; Lao et al., 2007). The results, however, indicate that the Y55 motif is not 
essential for the interaction to take place, since the Y55F mutant of Spry2 is still able 
to interact with PLCγ1. 
 Since the interaction between PLCγ1 and Spry2 does not reflect the pattern or 
specificity of the PKCδ-Spry2 interaction, it was postulated that the PLCγ1-Spry2 
interaction was unlikely to provide clues as to the possible mechanism of action of 
Spry2 on PKCδ. It does not exclude the possibility, however, that the Spry isoforms 
are able, in some way, to influence signaling downstream of PLCγ1 signaling by their 
interaction with PLCγ1. While this interaction deserves further examination, it will 
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Figure 3.3.2 Spry2 interacts with PLCγ1 through its N-terminal domain.
(A) Schematic representation of the Spry2 truncation constructs used to 
determine the region of interaction between Spry2 and PLCγ1. (B) 293T cells 
were transfected with FLAG-tagged Spry2 N- and C-terminal truncated 
constructs, with or without FGFR1. Cell lysates were immunoprecipitated 
using FLAG antibody, and immunoblotting was carried out using the 
antibodies indicated.
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3.3.2 Spry2 does not affect phosphorylation of T505 on PKCδ 
 Like many other kinases, PKCδ requires post-translational modification upon 
stimulation for it to be catalytically active. PKCδ has been reported to be 
phosphorylated within the activation loop on threonine 505 (T505) by an upstream 
kinase. This upstream kinase has variously been reported to be PDK1 (Newton, 2003) 
or PKCε (Rybin et al., 2007). While PKCδ may be catalytically competent in the 
absence of T505 phosphorylation, this phosphorylation is essential for full PKCδ 
activity (Stempka et al., 1999; Rybin et al., 2007). Since Spry2 has been reported to 
inhibit PKCδ signaling (Sivak et al., 2005), the possibility that Spry2 inhibited the 
activity of PKCδ through this residue in the presence of FGFR1, was investigated.  
In this set of experiments, the phosphorylation of T505 was examined in the 
presence and absence of Spry2. 293T cells that had been transfected with Spry2 in the 
presence or absence of activated FGFR1 were harvested and the cell lysates were 
immunoprecipitated and then immunoblotted for the presence of phosphorylated T505 
PKCδ. The results in Figure 3.3.3 show that while PKCδ is phosphorylated upon 
FGFR1 activation, this phosphorylation did not decrease in the presence of Spry2. 
This suggests that the presence of Spry2 does not affect the interaction between PKCδ 
and its upstream kinase. 
 
3.3.3 Spry2 prevents the phosphorylation of PKD1 by PKCδ 
 As Spry2 did not affect PKCδ phosphorylation on T505, it was necessary to 
determine if Spry2 affected the phosphorylation of downstream substrates by its 
association with PKCδ. A former member of the PKC family of kinases, PKD1 
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293T cells were transfected with Spry2-FLAG and FGFR1. Cell lysates were 
immunoprecipitated (IP) with PKCδ
 
antibody and subsequently 
immunoblotted using the antibodies indicated on the left. Whole cell lysates 
(WCL) were also immunoblotted to verify the expression of the proteins. 
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members of the PKC family, including PKCδ (Storz et al., 2004). Activation of PKD1 
occurs upon phosphorylation of two residues within the activation loop: S738 and 
S742 (S744 and S748 in mouse) (Waldron et al, 2001). In order to ascertain that 
PKCδ and its cognate kinase activity is required for the phosphorylation and 
subsequent activation of PKD1, 293T cells were transfected with wild-type and 
kinase-dead PKCδ in the presence of FGFR1 activation. Cell lysates were 
immunoprecipitated using PKD1 antibody and the level of PKD1 phosphorylation 
was determined by immunoblotting using a phospho-S738/742 PKD1-specific 
antibody.  
 As seen in Figure 3.3.4, in the absence of stimulation, PKD1 is not 
phosphorylated when only endogenous PKCδ is present. When activated with 
FGFR1, however, PKD1 is phosphorylated on S738 and S742. On the other hand, 
overexpression of PKCδ in the absence of FGFR1 stimulation causes auto-activation 
of the kinase, leading to the phosphorylation of PKD1 on S738/742 even in the 
absence of FGFR1 stimulation. This phosphorylation can be suppressed by the 
presence of kinase dead PKCδ alone, which persists even in the presence of FGFR1 
stimulation, supporting previously reported data that PKD1 is a substrate of PKCδ. 
 The next step was to determine if Spry2 affected the phosphorylation of PKD1 
through its association with PKCδ. In order to do this, Spry2 and its Y55F mutant 
were expressed in 293T cells in the presence or absence of FGFR1 activation. Lysates 
from these cells were immunoprecipitated using PKD1 antibody, and the levels of 
phosphorylated PKD1 were observed. The effect of Spry2 on PKD1 phosphorylation 
was also examined in the presence of over-expressed, auto-activating PKCδ. The 
results from the experiment show that PKD1 showed basal levels of phosphorylation 
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Figure 3.3.4 PKD1 is a substrate of PKCδ
Wild-type or kinase dead (KD) PKCδ
 
were co-expressed with FGFR1 in 293T 
cells. Endogenous PKD1 was immunoprcipitated (IP) from cell lysates using 
PKD1 antibody, and both the immunoprecipitates and WCL were subjected to 
immunoblotting with the antibodies stated on the left. 
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and, like before, overexpressed PKCδ increased phospho-PKD1 levels (Figure 
3.3.5A, lanes 4-6), as did activation with FGFR1 (Lane 7). However, in the presence 
of Spry2 and FGFR1, the phosphorylation of PKD1 was markedly reduced (Lane 8, 
compared to Lane 7), almost to the same level as seen without FGFR1 stimulation 
(Lane 2). The Y55F mutant of Spry2, which does not interact with PKCδ, did not 
reduce PKD1 phosphorylation (Lane 9). Interestingly, the reduction of PKD1 
phosphorylation by Spry2 could be rescued by overexpressing wild type PKCδ (Lane 
11), suggesting that Spry2, through its interaction with PKCδ, is able to inhibit the 
kinase activity of PKCδ. Furthermore, by increasing the levels of PKCδ in the cell, 
the inhibitory effect of Spry2 on the kinase activity of PKCδ is countered so that 
PKD1 phosphorylation is rescued.  
 The phospho-PKD1 immunoblot bands were quantified using a densitometer 
and the levels of phospho-S738/742 PKD1 relative to the amount of 
immunoprecipitated PKD1 were determined. The bar chart in Figure 3.3.5B 
represents the quantitated phosphorylation levels from Figure 3.3.5A. As seen in 
Figure 3.3.5B, the phospho-S738/742 PKD1 level was reduced almost five times in 
cells expressing Spry2, compared to vector-transfected cells, in the presence of active 
FGFR1. With overexpressed PKCδ, cells expressing Spry2 show a PKD1 
phosphorylation level that is comparable to both vector- and Y55F-transfected cells.  
 
3.3.4 Spry2 interacts more strongly with PKCδ in the presence of PKD1 
 The results obtained so far suggest that Spry2 is able to inhibit the 
phosphorylation of a PKCδ substrate by somehow intervening in the kinase-substrate 
interaction and abrogating the downstream signaling from PKCδ, as seen with the 













- - - +      +      +      - - - +      +      +








































































Figure 3.3.5 Spry2 blocks PKCδ
 
from phosphorylating its susbstrate PKD1.
(A) Wild-type or Y55F mutant of Spry2 was co-expressed in 293T cells with 
either endogenous PKCδ
 
or myc-tagged wild-type PKCδ, and FGFR1. Cell 
lysates were IP using PKD1 antibody, and the immunoprecipitates were 
immunoblotted with the antibodies shown on the left. WCL were also 
immunoblotted to confirm the presence of equal levels of proteins. (B) The 
immunoblot data was scanned using a densitometer and represented in the bar 









may be able to accomplish this are put forward, illustrated in Figure 3.3.6. The first 
possibility involves the sequestration of PKCδ, or the competition between PKD1 and 
Spry2 for the interaction with PKCδ, such that the physical interaction between PKCδ 
and PKD1 is prevented, leading to a reduction in PKD1 phosphorylation. A second 
possible mode of action is that Spry2 blocks the active site on PKCδ so that, although 
PKCδ may still bind to PKD1, it will be unable to phosphorylate its key residues 
(S738 and S742). In this second scenario, the interaction between PKCδ and PKD1 
need not be disrupted.  
 To distinguish between the two alternative possibilities, increasing amounts of 
PKD1 were expressed in 293T cells, either in the presence or absence of FGFR1 
activation, to determine whether PKD1 would influence the relative association 
between PKCδ and Spry2. PKCδ was immunoprecipitated from cell lysates, and the 
immunoprecipitates were then assayed for the relative amounts of Spry2 and PKD1 
present by immunoblotting with FLAG and PKD1 antibodies respectively. Based on 
the results shown in Figure 3.3.7A it was observed that, under activated conditions, 
the amount of Spry2 co-immunoprecipitating with PKCδ increased in the presence of 
increasing amounts of PKD1, suggesting a strengthening of the Spry2-PKCδ 
interaction. The amount of PKD1 co-immunoprecipitating with PKCδ likewise 
increased, as expected, given the increasing levels of PKD1 in the cells. More 
importantly, the results indicate that Spry2 does not sequester PKCδ, nor does it 
compete with PKD1 for the interaction with PKCδ. The amounts of 
immunoprecipitated Spry2 in the presence of increasing levels of PKD1, relative to 
the amount immunoprecipitated in the absence of overexpressed PKD1 is shown in 























Figure 3.3.6 The two alternatives for the mechanism of action by Spry2.
A schematic representation of the two possible modes of action by Spry2. The 
first possibility involves seqeuestration of PKCδ
 
or competition with PKD1. The 
second possibility involves the formation of a trimeric complex with PKCδ
 
and 
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(A) 293T cells were transfected with increasing amounts of PKD1, with or without 
FGFR1 activation. Cell lysates were immunoprecipitated (IP) using PKCδ
 
antibody and subsequently immunoblotted using the antibodies shown on the left. 
WCL were also immunoblotted to verify the presence of equal levels of proteins. 
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This experiment was repeated to determine if similar results would be obtained with a 
reverse immunoprecipitation. 293T cells were transfected in the same manner 
described in the previous experiment, and the cell lysates were immunoprecipitated 
using FLAG antibody. Figure 3.3.8A shows that a similar result was obtained, where 
PKCδ co-immunoprecipitated with Spry2 in a positive relationship with increasing 
PKD1. The relative amount of immunoprecipitated PKCδ is shown in the bar chart in 
Figure 3.3.8B. Taken together, the data from these experiments suggest that 
sequestration is not the mechanism by which Spry2 inhibits PKCδ signaling ruling out 
the first hypothesis. This suggests the alternative possibility that Spry2 can block the 
active site of PKCδ so that it is unable to phosphorylate PKD1. Since PKD1 
seemingly increased the interaction between Spry2 and PKCδ, it is possible that the 
three proteins participate in a trimeric complex. 
 
3.3.5 Spry2 co-localizes with both PKCδ and PKD1           
 In order for PKD1 to interact with Spry2 and PKCδ simultaneously, these 
three proteins would need to have the same cellular localization after stimulation. 
COS1 cells expressing Spry2 were examined using immunofluorescence microscopy 
for the localization of the three proteins before and after stimulation with bFGF. Prior 
to stimulation, both endogenous PKCδ and PKD1 were found in the cytoplasm, while 
Spry2 was mainly localized to the microtubules of COS1 cells, as previously reported 
(Lim et al., 2000). Upon bFGF stimulation, all three proteins co-localized at the cell 
membrane, as seen in Figure 3.3.9. This supports the possibility of a trimeric complex 
consisting of Spry2, PKCδ and PKD1. This was verified by more than one cell in the 
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Figure 3.3.8 Verification that PKD1 increases the interaction between 
Spry2 and PKCδ
(A) 293T cells were transfected with increasing amounts of PKD1, with or 
without FGFR1 activation. Cell lysates were immunoprecipitated (IP) using 
FLAG antibody and subsequently immunoblotted using the antibodies shown 
on the left. WCL were also immunoblotted to verify the presence of equal 
levels of proteins. (B) The relative amounts of immunoprecipitated Spry2 are 





























COS1 cells were transfected with FLAG-tagged Spry2 and serum starved 
overnight. The cells were then either left untreated (panels e) or stimulated with 
bFGF (100ng/ml) (panels f) for 1h. Cells were fixed and stained with mouse 
anti-FLAG, rabbit anti-PKD1 and goat anti-PKCδ, followed by anti-mouse IgG 
(green), anti-rabbit IgG (red) and anti-goat IgG (beige) staining. Panels a, b, c 
and d show COS1 cells stained for PKD1 and PKCδ
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Figure 3.3.10 Verification of co-localization of PKD1, PKCδ
 
and Spry2.
PKD1 co-localizes with both PKCδ
 
and Spry2. Cos 1 cells were transfected 
with FLAG-tagged Spry2 and serum starved overnight. The cells were then 
either left untreated (panels e) or stimulated with bFGF (100ng/ml) (panels f) 
for 1h. Cells were fixed and stained with mouse anti-FLAG, rabbit anti- 
PKD1 and goat anti-PKCδ, followed by anti-mouse IgG (green), anti-rabbit 
IgG (red) and anti-goat IgG (beige) staining. Panels a, b, c and d show Cos 1 
cells stained for PKD1 and PKCδ
 
in the absence of Spry2, as controls. The 
image of more than one cell in each field was captured to verify co- 
localization in cells expressing all three proteins.
126
3.3.6 Spry2 binds directly to both PKCδ and PKD1 
 In order to further verify a trimeric complex, it was necessary to determine 
how Spry2, PKCδ and PKD1 interacted. If the three proteins associated in a trimeric 
complex, Spry2 should be able to interact directly with both PKCδ and PKD1. To 
validate this, a Far-Western blot using GST-tagged Spry2 proteins was performed. 
HA-tagged PKCδ and PKD1 were immunoprecipitated from 293T cell lysates in the 
presence of FGFR1 using HA antibody, with Cdc2 employed as a negative control. 
After the proteins were transferred onto PVDF membranes, they were overlaid with 
either GST-tagged Spry2 protein or GST protein as a negative control. An interaction 
was determined using GST antibody, where the positive bands show up at the size of 
the interacting protein (76kD for PKCδ, and 110kD for PKD1). As seen in Figure 
3.3.11, both PKCδ and PKD1 were found to bind directly to Spry2, whereas binding 
was not observed with Cdc2. This direct binding evidence supports the hypothesis 
that these proteins could potentially form a trimeric complex.         
 
3.3.7 Spry2 requires the ATP-binding site on PKCδ for the interaction            
 It has been shown in earlier experiments that Spry2 is able to reduce the 
phosphorylation of PKD1 by PKCδ, and that it is likely this mechanism does not 
involve sequestering either PKCδ or its substrate, PKD1. Based on the two 
possibilities put forward earlier, it would appear that a more probable mode of action 
of Spry2 is to block the active or ATP-binding site of PKCδ, thereby preventing it 
from phosphorylating its substrate, PKD1.   
 In order to verify this, a kinase dead PKCδ (PKCδ-KD) construct was made 
(Figure 3.3.12A), where the ATP-binding site Lys376 was mutated to arginine (Arg) 
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Figure 3.3.11 Spry2 interacts directly with both PKCδ
 
and PKD1.
293T cells were transfected with HA-tagged PKCδ, PKD1 or Cdc2 (negative 
control) and FGFR1. The cell lysates were then immunoprecipitated (IP) using 
HA antibody, separated on SDS-PAGE and transferred onto PVDF membrane. 
These membranes were overlaid with either Spry2-GST proteins or GST 
proteins generated in E. coli DH5α, and immunoblotted with GST antibody; a 
(HA-PKD1), b (HA-PKCδ), c (HA-Cdc2). For each set of overlay, control 
blots were directly immunoblotted with anti-HA to verify successful 
immunoprecipitation. 
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were immunoprecipitated using PKCδ antibody. The immunoprecipitates were 
immunoblotted for the presence of FLAG-tagged Spry2. As shown in Figure 3.3.12B, 
Spry2 only interacted with endogenous and overexpressed wild type PKCδ, and not 
with PKCδ-KD. This implies that the ATP-binding site on Lys376 is required for the 
interaction between PKCδ and Spry2. Interestingly, there is also little discernible 
interaction between Spry2 and endogenous PKCδ when PKCδ-KD is present. It is 
hypothesized that although PKCδ-KD is unable to bind to Spry2, it can still bind to its 
substrate PKD1, but without its activating effects. Since PKCδ-KD is present in cells 
at a higher level than the endogenous PKCδ, most of the endogenous PKD1 would 
have been sequestered by PKCδ-KD, leaving little PKD1 available to interact with the 
endogenous PKCδ. As shown earlier, PKD1 increases the interaction between PKCδ 
and Spry2. Therefore, with less PKD1 available for interaction with endogenous 
PKCδ, binding of Spry2 to PKCδ is likewise reduced, resulting in little detectable 
interaction between endogenous PKCδ and Spry2 in the presence of PKCδ-KD.  
 In order to validate this argument, PKCδ-KD was expressed in increasing 
amounts in 293T cells in the presence of Spry2, and total PKCδ was 
immunoprecipitated from cell lysates. The amount of Spry2 protein co-
immunoprecipitating with total PKCδ was then studied. The results of this experiment 
are seen in Figure 3.3.13A. Spry2 co-immunoprecipitates with endogenous PKCδ in 
the absence of PKCδ-KD upon FGFR1 activation. This interaction is progressively 
reduced, however, in the presence of increasing levels of PKCδ-KD. The results 
therefore support the argument that PKCδ-KD is able to sequester PKD1 away from 
endogenous PKCδ so that there is insufficient endogenous PKCδ-PKD1 complex for 
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Figure 3.3.12 PKCδ-KD prevents the interaction between Spry2 and 
endogenous PKCδ.
(A) Schematic diagram showing the different constructs of PKCδ; wild type 
PKCδ
 
(WT-PKCδ) and PKCδ-KD (K376R, lysine at 376 is substituted with 
arginine). (B) Myc-tagged WT-PKCδ
 
or kinase dead PKCδ
 
(PKCδ-KD) were 
expressed in 293T cells with FGFR1 with FLAG-tagged Spry2. Total PKCδ
 
was 
immunoprecipitate (IP) using PKCδ
 
antibody, and the immunoprecipitates were 
immunoblotted according to the antibodies shown on the left. WCL were also 
immunoblotted to confirm the presence of equal amounts of proteins between 
the samples. 
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representing the relative amounts of FLAG-tagged Spry2 that co-immunoprecipitates 
with endogenous PKCδ is shown in Figure 3.3.13B.  
 
3.3.8 Spry2 requires a PKCδ-PKD1 interaction to associate with PKCδ 
 In order to verify that the Spry2-PKCδ complex is dependent on a pre-existing 
PKCδ-PKD1 interaction, it is necessary to first disrupt the interaction between PKCδ 
and PKD1. This is achieved by constructing a mutant of PKCδ that is lacking the C2 
domain in the N-terminus (PKCδ-ΔC2) as shown in Figure 3.3.14A. It has been 
reported previously that the C2 domain of PKCδ is able to recognize and bind to the 
motif (Y/F)-(S/A)-(V/I)-pY-(Q/R)-X-(Y/F)-X (Benes et al., 2005), which is present in 
PKD1 (FYGMYD) (Döppler and Storz, 2007). If the C2 domain and this motif are 
indeed important for the interaction between PKCδ and PKD1, then there should be 
no interaction between PKD1 and PKCδ-ΔC2. More importantly, there should also be 
a reduction in interaction between Spry2 and either PKD1 or PKCδ for the argument 
to be substantiated.  
 Using the two PKCδ mutants, PKCδ-KD and PKCδ-ΔC2, PKD1 
immunoprecipitates were assayed for the presence of total PKCδ and Spry2. In line 
with the earlier results, Spry2 failed to co-immunoprecipitate with PKD1 in the 
presence of PKCδ-KD and FGFR1 (Figure 3.3.14B, top panel, Lane 9), compared to 
endogenous and wild type PKCδ (Top panel, Lanes 7 and 8). It should be noted that 
PKCδ-KD still bound to PKD1 (Second panel, Lane 9). At the same time, PKCδ-ΔC2 
showed significantly reduced binding to PKD1, indicating that the C2 domain of 
PKCδ is important for the PKCδ-PKD1 interaction (Second panel, Lane 10). 
Consistent with this observation is the reduced interaction between Spry2 and PKD1 
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Figure 3.3.13 Increasing PKCδ-KD levels decrease the endogenous PKCδ- 
Spry2 interaction.
(A) Increasing amounts of myc-tagged PKCδ-KD were transfected into 293T 





antibody, and the immunoprecipitates were 
immunoblotted using the antibodies indicated. (B) The relative amounts of 






(Top panel, Lane 10), where the interaction is about 50% of the interaction that occurs 
in the presence of endogenous PKCδ (Top panel, Lane 7).  
 
3.3.9 Summation 
 Taken together, the results show that the ATP-binding site is important for 
Spry2-PKCδ interaction. Spry2 appears to inhibit the phosphorylation of PKD1 by 
blocking this site on PKCδ. At the same time, the PKCδ-PKD1 interaction is 
important for Spry2 to interact with PKCδ. The absence of an interaction between 
PKCδ and PKD1 negatively affects the interaction between Spry2 and PKCδ. This 
supports the earlier argument for the formation of a trimeric complex between Spry2, 
PKCδ and PKD1, where its formation is dependent on a PKCδ-PKD1 interaction, and 
where Spry2 blocks the ATP-binding site of PKCδ. The resulting reduction in 
phosphorylation of PKD1 seems to hinge on Spry2 being a key player within this 
complex. Since the interaction of Spry2 is dependent on the presence and interaction 
of PKCδ and PKD1, it would seem probable that the role of Spry2 is to increase the 
existing interaction between the two kinases. At the same time, by interacting with the 
ATP-binding site of PKCδ, Spry2 effectively blocks the transfer of a γ-phosphate 
group to PKD1. The net result of this trimeric complex, therefore, is to create a 
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Figure 3.3.14 Interaction between PKCδ
 




(A) Schematic diagram showing the different mutation constructs of PKCδ; 
wild type PKCδ
 
(WT-PKCδ), PKCδ-KD (K376R, lysine at 376 is substituted 
with arginine), and PKCδ-ΔC2 (C2 domain of PKCδ
 
has been deleted). (B) 
293T cells were transfected with myc-tagged PKCδ, PKCδ-KD or PKCδ-ΔC2, 
and FGFR1.Endogenous PKD1 was IP with anti-PKD1 and the 
immunoblotting was carried out on both immunoprecipitates and WCL using 
the antibodies indicated on the left. The position of the PKCδ-ΔC2 band is 
indicated with an asterisk, *. 134
3.4 Effect of Spry2 on PKCδ signaling in ERK1/2 activation 
 There have been several reports to date implicating PKCδ in ERK1/2 activity. 
This has been reported to take place downstream of various stimulatory signals (Wert 
and Palfrey, 2000; Gliki et al., 2001). However, the regulatory mechanisms regarding 
this particular pathway have not been well studied. This section aims to more closely 
examine the possible regulatory effect of Spry2 on PKCδ signaling leading to ERK 
phosphorylation and activation.  
 
3.4.1 PKCδ contributes to ERK1/2 activity 
 First of all, to verify that PKCδ contributes to the activation of ERK1/2, 
endogenous PKCδ was knocked down using two different shRNA constructs specific 
to PKCδ. As shown in Figure 3.4.1A, both PKCδ-specific shRNAs significantly 
knocked down the level of endogenous PKCδ, as compared to a vector control and 
non-specific shRNA negative control (Second panel). In comparison, the protein 
levels of three other PKCs: PKCα, PKCε and PKCζ, remained unaffected by the 
PKCδ-specific shRNA. In shRNA-transfected cells stimulated with FGF, phospho-
ERK1/2 levels decrease markedly, but not completely, compared to cells transfected 
with either the vector or non-specific shRNA control (Top panel, Lanes 5 to 8). Since 
the protein levels of the other PKCs are not affected by the shRNA, it implies that the 
reduction in phospho-ERK1/2 levels is linked directly to the decrease in PKCδ levels. 
 The results for phospho-ERK1/2 reduction shown in Figure 3.4.1A have been 
quantified and are represented as a bar chart in Figure 3.4.1B. Effective knockdown of 
PKCδ expression results in approximately 50% of ERK1/2 phosphorylation. Since a 



























































contributes to ERK1/2 phosphorylation.
(A) 293T cells were transfected with vector control, non-specific shRNA or 
PKCδ-specific shRNA constructs; (1) shRNA construct from Origene; (2) 
shRNA construct from Sigma Aldrich, and stimulated with bFGF (20ng/ml) for 
2h, or left untreated. Lysates were collected and separated on SDS-PAGE before 
immunoblotting with the antibodies indicated on the left. (B) The relative levels 





0.05, n = 4). 
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responsible, including the incomplete abrogation of PKCδ expression and the 
activation of other signaling pathways downstream of FGF stimulation that result in 
ERK1/2 phosphorylation. 
 
3.4.2 Kinase activity of PKCδ is required for ERK1/2 phosphorylation 
 In order to verify that the kinase activity of PKCδ, and not just its presence, is 
required for activation of ERK1/2, the phosphorylation of ERK1/2 was studied in the 
presence of kinase dead PKCδ (PKCδ-KD). As seen in Figure 3.4.2A, upon bFGF 
stimulation, ERK1/2 shows a marked decrease in phosphorylation in the presence of 
PKCδ-KD (Lane 6) when compared to endogenous PKCδ or overexpressed wild type 
PKCδ (Figure 3.4.2A, Lanes 2 and 4), indicating that the kinase activity of PKCδ, 
while not being the sole determinant of ERK1/2 phosphorylation, plays an important 
role in affecting ERK1/2 activation.  
 The results in Figure 3.4.2A were quantified and shown in the bar chart in 
Figure 3.4.2B. The bar chart shows that the decrease in PKCδ kinase activity results 
in an approximately 70% decrease in phospho-ERK1/2 levels, indicating that the 
kinase activity of PKCδ contributes to a significant proportion of ERK1/2 activity.  
 
3.4.3 Spry is able to inhibit ERK1/2 phosphorylation downstream of PKCδ  
 Previous studies have shown that Spry2 can inhibit ERK1/2 phosphorylation 
upon FGFR1 activation through the main Grb2-SOS-Ras-Raf-MEK-ERK1/2 pathway 
(Yusoff et al., 2002; Hanafusa et al., 2002; Lao et al., 2006). Within this study, Spry2 
has also been shown to prevent the phosphorylation of PKD1 via PKCδ. Since PKCδ 
signaling via PKD1 has been reported to result in the phosphorylation of ERK1/2 
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Figure 3.4.2 The kinase activity of PKCδ
 
is necessary for ERK1/2 
phosphorylation.
(A) Wild type PKCδ
 
or PKCδ-KD were expressed in 293T cells. The cells 
were stimulated with bFGF or left untreated after 4h of serum starvation. 
Immunoblotting was performed on WCL using the antibodies shown on the 
left. (B) The relative amounts of phospho-ERK as a proportion of the vector 
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Spry2 could inhibit ERK1/2 activation via PKCδ. In order to determine this, 293T 
cells were transfected with Spry2 or its Y55F mutant alone, or co-transfected with 
myc-tagged wild type PKCδ. Consistent with earlier reports, the level of 
phosphorylated ERK1/2 decreases in the presence of Spry2 and bFGF stimulation 
(Figure 3.4.3A, Lane 8), but remains the same in the presence of the Spry2 Y55F 
mutant, which does not interact with PKCδ (Lane 9). However, when PKCδ levels in 
the cells are increased with overexpression such that there is insufficient Spry2 
available to block its ATP-binding site, the inhibition of ERK1/2 phosphorylation by 
Spry2 is reversed (Lane 11). This indicates that Spry2 is able to inhibit ERK1/2 
activation by negatively affecting the ability of PKCδ to phosphorylate its substrate. 
The phospho-ERK1/2 levels were quantified and shown in the bar chart in Figure 
3.4.3B.  
 
3.4.4 Spry2 increases RIN1 interaction with Ras 
 The results in this study have so far indicated that Spry2 is able to inhibit 
ERK1/2 activation via PKCδ-PKD1 signaling. It has been previously reported that 
PKD1 directly phosphorylates RIN1 (Wang et al., 2002), and that RIN1, upon 
phosphorylation, dissociates from active Ras. When RIN1 is not phosphorylated, it 
will bind to active Ras, and will furthermore directly compete with Raf1 for binding 
to Ras and disrupt downstream ERK1/2 activation (Wang et al., 2002). Given that 
Spry2 blocks the phosphorylation of PKD1 on S738/742 by PKCδ, this led to the 
question as to whether Spry2, through its action on PKCδ, could affect the interaction 
between RIN1 and Ras. 
 In order to determine if Spry2 affects the RIN1-Ras interaction, active Ras 
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(A) Spry2 or the Y55F mutant was co-expressed with either myc-tagged PKCδ
 
or a vector control, and stimulated with bFGF, or left untreated after 4h of 
serum starvation. Lysates were subjected to SDS-PAGE and immunoblotting 
using the antibodies indicated on the left. (B) The levels of phospho-ERK as 
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mutant Y55F. The cell lysates were immunoprecipitated for HA-tagged Ras, and the 
immunoprecipitates were then assayed for the presence of RIN1. As shown in Figure 
3.4.4, RIN1 was able to associate with RasV12 upon FGFR1 activation. Moreover, 
the interaction strengthened upon expression of Spry2. This implies that Spry2, by 
blocking phosphorylation of PKD1 by PKCδ, also subsequently blocks 
phosphorylation of RIN1. The unphosphorylated RIN1 is therefore unable to be 
released from RasV12. This would mean that Raf1 is competed away from Ras, 
resulting in reduced activation of ERK1/2. In contrast, the presence of Spry2 Y55F, 
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Figure 3.4.4 Spry2 increases the interaction between RIN1 and active Ras.
(A) 293T cells were transfected with HA-tagged RasV12, FLAG-tagged Spry2 
and RIN1. Immunoprecipitation was carried out using Ras antibody, and the 
immunoprecipitates were immunoblotted using the antibodies indicated. (B) 
The levels of immunoprecipitated RIN1 relative to the WCL expression is 





3.5 Effect of Spry2 on PKCδ signaling in cell invasion 
 Cell invasion is an important process in metastatic cancer cells. PKCδ has 
been reported to be important in different diseases and, in prostate cancer cells, PKCδ 
has been shown to be important for cell invasion (Villar et al., 2007). To gain an 
insight into the physiological relevance of the interaction between Spry2 and PKCδ, 
the effect of Spry2 on the cell invasiveness of a prostate cancer cell line, PC-3 was 
investigated.  
 
3.5.1 PKCδ affects cell invasion of PC-3 cells 
 It was first ascertained that PKCδ was involved in PC-3 cell invasion by using 
a Boyden chamber cell invasion assay. PC-3 cells were transfected with either PKCδ-
specific shRNA or PKCδ-KD in the presence of FGFR1, and cell invasiveness was 
subsequently measured. As shown in Figure 3.5.1A, PC-3 cells transfected with 
PKCδ-KD or PKCδ-specific shRNA showed about 50% decrease in invasiveness, 
compared to vector-transfected cells. To verify that the decrease in cell invasion was 
due to the expression of the respective transfected plasmids, the protein level of PKCδ 
was monitored after three days, to match the duration of the cell invasion assay. As 
shown in Figure 3.5.1B, endogenous PKCδ levels decreased three days after 
transfection of the shRNA compared to vector-transfected cells, while PKCδ-KD was 
still expressed after the same time period. This implies that the effect on PC-3 cell 






















































Figure 3.5.1 PC-3 cell invasion is dependent on PKCδ
 
kinase activity.
(A) PC-3 cells were transfected with the constructs indicated. Cells were 
serum starved for 24 h post-transfection, harvested 24 h thereafter and seeded 
into Boyden chambers. The cells were allowed to invade for 24 h before being 
quantified. The results are represented in the bar chart as a percentage of 




0.05, n=3). (B) Expression of 
proteins was verified by harvesting transfected PC-3 cells three days post- 
transfection and immunoblotting the WCL using the antibodies indicated. 
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3.5.2 Spry2 reduces invasion of PC-3 cells 
 In order to examine the effect of Spry2 of PC-3 cell invasion, either Spry2 or 
the Y55F mutant was transfected into the cells and the effect was compared with 
vector-transfected cells. As shown in Figure 3.5.2A, Spry2 was able to inhibit PC-3 
cell invasion in the Boyden chamber assay by about 50% compared to vector-
transfected cells. This was comparable to cells transfected either PKCδ-specific 
shRNA or PKCδ-KD, implying that the net effect is similar to having a non-
functional PKCδ present. The Y55F mutant, on the other hand, had no effect on the 
invasiveness of PC-3 cells under the same conditions. As Spry2Y55F does not 
interact with PKCδ, it is unable to exert an effect on PKCδ signaling. As a result, cell 
invasion is not reduced in the presence of Spry2Y55F. Again, in order to determine if 
protein expression of the transfected plasmids persisted three days after transfection, 
whole cell lysates were examined for the expression of FLAG-tagged Spry2 and 
Spry2Y55F. The results in Figure 3.5.2B indicate that both FLAG-tagged proteins 
were expressing strongly three days after transfection. Therefore, the changes in cell 
invasion of PC-3 cells were due to the presence of the proteins. 
 
3.5.3 PKCδ is able to reverse the effect of Spry on PC-3 cell invasion 
 It has been shown in the previous two sections that PKCδ has some bearing on 
the invasive potential of PC-3 cells, and that Spry2 is able to, at least in part, inhibit 
the cell invasion process. The question then arose as to whether the effect of Spry2 on 
cell invasion occurred through its association with PKCδ. To address this, PC-3 cell 
invasion was studied in both the presence and absence of overexpressed PKCδ, on a 
background of Spry2 expression. As shown before, Spry2 was able to reduce invasion 












Figure 3.5.2 Spry2 blocks cell invasion in PC-3 cells.
(A) PC-3 cells were transfected with the constructs indicated. Cells were 
serum starved for 24 h post-transfection, harvested 24 h thereafter and seeded 
into Boyden chambers. The cells were allowed to invade for 24 h before being 
quantified. The results are represented in the bar chart as a percentage of 




0.05, n=3). (B) Expression of 
proteins was verified by harvesting transfected PC-3 cells three days post- 





































Spry2 and PKCδ, indicating that when PKCδ expression in cells is increased to levels 
such that there is insufficient Spry2 available to block its action, the reduction in cell 
invasion by Spry2 is abrogated. The results here support the biochemical data shown 
earlier. Protein expression of both PKCδ and Spry2 was verified three days after 
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Figure 3.5.3 Overexpressed PKCδ
 
rescues inhibition of cell invasion by 
Spry2.
(A) PC-3 cells were transfected with the constructs indicated. Cells were 
serum starved for 24 h post-transfection, harvested 24 h thereafter and seeded 
into Boyden chambers. The cells were allowed to invade for 24 h before being 
quantified. The results are represented in the bar chart as a percentage of 




0.05, n=3). (B) Expression of 
proteins was verified by harvesting transfected PC-3 cells three days post- 




 The main focus of this study has been to gain a deeper understanding of the function 
of the RTK inhibitor Spry2. While different signals are able to feed into the ERK pathway 
downstream of receptors such as RTKs and GPCRs, Spry2 has generally been considered an 
inhibitor of the canonical Grb2-Sos-Ras-Raf-MEK-ERK pathway. The field of signal 
transduction, however, has shown that disparate signaling relays do not exist in isolation, and 
hence as different pathways may influence ERK phosphorylation and activity, Spry2 may 
also affect these pathways leading to ERK. In order to examine which of these pathways 
Spry2 can potentially influence, the identification of novel interacting partners of Spry2 was 
used in part as the strategy of choice.  
The initial results of this study have led to the identification of Plscr3 as an 
interacting partner of Spry2, and through it the discovery of a novel interaction with PKCδ. 
Experimental evidence demonstrates that Spry2 is able to inhibit PKCδ signaling through this 
interaction, which is supported by previous studies (Sivak et al., 2005). Furthermore, the 
interaction between Spry2 and PKCδ leads to the inhibition of ERK1/2 phosphorylation, at a 
point in the ERK signaling pathway which has been implicated in earlier studies (Yusoff et 
al., 2002; Sasaki et al., 2003). The findings in this study therefore provide evidence that 
Spry2 is able to influence pathways other than the canonical Ras-ERK cascade. More 
importantly, through its regulatory action, Spry2 is able to limit the contribution of this 
pathway to ERK activation. Some of the implications and issues in this work are discussed in 
this chapter. 
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4.1 Conformation as a factor in the interaction specificity of Spry2 and PKCδ 
 Spry2 was observed to interact specifically with PKCδ only upon FGFR1 activation. 
Furthermore, the Y55F mutant of Spry2 was unable to do so. This implies that the 
phosphorylation that takes place on the Y55 residue is important for the interaction between 
PKCδ and Spry2. Phosphorylation on this residue has been reported to be important in two 
cases: as a binding site for the E3 ligases c-Cbl (Fong et al., 2003; Ng et al., 2008), and 
causing a conformational change in Spry2 (Lao et al., 2006). Since PKCδ does not appear to 
recognize the specific motif surrounding the Y55 residue, it is likely that phosphorylation of 
the Y55 residue is required to induce a conformational change in Spry2 to facilitate its 
binding to PKCδ.  
Protein conformation is also possibly one factor that determines the specificity in the 
interaction between Spry2 and PKCδ. In this study, it is observed that the interaction between 
Spry2 and PKCδ is dependent on a pre-existing PKCδ-PKD1 association. Spry1 and Spry4, 
while very similar to Spry2, are unable to interact with PKCδ because the pre-existing 
PKCδ-PKD1 interaction presents a structure which only Spry2 can bind to. This could 
explain why even though PKCδ was not shown to bind to any unique sequence within Spry2, 
their interaction is unique among the different Spry isoforms. 
 
4.2 Spry2 does not inhibit the phosphorylation of PKCδ by its upstream kinase 
 In this study, the Spry2-PKCδ interaction occurs at the plasma membrane in 
mammalian cells following stimulation with FGF. These findings contrast with those seen in 
Xenopus cells, where Spry2 was reported to inhibit the activation of PKCδ, and hence its 
membrane translocation (Sivak et al., 2005). These findings were expanded on, and it was 
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shown that the phosphorylation of the Thr505 residue of PKCδ was not affected by the 
presence of Spry2, implying that the cognate kinase for PKCδ was not blocked from 
phosphorylating its substrate. This has been reported to be either PDK1 or PKCε (Newton, 
2003; Rybin et al., 2007). While others have reported that a Glu residue at position 500 
renders the Thr505 phosphorylation within the activation loop redundant, maximal activity 
and specificity still requires the phosphorylation of Thr505 (Stempka et al., 1999). Therefore, 
from these two observations, Spry2 does not appear to interfere with the phosphorylation and 
enzymatic activation of PKCδ.  
 
4.3 Implications of PLCγ1-Spry interaction 
 As part of an effort to unravel the mechanism of action of Spry2 on PKCδ, the 
interaction between Spry proteins and an upstream signaling molecule, PLCγ1 was 
examined. It was found that the interaction between PLCγ1 and the Spry isoforms is 
completely stimulation dependent. However, phosphorylation of the conserved N-terminal 
Tyr residue (Y55 in Spry2) does not seem to be critical, since a significant, albeit reduced, 
level of interaction between PLCγ1 and Spry2Y55F still takes place. This immediately 
presents an interesting question as to how the Spry proteins and PLCγ1 interact. Rather 
surprisingly, the interaction between Spry2 and PLCγ1 does not take place with the 
conserved C-terminal Cys-rich domain. It was expected that this region would be the main 
player in these interactions as most of the known Spry2 interactions take place at this region 
(reviewed by Guy et al., 2009). Because of the relatively low level of sequence conservation 
of the N-terminus among the Spry isoforms, the number of possible interaction sites is 
immediately reduced. However, an N-terminal interaction still poses a challenge in 
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understanding these interactions as its function is not as well understood as the C-terminus of 
Spry. 
 Interestingly, Spry1 and Spry2 expression have been found to be induced by PLCγ 
and Ca2+ signaling (Abe and Naski, 2004). Furthermore, Spry4 has been reported to inhibit 
phosphatidylinositol 4,5-biphosphate hydrolysis by PLC, but not necessarily PLCγ (Ayada et 
al., 2009). This is reminiscent of how Spry expression is induced by ERK1/2, and its activity 
is subsequently inhibited by Spry. Therefore, besides ERK1/2, Spry may play a role as a 
negative feedback inhibitor of PLCγ signaling.  
 
4.4 Formation of a Spry2-PKCδ-PKD1 complex: is Spry2 a PKCδ substrate? 
 The results within this study indicate that Spry2 is able to inhibit phosphorylation of a 
PKCδ substrate, PKD1. It accomplishes this by forming a trimeric complex with PKCδ and 
PKD1, and in doing so, locks the interaction between PKCδ and PKD1, and at the same time, 
blocks the transfer of the γ-phosphate group of ATP from PKCδ to PKD1. The mechanism in 
which Spry2 does this has still not been elucidated. Two possibilities are suggested. The first 
proposes that the actual ATP-binding residue (Lys376) provides the interaction interface 
between Spry2 and PKCδ. This interaction prevents the binding of ATP to the residue, and as 
such no phosphate groups are available for phosphorylating PKD1. The second possibility is 
that Spry2 recognizes and binds to an ATP-bound Lys376 residue on PKCδ. Transfer of the 
phosphate group to PKD1 is then inhibited through a lack of cleavage of the γ-phosphate 
group from ATP. In either case, the Lys376 residue is necessary for the interaction between 
Spry2 and PKCδ, which was demonstrated in this study. 
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 The second possibility gives rise to a third interesting scenario. Rather than 
preventing ATP-cleavage, Spry2 may act as a substrate of PKCδ itself, and thus competes 
with PKD1 for the phosphate group. A protein motif scan using the Motif Scan program 
(website: http://scansite.mit.edu/motifscan_seq.phtml) revealed the presence of Ser/Thr 
residues that may be phosphorylated by PKCδ. These include the residues Ser110, Ser113, 
Ser125 and Thr190. Interestingly, three of these four residues lie within a Ser-rich sequence 
of Spry2. Specific residues within this sequence were found to be phosphorylated prior to 
stimulation, and dephosphorylated upon growth factor stimulation (Lao et al., 2007). 
Dephosphorylation of these residues is necessary for Spry2 to carry out its function in 
inhibiting ERK phosphorylation. Due to time constraints however, this issue was not more 
thoroughly investigated. 
 
4.5 The function of the PKCδ C2 domain in the PKCδ-PKD1 interaction 
 It has been reported that the C2 domain of PKCδ is involved in interacting with its 
substrate PKD1 through the motif (Y/F)-(S/A)-(V/I)-pY-(Q/R)-X-(Y/F)-X. This motif was 
found in the N-terminus of PKD1, consisting of the sequence FYGMYD (Benes et al., 2005; 
Döppler and Storz, 2007). In the experiments conducted to determine if the interaction of 
Spry2 and PKCδ depended on a pre-existing PKCδ-PKD1 interaction, a truncation mutation 
of PKCδ lacking the C2 domain was made. Experimental results showed that the PKCδ 
mutant demonstrated reduced interaction with both PKD1 and Spry2. Earlier experimental 
results in this study indicate that the interaction between the three proteins occurs at the cell 
membrane. The question that arose then was whether removal of the C2 domain of PKCδ 
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affected its ability to translocate to the membrane, since literature states that the C2 domain 
binds phospholipids. 
 This question is answered in an earlier report which states that the C2 domain is not a 
major determinant in membrane translocation in PKCδ, as opposed to cPKCs (Giorgione et 
al., 2006). Instead, it was demonstrated that the C1B domain is responsible for targeting 
PKCδ to the membrane, and that deletion of the C2 domain does not affect the stimulus-
dependent translocation of PKCδ.  
 It was decided that the PKD1 motif recognized by the C2 domain of PKCδ should be 
mutated to provide conclusive evidence that the lack of interaction between PKD1 and this 
mutant is not due to translocation problems. In doing so, a second sequence matching the C2 
domain recognition motif was found in the C-terminus of PKD1. This sequence, 
S578TVYQIFP, matches the canonical one more closely than the one currently reported. 
Mutational analysis was carried out to determine if it is a genuine recognition motif for the 
C2 domain of PKCδ, but these studies were not successful. Therefore, this question currently 
remains unanswered. 
 
4.6 The impact of Spry2 on HDAC5 
 This study shows that the result of the interaction between Spry2, PKCδ and PKD1 is 
the inability of PKD1 to phosphorylate its substrates. Extensive work on two PKD1 
substrates, RIN1 and HDAC5, has been carried out (Wang et al., 2002; Huynh and 
McKinsey, 2006). This work has focused on the effect of PKD1 inactivity on RIN1, and its 
subsequent effect on ERK1/2 phosphorylation, which will be discussed in a later section.  
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 While not shown in this study, it is perhaps to be expected that the lack of 
phosphorylation and activation of PKD1 in the presence of Spry2 would result in the absence 
of phosphorylation of all the substrates of PKD1, provided there are no compensatory 
mechanisms in place. This, by default, would imply that like RIN1, HDAC5 would fail to be 
phosphorylated on Ser259 and Ser498 (Ha et al., 2008). Since HDAC5 has been shown to be 
involved in angiogenesis, it is possible that Spry2 is able to negatively regulate angiogenesis 
through PKCδ, PKD1 and HDAC5. However, these studies have been carried out using 
VEGF as a stimulant. While Spry2 has been shown to inhibit signaling downstream of VEGF 
(Impagnatiello et al., 2001), it has not been demonstrated if Spry2 is able to affect PKCδ in a 
similar manner upon VEGF stimulation.  
 
4.7 Spry2 inhibits ERK1/2 phosphorylation via PKCδ and PKD1 
 There have been several reports describing Spry2 as an inhibitor of ERK1/2 
signaling, and it is likely that this inhibition occurs at several points in the pathway. PKCδ 
activation of ERK1/2, on the other hand, has been reported to occur via PKD1 and its 
downstream effectors possibly resulting in the activation of Raf (Ueda et al., 1996; Wang et 
al., 2002). The results from this study support this observation, as it was demonstrated that 
the expression of kinase-dead PKCδ can inhibit ERK1/2 phosphorylation. While many 
pathways feed into the ERK1/2 signaling pathway, Spry2 has, to date, been generally 
considered to be a negative feedback inhibitor of the classical Grb2-Sos-Ras-Raf-MEK-ERK 
pathway. The recent increase in literature related to Spry proteins have served to underscore 
the many possible pathways upon which Spry proteins may act (Chi et al., 2004; Edwin and 
Patel, 2008; Lito et al., 2009).  
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 The findings of this study demonstrate an alternate mode of inhibition of ERK1/2 
signaling for Spry2. FGF stimulation is able to activate different pathways, including the 
PLCγ-PKCδ and Ras-ERK signaling pathways. Stimulation also allows Spry2 to adopt a 
conformational change which allows it to interact with PKCδ and PKD1. This interaction 
prevents the phosphorylation of PKD1 within the activation loop, which subsequently 
prevents the phosphorylation of a PKD1 substrate, RIN1. It has been shown that RIN1 
interacts with activated Ras, thus actively competing with Raf1 for binding (Wang et al., 
2002). Phosphorylation of RIN1 on Ser315 by PKD1 allows the dissociation of RIN1 from 
active Ras, thus allowing Ras-mediated activation of Raf1 to occur. Spry2, by preventing 
phosphorylation of RIN1 by PKD1, effectively inhibits ERK1/2 phosphorylation due to the 
continued interaction between RIN1 and Ras. Therefore, in this scenario, ERK1/2 activation 
would be dependent on two separate inputs: the activation of Ras by growth factors such as 
FGF, and the phosphorylation of PKD1 by PKCδ, resulting in a phosphorylated RIN1. 
 One unexplained aspect stems from reports showing that Spry2 is able to inhibit 
ERK1/2 phosphorylation upstream of Ras, which would result in the absence of active Ras 
(Hanafusa et al., 2002; Lao et al., 2006). However, it is uncertain how complete an inhibition 
is achieved by Spry2 upstream of Ras, and whether an alternate signal through a parallel 
pathway comes in to activate Ras. If this is the case, then an active form of Ras may still be 
available for interaction with RIN1, which is sustained in the presence of Spry2. This would 





4.8 The implications of Spry2 on signaling downstream of RIN1 
 The lack of phosphorylation of RIN1 caused indirectly by Spry2 leads to its sustained 
interaction with activated Ras. While this naturally has implications on signaling leading to 
ERK1/2 phosphorylation, other issues also need to be considered. Two effectors of RIN1 
have been identified, and the implications of the effect Spry2 has on RIN1 is discussed from 
the perspective of these two effectors.  
 
4.8.1 RIN1 and Abl  
 The tyrosine kinase Abl has been reported to be activated by RIN1 (Hu et al., 2005; 
Cao et al., 2008). RIN1 binds Abl and active Ras in a trimeric complex, where activated Ras 
stimulates the tyrosine kinase-activation function of RIN1. The tyrosine kinase activity of 
Abl is increased by Ras-associated RIN1 in this way, in a manner that is independent of Src-
mediated phosphorylation (Cao et al., 2008). This results in increased actin remodeling and 
epithelial cell adhesion (Hu et al., 2005).  
 Since the action of Spry2 is able to increase the association between active Ras and 
RIN1, it can be speculated that it indirectly plays a role in Ras- and Abl-mediated actin 
remodeling and cell adhesion. It would also imply that by allowing a bias towards a Ras-
RIN1 interaction, Spry2 is able to simply more than abrogate ERK1/2 phosphorylation. 
 
4.8.2 RIN1 and Rab5 
 RIN1 has been reported to interact with Rab5, a prototypical member of the Rab 
family of GTPases, and a key regulator of receptor-mediated endocytosis (Tall et al., 2001). 
It was demonstrated that RIN1 is a guanine nucleotide exchange factor (GEF) specific for 
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Rab5 proteins, and that this Rab5-GEF activity is potentiated by activated Ras. This leads to 
increased rates of receptor-mediated endocytosis (Tall et al., 2001). Additionally, RIN1 was 
also found to be able to bind to RTKs through its SH2 domain, and regulate endocytosis of 
these receptors (Barbieri et al., 2003).  
 The implication of these observations is that Spry2, by mediating increased 
interaction between RIN1 and active Ras, promotes receptor-mediated endocytosis. This is a 
pathway that is distinct from its well documented function in modulating ERK1/2 
phosphorylation. Interestingly, another study done by a separate group also implicates Spry2 
in regulating endocytosis. However, in this case, Spry2 was found to negatively regulate the 
process by blocking the transition from early to late endosomes (Kim et al., 2007).  
 
4.9 A working model for the Spry2-PKCδ-PKD1 interaction 
 Based on the collective results from this study, a simple working hypothesis for the 
interaction between the three proteins, Spry2, PKCδ and PKD1 has been reached. Upon RTK 
activation, Spry2 undergoes the necessary conformational changes and interacts with PKCδ. 
At the same time, activated PKCδ associates with its substrate, PKD1 through its C2 domain. 
The binding of Spry2 to PKCδ is dependent on a pre-existing interaction between PKCδ and 
PKD1. This allows Spry2 to lock the interaction between the two kinases, while at the same 
time associating with PKCδ at the ATP-binding interface. This prevents phosphorylation of 
PKD1 by PKCδ, and thus Spry2 inhibits signaling downstream of PKD1. This proposed 
model is summarized in Figure 4.9.1. The effect of this interaction on different signaling 
pathways is shown in Figure 4.9.2. 






















The interaction between the three proteins is shown schematically here. 
PKCδ
 
binds to PKD1 via its C2 domain by recognizing the FYGMYD 
motif. This allows it to phosphorylate PKD1 on S738 and S742. In the 
presence of Spry2, the interaction between PKCδ
 
and PKD1 is not 
interrupted. However, Spry2 blocks the access of the ATP-binding site on 
PKCδ
 


























Figure 4.9.2 The impact of Spry2 on different signaling pathways.
RTK signaling causes the activation of the Ras-ERK and PLCγ-PKCδ
 
signaling 
pathways. Spry2 is able to inhibit the canonical Ras-ERK pathway, while results 
from this study show that Spry2 blocks PKCδ
 
signaling. This implies that signaling 
downstream from PKD1, for example to HDAC5 and RIN1 would be blocked. In 
the case of RIN1, this results in reduced Ras-Raf interaction, whereas RIN1 
signaling that is dependent on its interaction with activated Ras will increase. The 
role that Spry2 plays in these pathways is shown here. Effects of Spry2 that have 
been demonstrated previously or here are shown in bold arrows, while hypothetical 
ones are shown in dotted lines. 160
4.10 Areas for future research 
 Some of the work presented in this study gives rise to further questions, and these 
warrant further investigation. The first among these is the physiological impact of Spry2 on 
PKCδ. The results from this study yield a few clues with regard to this. Spry2 was found to 
inhibit PKCδ-mediated invasion of PC-3 cells. This has significant implications in the 
process of development, as well as in cancer development and metastasis. Reports also 
suggest that physiologically, there is significant overlap in the functions that they both 
regulate. These include embryo development and angiogenesis (Impagnatiello et al., 2001; 
Murakami et al., 2002; Kinoshita et al., 2003; Sivak et al., 2005; Basu et al., 2008). By 
examining the substrates of PKCδ in these processes, it would be possible to examine if the 
mechanism of Spry2 in blocking PKCδ-mediated PKD1 phosphorylation described in this 
study also applies to these other PKCδ substrates. If so, this would have significant 
implications with regards to the physiological role of Spry2.  
 This then raises the question as to whether Spry2 is itself a substrate of PKCδ. The 
exact mechanism in which Spry2 is able to prevent the transfer of a phosphate group from 
PKCδ to PKD1 is currently unknown. One possible explanation is that it competes with 
PKD1 for that phosphate group, which would imply that Spry2 is a direct substrate of PKCδ.  
Another area that merits further examination is the interaction between Spry and 
PLCγ1. As shown earlier, all the Spry isoforms interact with PLCγ1. The implications of 
these interactions are not understood. It is possible that these interactions represent a novel 
feedback or inhibitory role for Spry proteins. If this is the case, it would mean that unlike the 
situation with PKCδ, this role is not confined only to one Spry isoform. Furthermore, since 
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PLCγ1 is a signaling molecule that acts upstream of PKCδ, the impact of the Spry-PLCγ1 on 
PKCδ itself should be more closely examined. 
In this study, the indirect effect of Spry2 on RIN1 has been examined only in a 
cursory manner. The implications of RIN1 signaling are wide, involving processes such as 
endocytosis through Rab5 (Tall et al., 2001), and cell adhesion through the Abl kinase (Hu et 
al., 2005). If Spry2 is able to mediate RIN1 signaling indirectly through its actions on PKCδ 
and PKD1, then it is likely that it has a role wider than simply inhibiting ERK1/2 
phosphorylation through RIN1.  
Lastly, the initial observation of an interaction between Plscr3 and Spry2 hints at a 
role for Spry2 beyond inhibition of RTK-induced ERK1/2 phosphorylation. Plscr3 was 
initially reported to be involved in the maintenance of membrane asymmetry (Wiedmer et 
al., 2000). It has now been reported to regulate UV-induced apoptosis and tBid signaling 
(Liu et al., 2003; He et al., 2007). As the functions of Plscr3 become clearer, it may be found 
that Plscr3 is involved in more mainstream or well characterized pathways. The association 
of Spry2 with Plscr3 can therefore be more closely examined in those contexts.  
 
ADDENDUM 
 In the early part of my PhD candidature, initial research work was focused on a 
relatively novel member of the ERK family, ERK5 (also known BMK1). This resulted in the 
identification of a novel splice variant of ERK5. Briefly, the alternative splicing introduces 
an in-frame premature stop codon that directs translation of an ERK5 protein lacking the 
nuclear localization signal (NLS). This has an impact on ERK5 signaling as the splice variant 
ERK5 heterodimerizes with wild type ERK5 and prevents nuclear translocation of the wild 
type ERK5 protein. The results from this work have been published, and are described in 
greater detail in the attached paper: Identification and characterization of mErk5-T, a novel 
Erk5/BMK1 splice variant. Further work on this project was discontinued so as to focus on 
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Abstract
Extracellular regulated kinase 5 (ERK5) is an unusually large member of the MAP kinase family of signaling molecules that plays an
important role in cellular proliferation, differentiation and survival. Recently, three transcriptional variants of murine Erk5 were described
(mErk5-a, -b and -c) that result from alternate splicing across introns 1 and/or 2, the net effect of which is translation of a peptide that lacks
the kinase domain. It has been demonstrated that expression of mErk5-b and -c impinge on the function of the full length mErk5 protein
product via a dominant negative effect. Here, we report the identification of another murine Erk5 splice variant and the orthologous human
transcript that arise due to alternate splicing of intron 4. Failure to splice out intron 4 introduces a premature in-frame stop codon that directs
translation of a peptide lacking the nuclear localization signal (NLS) and proline-rich region (PR). Experimental characterization
demonstrated that like mERK5, mERK5-T becomes phosphorylated by co-expression with a constitutively active mMEK5 (mMEK5DD),
and is able to coimmunoprecipitate with both itself and mERK5. Unlike mERK5, however, activated ERK5-T is unable to translocate from
the cytoplasm to the nucleus in HeLaS3 cells, causing the retention of active mERK5 in the cytoplasm. Taken together with previous reports
of domain content modification of ERK5 via alternate splicing, these observations add to the suggestion that regulation of ERK5 signaling
may be mediated, at least in part, at the level of RNA processing.
D 2004 Elsevier B.V. All rights reserved.
Keywords: MAPK; Regulation; Signaling; Alternate splicing; Sub-cellular localization1. Introduction
Extracellular regulated kinase 5 (ERK5) is an unusually
large member of the mitogen-activated protein kinase
(MAPK) family that was independently identified by two0378-1119/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.gene.2004.11.011
Abbreviations: T, truncated; MAPK, mitogen-activated protein kinase;
ERK, extracellular regulated kinase; MEK, MAPK/ERK kinase; NLS,
nuclear localization signal; PR, proline-rich domain; BMK1, big MAP
kinase 1; PCR, polymerase chain reaction; RT, reverse transcriptase; RPMI,
Roswell Park Memorial Institute; PAGE, polyacrylamide gel electro-
phoresis; HEK, human embryonic kidney; EST, expressed sequence tag.
B The nucleotide sequences reported in this paper have been submitted
to GenBank with accession numbers AY534740 (mErk5 -T) and
AY534741(hErk5-T).
* Corresponding author. Tel.: +65 6586 9614; fax +65 6779 1117.
E-mail address: mcbgg@imcb.a-star.edu.sg (G.R. Guy).
1 These authors contributed equally to this work.groups (Lee et al., 1995; Zhou et al., 1995). Various
investigations have revealed that ERK5 plays an essential
but poorly understood role in various cellular processes
such as proliferation (Mulloy et al., 2003; Dong et al.,
2001; Kato et al., 1998), differentiation (Reddy et al.,
2002; Dinev et al., 2001) and cell survival (Zheng et al.,
2004). Like all members of the MAPK family, ERK5
contains dual phosphorylation sites (TXY) and a conserved
serine/threonine kinase domain. In addition, the molecule
contains an oligomerization domain (OD), nuclear local-
ization signal (NLS), and proline-rich region (PR) (Yan et
al., 2001). The immediate upstream activator of ERK5 is
the MAPK kinase, MEK5 (Kato et al., 1997). Upon
activation, ERK5 translocates to the nucleus and phos-
phorylates various downstream targets including MEF2C
(Kato et al., 1997) and possibly c-myc (English et al.,
1998).) 183–190
B.J. McCaw et al. / Gene 345 (2005) 183–190184The expressed portion of the mouse Erk5 gene is spread
over approximately 6 kilobases (kb) at the distal end of
cytogenetic band B1.3 on chromosome 11 (NCBI Mus
musculus Genome View). The major expression product
from the locus is a 3-kb transcript that contains seven exons
and codes for a 816 residue protein. The message is present
at a relatively high level in various embryonic tissues
between E11 and E17 and at a low level in most adult
tissues (Regan et al., 2002). Alternate splicing of Erk5
mRNA has been reported (Yan et al., 2001). Analysis of
various EST databases revealed the existence of two rare
murine Erk5 (mErk5) transcript variants that arise by
differential splicing of introns 1 and 2. In both cases,
inclusion of the intron introduces a premature stop codon
downstream of the kinase domain coding region, with
translation beginning again at an in-frame ATG located
further 3V. Presumably, this is facilitated by an as-yet
uncharacterized mammalian internal ribosome entry site
(IRES). N-terminally truncated ERK5 translated from the
alternately spliced message lacks the kinase domain and is
able to inhibit the kinase activity of full length ERK5. Thus,
it appears that splicing events contribute to ERK5 regu-
lation. Here, we report the existence of another Erk5 splice
variant, Erk5-T (Erk5-Truncated) that originates by alternate
splicing across intron 4, the functional consequence being
introduction of a premature stop codon that eliminates the
nuclear translocation and proline-rich domains from the
protein. Experimental observations confirmed that mERK5-
T is able to hetero-oligomerize with mERK5 in both active
and inactive states. In addition, using immunofluorescence,
we show mERK5-T remains in the cytoplasm upon
stimulation and is able to retard nuclear translocation of
activated mERK5 in a concentration-dependent manner.
These data should help us understand how pre-translation
events help regulate ERK5 signaling.2. Materials and methods
2.1. Isolation of mouse mErk5-T cDNA
Mammalian expressed sequence tags (ESTs) deposited in
GenBank were searched for sequences similar to human
Erk5 (GenBank accession no. BC030134) using the
BLASTn program at NCBI (Altschul et al., 1997).
2.2. RNA isolation and reverse transcriptase-polymerase
chain reaction (RT-PCR)
Cytoplasmic total RNA was extracted from approxi-
mately 25 mg fresh tissue (or 5106 bone marrow cells)
harvested from 6-week-old C57B/6 male mice using an
RNeasy mini spin kit (Qiagen) according to the manufac-
turer’s instructions. First-strand cDNA was reverse tran-
scribed from 250 ng total RNA primed with oligo dT15–18 in
a 20-Al reaction containing 50 U SuperScriptII RT(Invitrogen). mErk5-T was amplified from first-strand
cDNA using 5V-GCCTACTGTGCCCTATGGAG-3V
(sense); 5V-TCTGTCCCAGAATCCCTGTC-3V (anti-sense)
specific primers. mErk5 was amplified using the same sense
primer in combination with the antisense primer 5V-
CGCTTCTCTTCTCGTTCTCG-3V. Primers specific for




2.3. Construction of expression plasmids
All expression constructs were generated by PCR
amplification from first-strand murine bone marrow cDNA.
Fragments were cloned into the HindIII and NotI sites of
either pXJ40-HA or -FLAG in-frame with the N-terminal










Full-length mErk5 clones containing intron 4 were
identified by screening colonies with oligonucleotides flank-
ing the splice junction: 5V-GAGCTTGCTCCAC-
CAAAAAG-3V (sense); 5V-CGCTTCTCTTCTCGTT
CTCG-3V (antisense). mMek5DD (S311D, T315D) and
mMek5AA (S311A, T315A) were created using single
primer mutagenesis (Makarova et al., 2000), respectively;
5V-CACAGCTGGTGAATGATATAGCCAAGGAT-
T AT G T T G G A A C A A AT G C T TA C - 3 V; 5 V-
CACAGCTGGTGAATGCTATAGCCAAGGCGTATGTT-
GGAACAAATGCTTAC-3V.
2.4. Cell culture and transfection
SV40 transformed human embryonic kidney 293 T
(HEK293 T) were maintained in RPMI-1640 medium
(Sigma) supplemented with 10% fetal calf serum, 50 U
ml1 penicillin and 50 Ag ml1 streptomycin. HeLa cells
were cultured in Dulbecco’s Modified Eagles Medium
(DMEM) supplemented with 4500 mg glucose, 10%
inactivated fetal bovine serum (FBS from HyClone Labo-
ratoriesk Logan, UT) and 1% glutamine.
2.5. Western blot analysis
Cells were rinsed with phosphate-buffered saline (PBS)
while attached to the plate and subsequently lysed with 0.5
B.J. McCaw et al. / Gene 345 (2005) 183–190 185ml RIPA lysis buffer (10 mM Tris, pH 7.4, 150 mM NaCl,
1% Triton X-100, 1 mM EDTA, 25 mM NaF) containing
fresh 100 AM Na3VO4 and 1 protease inhibitor cocktail
(Roche). Lysates were recovered by scrapping and centri-
fugation before being boiled in the presence of 1 sample
buffer (50 mM Tris–HCl, pH 6.8, 10% glycerol, 2% SDS,
4% 2-mercaptoethanol, 0.02% bromophenol blue) and
separated by SDS–polyacrylamide gel electrophoresis
(PAGE). Fractionated proteins were electrotransferred to
an activated PVDF membrane (Biorad). Protein containing
membranes were blocked for 1–2 h at room temperature
with 5% skim milk powder (Devondale) and then incubated
for 1 h at room temperature with a primary antibody;
followed by a 1-h incubation with an appropriate horse-
radish peroxidase-conjugated secondary antibody. Antibody
binding was visualized by chemiluminescence (ECL,
Amersham Pharmacia Biotech).
2.6. Co-immunoprecipitation
293 T cell lysates (0.5 ml) were incubated with anti-
FLAG M2 agarose-conjugated beads (Sigma) for 2 h at 4
8C. The beads were washed five times with 1 ml lysis buffer
and subsequently boiled for 5 min in 25 Al 1 sample
buffer. Five microliters of each sample was subjected to
SDS–PAGE and proteins were detected by Western blotting.
2.7. Immunofluorescence
Cells were seeded on poly-d-lysine (Iwakik Chiba,
Japan)-coated coverslips, and transfected with 0.6–1.5 Ag of
plasmid DNAs using Lipofectaminek 2000 reagent (GibcoFig. 1. Schematic representation of the human and mouse Erk5 locus showing alter
(bottom panel). Solid boxes indicate GenBankR sequence and nucleotide position
mErk5-T EST (AA066727) . Shaded boxes represent sequence generated from Erk
demonstrates the introduction of a premature stop codon in both the human andBRL) according to the manufacturer’s instructions. At 24 h
post-transfection, cells were fixed with 3% paraformalde-
hyde for 30 min at 4 8C and then permeabilized with 0.1%
saponin (Sigma-Aldrich) in PBSCM (PBS+1 mM
CaCl2+1mM MgCl2) for 20 min at room temperature. For
single stains, a monoclonal directed against the FLAG
epitope tag (Transduction Laboratories, Lexington, KY) was
used at 1 Ag/100 Al in FDB (7% FBS+2% BSA in PBSCM);
followed by Fluorescein isothiocyanate (FITC)-conjugated
AffiniPure rabbit anti-mouse IgG (Jackson ImmunoRe-
search Laboratories, West Grove, PA). For double stainings
of FLAG-tagged ERK5 full-length and HA-tagged ERK5-T
splice variant, HA-ERK5-T was detected using polyclonal
anti-HA (Roche Molecular Biochemicals, Indianapolis, IN)
and Texas Redk dye-conjugated AffiniPure goat anti-rabbit
IgG (Jackson ImmunoResearch). Coverslips were mounted
in Crystal Mount reagent (Biameda) and viewed by MRC-
1024 laser scanning confocal microscopy (Bio-Rad Labo-
ratories) dye under 40 oil immersion and a 1.4 numerical
aperture bright-field objective. The microscopic images
were processed with the aid of the LaserSharp software
(Bio-Rad Laboratories) and Adobe Photoshop (Adobe
System).3. Results
3.1. Identification of murine and human intron 4 alter-
natively spliced Erk5 mRNA (Erk5-T)
The mammalian EST databases at NCBI were interro-
gated with full length human Erk5 mRNA sequencenate splicing across intron 4. Human Erk5/-T (top panel) and mouse Erk5/-T
for hErk5 (BC030134), hErk5-T EST BE300027, mErk5 (NM_011841) and
5-T RT-PCR products. A local in-frame translation of Erk5-T across intron 4
mouse transcripts (putative splice acceptor and donor sites underlined).
Fig. 2. RT-PCR analysis of mErk5 and mErk5-T in various adult C57B/6
mouse tissues. cDNA reverse transcribed from approximately 25 ng RNA
(1/10 250 Ag reverse transcription reaction) was amplified by 30 cycles of
PCR. Amplification products were electrophoresed through a 1.5% agarose
gel and visualized by ethidium bromide staining. A 1-kb marker (NEB)
served as a size marker. Template from cDNA synthesis reactions lacking
reverse transcriptase were included to control for amplification from
residual genomic DNA (no RT). (1) Brain, (2) bone-marrow, (3) lung, (4)
heart, (5) kidney, (6) testis, (7) skeletal muscle, (8) small intestine, (9)
spleen, (10) H2O control.
Fig. 3. Detection of phospho-mERK5-T in HEK293T fibroblasts over-expressi
constructs. (b) Western blot. 293T cells were transfected with 0.2 Ag HA-tagged
with either mMek5DD or mMek5AA. Western blotting of lysates was performe
inferred by the presence of an up-shifted band (lanes 2, 5 and 7)—see part c. (c
mERK5 or mERK5-T and MEK5AA or MEK5DD were separated on a 7.5% SDS–
was probed with monoclonal anti-HA (Roche) as a loading control.
B.J. McCaw et al. / Gene 345 (2005) 183–190186(GenBank accession no. BC030134) using the BLASTn
program (Altschul et al., 1997). Both human and mouse
EST clones (human; GenBank accession no. BE300027,
mouse; GenBank accession no. AA066727) were identified
that contain a segment of extra internal sequence, which in
both cases corresponded to intron 4 of the Erk5 gene
(Fig. 1). The mouse variant contains a 103-bp insertion at
position 1516, while the alternatively spliced human tran-
script contains an additional 94 bp inserted at position 1497.
We postulated that these EST clones represented a novel
Erk5 splice variant (Erk5-T). The entire mErk5-T open
reading frame (ORF) was obtained by direct sequence
analysis of two overlapping PCR products amplified from
murine bone marrow cDNA. These were generated by (a)
coupling a sense primer within the insertion sequence with
an antisense primer in the published Erk5 3VUTR; and (b)
coupling an antisense primer specific for the insertion
sequence with a sense primer in the mErk5 5V UTR. A
similar strategy was employed to obtain sequence of the
human orthologue using placental cDNA as the template.
In silico translation of the mouse mErk5-T ORF identified
an in-frame stop codon within the unspliced intron.ng mERK5T and mMEK5DD. (a) Schematic representation of mErk5/-T
mErk5, mErk5-T or mErk5-i4us (for details, see schematic) in combination
d with monoclonal anti-HA (Roche). Phosphorylation of mERK5/-T was
) Western blot. Lysates made from 293T cells over-expressing HA-tagged
PAGE and probed with anti-phospho Erk5 (CalBiochem). The stripped blot
B.J. McCaw et al. / Gene 345 (2005) 183–190 187Similarly, retention of intron 4 in human Erk5-T mRNA
introduced an in-frame stop codon 33 bases 5V of the exon
4/5 junction via a +1-bp frame shift. Thus in both human
and mouse, the alternately spliced mRNA species result in
translation of an ERK5 variant that is essentially truncated
after amino acid 492. The truncated protein retains the
cytoplasmic targeting-, kinase- and oligomerization-
domains, while the nuclear localization signal and pro-
line-rich domains are lost.
3.2. mErk5-T mRNA is expressed in multiple adult tissues
RT-PCR analysis of RNA extracted from mouse organs
was used to verify the existence of mErk5-T in the
cytoplasm as well as gauge expression levels of the
transcript across a range of adult tissues. This was
accomplished using an oligonucleotide set specific for
mErk5-T; in parallel with a set designed to amplify mErk5
cDNA spliced across intron 4 (Fig. 2). To prevent
amplification from residual genomic DNA or unspliced
heteronuclear RNA, the amplicon spanned intron 2 (2.4 kb).
Compared with other tissues, Erk5 mRNAwas high in bone
marrow, lung, skeletal muscle and testis. Expression of
mErk5-T generally correlated with Erk5 expression,
although at lower levels. The only exception being the
bone marrow, where a disproportionately high level of
mErk5-T relative to Erk5 was consistently observed.
Although an attempt was made to detect mErk5-T in
tissue lysates by Western blotting, antibodies that recognize
N-terminal epitopes performed poorly in our hands, failing
to detect endogenous mErk5 in mouse embryonic tissue
lysates (data not shown).Fig. 4. mERK5-T remains in the cytoplasm upon stimulation. HelaS3 cells were co
control (A), MEKKDD (B) MEKKAA (C); or 1 Ag FLAG-mErk5-T and 0.5 Ag o
fixed, permeabilized and stained for FLAG-tagged ERK5 using an anti-FLAG
AffiniPure rabbit anti-mouse IgG (green).3.3. Intron 4 of mErk5 can be alternately spliced, and both
products are potential substrates of mMEK5
To assess whether intron 4 has the potential to be
alternately spliced, a construct was made that contained 5V
HA-tagged mErk5 cDNA unspliced with respect to intron 4
(mErk5-i4us, Fig. 3a). The construct was transfected into
293T cells in parallel with HA-tagged mErk5 and mErk5-T
alone. Whole cell lysates were separated on a 7.5% PAGE
and probed with monoclonal anti-HA. A 110-kDa immuno-
reactive band was detected in lysates made from cells
expressing HA-mERK5, and a 60-kDa band was detected in
lysates made from HA-mERK5-T transfected cells (Fig. 3,
lanes 1 and 3). Both the 110- and 60-kDa (albeit at a lower
intensity) bands were detected in lysates made from cells
transfected with mErk5-i4us, demonstrating that the (over-
expressed) alternatively spliced mErk5-T mRNA can be
exported from the nucleus to the cytoplasm and translated.
In order to investigate whether mERK5-T can be
phosphorylated by its upstream kinase (mMEK5), the three
mERK5 constructs (mErk5, mErk5-T and mErk5-i4us) were
co-transfected with either a constitutively active mMEK5
(mMEK5DD), or a dominant negative mMEK5 (mME-
KAA). Phosphorylation of mERK5 can be inferred by a
shift in mobility of the protein through a 7.5% SDS–PAGE
gel (Kato et al., 1998). A shift in both mERK5 and mERK5-
T mobility was consistently seen when co-transfected with
mMEK5DD relative to mMEK5AA (Fig. 3, compare lanes
1 with 2, 3 with 4 and 5 with 6) indicative of mERK5/-T
phosphorylation. The phosphorylation status of mERK5/-T
was confirmed by immunoreactivity of 110- and 60-kDa
bands with an anti-phospho Erk5 antibody (Fig. 3a). It is-transfected with 1 Ag FLAG-mErk5 full-length and 0.5 Ag of either vector
f either vector control (D), MEKKDD (E) MEKKAA (F). Cells were then
monoclonal followed by fluorescein isothiocyanate (FITC)-conjugated
Fig. 5. mERK5-T associates with itself and mERK5-T. HEK293T cells were
transfected with various combinations of differentially tagged (either FLAG
or HA) mErk5 and mErk5-T in the presence of mMek5AA or mMek5DD.
Co-immunoprecipitation was performed with anti-FLAG M2 conjugated
agarose beads (Sigma), and Western blot was performed with anti-HA
(Roche). Expression of constructs was confirmed by Western blot of whole
cell lysates (WCL) with either anti-HA and anti-FLAG.
B.J. McCaw et al. / Gene 345 (2005) 183–190188interesting to note however, that the level of mERK5-T
relative to mERK5 in lysates made from cells expressing
mErk4-i4us was much reduced in the presence of
mMEK5DD (relative to mMEK5AA).
3.4. mERK5-T remains in the cytoplasm upon stimulation
In line with other members of the MAPK family, ERK5
translocates from the cytoplasm to the nucleus upon
stimulation (Kato et al., 1997). However, as mERK5-T lacksFig. 6. mERK5-T inhibits nuclear translocation of phospho-mERK5. HelaS3 cells
mErk5-T and 0.2 Ag of either MEKKDD (a, b) or MEKKAA (c, d); or 0.2 Ag FLAG
or MEKKAA (g, h). Cells were then fixed, permeabilized and stained for FL
isothiocyanate (FITC)-conjugated AffiniPure rabbit anti-mouse IgG (green). HA
followed by Texas RedR dye-conjugated AffiniPure goat anti-rabbit IgG (red).the NLS of ERK5, its cellular localization in response to
stimulation warranted experimental investigation. Immuno-
fluorescence of HeLaS3 cells over-expressing HA-tagged
mErk5-T was used to monitor the cellular localization of
mERK5-T co-expressed with either mMEKAA or
mMEK5DD. The same experiment was performed with
mErk5 as a positive control. As expected, non-phosphory-
lated mERK5-T and ERK5 localized to the cytoplasm, while
only stimulatedmERK5was able to translocate to the nucleus
(Fig. 4). Stimulated mERK5-T failed to enter the nucleus and
displayed a sub-cellular distribution indistinguishable from
unstimulated mERK5-T. These data imply that a functional
consequence of alternate splicing across intron 4 is possibly
retention of activated mERK5 in the cytoplasm.
3.5. mERK5-T can heterodimerize with ERK5
mERK5 exists as a homo-oligomer in a manner that is
independent of the molecules’ phosphorylation status (Yan
et al., 2001). As the oligomerization domain is retained in
mERK5-T, its potential to associate with both itself and
mERK5 was assessed in co-immunoprecipitation experi-
ments. To accomplish this, FLAG-mERK5 was co-
expressed with HA-mERK5-T and either mMEK5AA or
mMEK5DD in HEK293T fibroblasts. As can be seen in Fig.
5, immunoprecipitation of phosphorylated and non-phos-
phorylated FLAG-ERK5 brought down HA-tagged
mERK5-T, indicating that mERK5/mERK-T heterodimers
can exist in both a stimulated and unstimulated state. The
potential for homo-oligomerization of mERK5-T was also
shown by successful co-precipitation of HA-mERK5-T with
FLAG- ERK5-T.were triply transfected with 0.2 Ag FLAG-mErk5 full-length, 0.2 Ag HA-
-Erk5 full-length, 1.0 Ag HA-mErk5-T and 0.2 Ag of either MEKKDD (e, f)
AG-ERK5 using an anti-FLAG monoclonal (a, c, e, g) and fluorescein
-tagged mERK5-T was visualized with an anti-HA polyclonal (b, d, f, h)
B.J. McCaw et al. / Gene 345 (2005) 183–190 1893.6. Effect of mERK5-T on phospho-mERK nuclear
localization
Translocation of phosphorylated mERK5 from the
cytoplasm to the nucleus is facilitated by the presence of a
NLS. As mERK5-T and mERK5 differ in this respect, and
potentially remain complexed upon phosphorylation, it was
postulated that co-expression of mErk5-T may inhibit
nuclear translocation of phospho-mERK5. To explore this
possibility, FLAG-tagged mErk5 was cloned into pIRES (3V
MCS) along with either mMek5AA or mMek5DD (5VMCS).
The mErk5 and mMek5 constructs were then co-transfected
with HA-mErk5-T or empty pXJ40HA into HeLaS3
fibroblasts at various ratios; 1 Ag mErk5:1/2/5 Ag mErk5-
T. The sub-cellular localization of mERK5 and mERK5-T
were visualized by confocal immunofluorescence (Fig. 6).
As seen previously, mERK5 localized to the cytoplasm
when expressed from bi-cistronic message with mMek5AA,
but translocated to the nucleus when expressed bi-cistro-
nicly with mMek5DD. Co-expression of mErk5-T however,
appeared to inhibit the translocation of the full length
molecule in a concentration dependent manner. At a DNA
transfection ratio of 1:1, the observed inhibition was evident
but slight, whereas at 1:2 (not shown) and 1:5 ratios, the
inhibition seemed complete.4. Discussion
Here, we report the identification and initial character-
ization of an alternative mammalian Erk5 splice variant
(mErk5-T) that retains the intervening sequence between
exons 4 and 5 (intron 4). Alternative splicing across intron 4
introduces a stop codon in the mouse and orthologous
human transcripts, the predicted effect being translation of
an ERK5 variant (ERK5-T) that is truncated at the C-
terminus and loses the NLS and PR domain. These
observations complement prior reports of alternate splicing
across mErk5 introns 1 and 2, leading to expression of an
ERK5 variant that lacks the kinase domain (Yan et al.,
2001).
The expression pattern of mErk5-T in adult tissues
correlates with that of mErk5, albeit at significantly lower
levels with possible relative enrichment of mErk5-T in the
total bone marrow transcriptome. These data however, do
not exclude the possibility that mErk5-T is expressed at a
relatively high level in specific cells under certain con-
ditions. While in situ hybridization can be used to address
this point, the subtle sequence difference between the
mErk5 and mErk5-T transcripts (+103 bp) may be
insufficient to distinguish the two splice forms.
As far as we are aware, this is the first example of an
Erk5 tissue expression analysis that includes the bone-
marrow. Interestingly, bone marrow is one of the four tissues
(testis, skeletal muscle, lung and bone marrow) that display
an enrichment of the Erk5 (and Erk5-T) transcript. Thisobservation is in-line with previously published signaling
data that suggests ERK5 is a down-stream component of
certain cytokine receptors involved in hematopoiesis, e.g.
G-CSFR (Dong et al., 2001).
Consistent with retention of the MEK5 phosphorylation
targets (T219, Y221), mERK5-T can be phosphorylated by
constitutively active MEK5DD. Preliminary data also
indicates that phosphorylation of mERK5-T seems to play
a determinate role in the ratio of mERK5/mERK5-T in cells
over-expressing an intron 4 unspliced transcript. Whether
this results from regulation at the level of mRNA splicing or
events further down-stream (mRNA/protein degradation)
remains unclear.
Retention of the oligomerization domain within mERK5-
T most likely explains the ability of mERK5-T to associate
with both itself and mERK5 in active and inactive states.
Similarly, the failure of mERK5-T to translocate from the
cytoplasm to the nucleus upon stimulation is consistent with
loss of the C-terminal NLS. The most profound observation
made of mERK5-T though, is the inhibitory effect on
nuclear translocation of activated mERK5. These data imply
that in a physiological context it is possible that expression
of mERK5-T serves to attenuate nuclear signaling of
mERK5, and/or may represent a mechanism of maintaining
mERK5 signaling in the cytoplasm through as yet unidenti-
fied downstream cytosolic targets. Although not elicited by
alternate splicing and domain content manipulation, it is
well established that ERK1/2 signaling elicits distinct
cellular processes through differential compartmentalization
of phospho-ERK. Sustained ERK1/2 activation leads to
differentiation through nuclear localization (and signaling)
of the active molecule, whereas transient activation stim-
ulates proliferation via cytosolic ERK1/2 signaling (Mar-
shall, 1995).
It has been observed in conventional knock-out studies
that mERK5-deficient mice develop angiogenic defects and
die in utero (Sohn et al., 2002). In a separate study,
conditional disruption of mErk5 led to loss of vascular
integrity and subsequent endothelial failure (Hayashi et al.,
2004). In both cases, transcriptional dysregulation of genes
downstream of mERK5 signaling was suggested to be
responsible for the observed phenotypes. Since mERK5-T
inhibits nuclear translocation of mERK5, this may represent
a novel regulatory mechanism of such physiological
activities. It is possible that changing ratios of mERK5-T/
mERK5 modulate the levels of phosphorylated mERK5 in
the nucleus, which subsequently affects transcriptional
activation of genes involved in these processes. This implies
that such physiological processes may not be regulated
simply by the presence or absence of mERK5, but the
degree of nuclear Erk5 activity, where moderate changes in
the availability of mERK5 to transcription factors may
affect physiological outcome.
In summary, data presented in this manuscript describes a
novel human and mouse ERK5 splice variant that lacks a
functional NLS and as such is unable to enter the nucleus
B.J. McCaw et al. / Gene 345 (2005) 183–190190upon activation. Taken together with prior reports of
mERK5 functional domain architecture modification by
alternative splicing, these data add to the suggestion that
regulation of ERK5 signaling could, at least in part, be
carried out at the level of mRNA processing.References
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